PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 5/00, 15/00, 15/09, 15/63

A1

(11) International Publication Number: WO 98/33887

(43) International Publication Date: 6 August 1998 (06.08.98)

(21) International Application Number: PCT/US98/02479

(22) International Filing Date: 5 February 1998 (05.02.98)

(30) Priority Data:

| | | |
|---|---|---|
| 08/795,071 | 5 February 1997 (05.02.97) | US |
| 08/847,910 | 28 April 1997 (28.04.97) | US |
| 08/862,445 | 23 May 1997 (23.05.97) | US |

(71) Applicant: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US).

(72) Inventors: LEE, Se-Jin; 6711 Chokeberry Road, Baltimore, MD 21209 (US). MCPHERRON, Alexandra, C.; 3905 Keswick Road, Baltimore, MD 21211 (US).

(74) Agent: HAILE, Lisa, A.; Fish & Richardson P.C., Suite 1400, 4225 Executive Square, La Jolla, CA 92037 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published**

*With international search report.*

*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: GROWTH DIFFERENTIATION FACTOR-8

(57) Abstract

A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-8 (GDF-8) chromosomally integrated into the germ cells of the animal is disclosed. Also disclosed are methods for making such animals, and methods of treating animals, including humans, with antibodies or antisense directed to GDF-8. The animals so treated are characterized by increased muscle tissue.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AL** | Albania | **ES** | Spain | **LS** | Lesotho | **SI** | Slovenia |
| **AM** | Armenia | **FI** | Finland | **LT** | Lithuania | **SK** | Slovakia |
| **AT** | Austria | **FR** | France | **LU** | Luxembourg | **SN** | Senegal |
| **AU** | Australia | **GA** | Gabon | **LV** | Latvia | **SZ** | Swaziland |
| **AZ** | Azerbaijan | **GB** | United Kingdom | **MC** | Monaco | **TD** | Chad |
| **BA** | Bosnia and Herzegovina | **GE** | Georgia | **MD** | Republic of Moldova | **TG** | Togo |
| **BB** | Barbados | **GH** | Ghana | **MG** | Madagascar | **TJ** | Tajikistan |
| **BE** | Belgium | **GN** | Guinea | **MK** | The former Yugoslav Republic of Macedonia | **TM** | Turkmenistan |
| **BF** | Burkina Faso | **GR** | Greece | | | **TR** | Turkey |
| **BG** | Bulgaria | **HU** | Hungary | **ML** | Mali | **TT** | Trinidad and Tobago |
| **BJ** | Benin | **IE** | Ireland | **MN** | Mongolia | **UA** | Ukraine |
| **BR** | Brazil | **IL** | Israel | **MR** | Mauritania | **UG** | Uganda |
| **BY** | Belarus | **IS** | Iceland | **MW** | Malawi | **US** | United States of America |
| **CA** | Canada | **IT** | Italy | **MX** | Mexico | **UZ** | Uzbekistan |
| **CF** | Central African Republic | **JP** | Japan | **NE** | Niger | **VN** | Viet Nam |
| **CG** | Congo | **KE** | Kenya | **NL** | Netherlands | **YU** | Yugoslavia |
| **CH** | Switzerland | **KG** | Kyrgyzstan | **NO** | Norway | **ZW** | Zimbabwe |
| **CI** | Côte d'Ivoire | **KP** | Democratic People's Republic of Korea | **NZ** | New Zealand | | |
| **CM** | Cameroon | | | **PL** | Poland | | |
| **CN** | China | **KR** | Republic of Korea | **PT** | Portugal | | |
| **CU** | Cuba | **KZ** | Kazakstan | **RO** | Romania | | |
| **CZ** | Czech Republic | **LC** | Saint Lucia | **RU** | Russian Federation | | |
| **DE** | Germany | **LI** | Liechtenstein | **SD** | Sudan | | |
| **DK** | Denmark | **LK** | Sri Lanka | **SE** | Sweden | | |
| **EE** | Estonia | **LR** | Liberia | **SG** | Singapore | | |

# GROWTH DIFFERENTIATION FACTOR-8

## BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates generally to growth factors and specifically to a new member of the transforming growth factor beta (TGF-β) superfamily, which is denoted, growth differentiation factor-8 (GDF-8) and methods of use for modulating muscle cell and adipose tissue growth.

2. Description of Related Art

The transforming growth factor β (TGF-β) superfamily encompasses a group of structurally-related proteins which affect a wide range of differentiation processes during embryonic development. The family includes, Mullerian inhibiting substance (MIS), which is required for normal male sex development (Behringer, *et al., Nature*, 345:167, 1990), Drosophila decapentaplegic (DPP) gene product, which is required for dorsal-ventral axis formation and morphogenesis of the imaginal disks (Padgett, *et al., Nature*, 325:81 -84, 1987), the Xenopus Vg-1 gene product, which localizes to the vegetal pole of eggs ((Weeks, *et al., Cell*, 51:861-867, 1987), the activins (Mason, *et al., Biochem, Biophys. Res. Commun.*, 135:957-964, 1986), which can induce the formation of mesoderm and anterior structures in Xenopus embryos (Thomsen, *et al., Cell*, 63:485, 1990), and the bone morphogenetic proteins (BMPs, osteogenin, OP-1) which can induce de novo cartilage and bone formation (Sampath, *et al., J. Biol. Chem.*, 265:13198, 1990). The TGF-βs can influence a variety of differentiation processes, including adipogenesis, myogenesis, chondrogenesis, hematopolesis, and epithelial cell differentiation (for review, see Massague, *Cell* 49:437, 1987).

The proteins of the TGF-β family are initially synthesized as a large precursor protein which subsequently undergoes proteolytic cleavage at a cluster of basic residues approximately 110-140 amino acids from the C-terminus. The C-terminal regions, or mature regions, of the proteins are all structurally related and the different family

members can be classified into distinct subgroups based on the extent of their homology. Although the homologies within particular subgroups range from 70% to 90% amino acid sequence identity, the homologies between subgroups are significantly lower, generally ranging from only 20% to 50%. In each case, the active species appears to be a disulfide-linked dimer of C-terminal fragments. Studies have shown that when the pro-region of a member of the TGF-β family is coexpressed with a mature region of another member of the TGF-β family, intracellular dimerization and secretion of biologically active homodimers occur (Gray, A. *et al.*, *Science*, 247:1328, 1990). Additional studies by Hammonds, *et al.*, (*Molec. Endocrin.* 5:149, 1991) showed that the use of the BMP-2 pro-region combined with the BMP-4 mature region led to dramatically improved expression of mature BMP-4. For most of the family members that have been studied, the homodimeric species has been found to be biologically active, but for other family members, like the inhibins (Ling, *et al.*, *Nature*, 321 :779, 1986) and the TGF-βs (Cheifetz, *et al.*, *Cell*, 48:409, 1987), heterodimers have also been detected, and these appear to have different biological properties than the respective homodimers.

In addition it is desirable to produce livestock and game animals, such as cows, sheep, pigs, chicken and turkey, fish which are relatively high in musculature and protein, and low in fat content. Many drug and diet regimens exist which may help increase muscle and protein content and lower undesirably high fat and/or cholesterol levels, but such treatment is generally administered after the fact, and is begun only after significant damage has occurred to the vasculature. Accordingly, it would be desirable to produce animals which are genetically predisposed to having higher muscle content, without any ancillary increase in fat levels.

The food industry has put much effort into increasing the amount of muscle and protein in foodstuffs. This quest is relatively simple in the manufacture of synthetic foodstuffs, but has been met with limited success in the preparation of animal foodstuffs. Attempts have been made, for example, to lower cholesterol levels in beef and poultry products by including cholesterol-lowering drugs in animal feed (see *e.g.* Elkin and Rogler, J. Agric.

Food Chem. 1990, 38, 1635-1641). However, there remains a need for more effective methods of increasing muscle and reducing fat and cholesterol levels in animal food products.

## SUMMARY OF THE INVENTION

The present invention provides a cell growth and differentiation factor, GDF-8, a polynucleotide sequence which encodes the factor, and antibodies which are immunoreactive with the factor. This factor appears to relate to various cell proliferative disorders, especially those involving muscle, nerve, and adipose tissue.

In one embodiment, the invention provides a method for detecting a cell proliferative disorder of muscle, nerve, or fat origin and which is associated with GDF-8. In another embodiment, the invention provides a method for treating a cell proliferative disorder by suppressing or enhancing GDF-8 activity.

In another embodiment, the subject invention provides non-human transgenic animals which are useful as a source of food products with high muscle and protein content, and reduced fat and cholesterol content. The animals have been altered chromosomally in their germ cells and somatic cells so that the production of GDF-8 is produced in reduced amounts, or is completely disrupted, resulting in animals with decreased levels of GDF-8 in their system and higher than normal levels of muscle tissue, preferably without increased fat and/or cholesterol levels. Accordingly, the present invention also includes food products provided by the animals. Such food products have increased nutritional value because of the increase in muscle tissue. The transgenic non-human animals of the invention include bovine, porcine, ovine and avian animals, for example.

The subject invention also provides a method of producing animal food products having increased muscle content. The method includes modifying the genetic makeup of the germ cells of a pronuclear embryo of the animal, implanting the embryo into the oviduct of a pseudopregnant female thereby allowing the embryo to mature to full term progeny,

testing the progeny for presence of the transgene to identify transgene-positive progeny, cross-breeding transgene-positive progeny to obtain further transgene-positive progeny and processing the progeny to obtain foodstuff. The modification of the germ cell comprises altering the genetic composition so as to disrupt or reduce the expression of the naturally occurring gene encoding for production of GDF-8 protein. In a particular embodiment, the transgene comprises antisense polynucleotide sequences to the GDF-8 protein. Alternatively, the transgene may comprise a non-functional sequence which replaces or intervenes in the native GDF-8 gene.

The subject invention also provides a method of producing avian food products having improved muscle content. The method includes modifying the genetic makeup of the germ cells of a pronuclear embryo of the avian animal, implanting the embryo into the oviduct of a pseudopregnant female into an embryo of a chicken, culturing the embryo under conditions whereby progeny are hatched, testing the progeny for presence of the genetic alteration to identify transgene-positive progeny, cross-breeding transgene-positive progeny and processing the progeny to obtain foodstuff.

The invention also provides a method for treating a muscle or adipose tissue disorder in a subject. The method includes administering a therapeutically effective amount of a GDF-8 agent to the subject, thereby inhibiting abnormal growth of muscle or adipose tissue. The GDF-8 agent may include an antibody, a GDF-8 antisense molecule or a dominant negative polypeptide, for example. In one aspect, a method for inhibiting the growth regulating actions of GDF-8 by contacting an anti-GDF-8 monoclonal antibody, a GDF-8 antisense molecule or a dominant negative polypeptide (or polynucleotide encoding a dominant negative polypeptide) with fetal or adult muscle cells or progenitor cells is included. These agents can be administered to a patient suffering from a disorder such as muscle wasting disease, neuromuscular disorder, muscle atrophy, obesity or other adipocyte cell disorders, and aging, for example.

The invention also provides a method for a method for identifying a compound that affects GDF-8 activity or gene expression includng incubating the compound with GDF-8 polypeptide, or with a recombinant cell expressing GDF-8 under conditions sufficient to allow the compounds to interact and determining the effect of the compound on GDF-8 activity or expression.

## BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1a is a Northern blot showing expression of GDF-8 mRNA in adult tissues. The probe was a partial murine GDF-8 clone.

FIGURE 1b is a Southern blot showing GDF-8 genomic sequences identified in mouse, rat, human, monkey, rabbit, cow, pig, dog and chicken.

FIGURE 2 shows partial nucleotide and predicted amino acid sequences of murine GDF-8 (FIGURE 2a; SEQ ID NO:11 and 12, respectively), human GDF-8 (FIGURE 2b; SEQ ID NO: 13 and 14, respectively), rat GDF-8 (FIGURE 2c; SEQ ID NO: 24 and 25, respectively) and chicken GDF-8 (FIGURE 2d; SEQ ID NO: 22 and 23, respectively). The putative dibasic processing sites in the murine sequence are boxed.

FIGURE 3a shows the alignment of the C-terminal sequences of GDF-8 with other members of the TGF-β superfamily. The conserved cysteine residues are boxed. Dashes denote gaps introduced in order to maximize alignment.

FIGURE 3b shows the alignment of the C-terminal sequences of GDF-8 from human, murine, rat and chicken sequences.

FIGURE 4 shows amino acid homologies among different members of the TGF superfamily. Numbers represent percent amino acid identities between each pair calculated from the first conserved cysteine to the C-terminus. Boxes represent homologies among highly-related members within particular subgroups.

FIGURE 5 shows the sequence of GDF-8. Nucleotide and amino acid sequences of murine (FIGURE 5a and 5b)(GenBank accession number U84005; SEQ ID NO:11 and 12, respectively) and human (FIGURE 5c and 5d; SEQ ID NO:13 and 14, respectively) GDF-8 cDNA clones are shown. Numbers indicate nucleotide position relative to the 5' end. Consensus N-linked glycosylation signals are shaded. The putative RXXR proteolytic cleavage sites are boxed.

FIGURE 6 shows a hydropathicity profile of GDF-8. Average hydrophobicity values for murine (FIGURE 6a) and human (FIGURE 6b) GDF-8 were calculated using the method of Kyte and Doolittle (*J. Mol. Biol.*, 157:105-132, 1982). Positive numbers indicate increasing hydrophobicity.

FIGURE 7 shows a comparison of murine and human GDF-8 amino acid sequences. The predicted murine sequence is shown in the top lines and the predicted human sequence is shown in the bottom lines. Numbers indicate amino acid position relative to the N-terminus. Identities between the two sequences are denoted by a vertical line.

FIGURE 8 shows the expression of GDF-8 in bacteria. BL21 (DE3) (pLysS) cells carrying a pRSET/GDF-8 expression plasmid were induced with i-sopropylthio-β-galactoside, and the GDF-8 fusion protein was purified by metal chelate chromatography. Lanes: total=total cell lysate; soluble=soluble protein fraction; insoluble=insoluble protein fraction (resuspended in 10 Mm Tris pH 8.0, 50 mM sodium phosphate, 8 M urea, and 10 mM β-mercaptoethanol [buffer B]) loaded onto the column, pellet=insoluble protein fraction discarded before loading the column; flow-through=proteins not bound by the column; washes=washes carried out in buffer B at the indicated pH's. Positions of molecular weight standards are shown at the right. Arrow indicates the position of the GDF-8 fusion protein.

FIGURE 9 shows the expression of GDF-8 in mammalian cells. Chinese hamster ovary cells were transfected with pMSXND/GDF-8 expression plasmids and selected in G418. Conditioned media from G418-resistant cells (prepared from cells transfected with constructs in which GDF-8 was cloned in either the antisense or sense orientation) were concentrated, electrophoresed under reducing conditions, blotted, and probed with anti-GDF-8 antibodies and [$^{125}$I]iodoproteinA. Arrow indicates the position of the processed GDF-8 protein.

FIGURE 10 shows the expression of GDF-8 mRNA. Poly A-selected RNA (5μg each) prepared from adult tissues (FIGURE 10a) or placentas end embryos (FIGURE 10b) at the indicated days of gestation was electrophoresed on formaldehyde gels, blotted, and probed with full length murine GDF-8.

FIGURE 11 shows chromosomal mapping of human GDF-8. DNA samples prepared from human/rodent somatic cell hybrid lines were subjected to PCR, electrophoresed on agarose gels, blotted, and probed. The human chromosome contained in each of the hybrid cell lines is identified at the top of each of the first 24 lanes (1-22, X, and Y). In the lanes designated M, CHO, and H, the starting DNA template was total genomic DNA from mouse, hamster, and human sources, respectively. In the lane marked B1, no template DNA was used. Numbers at left indicate the mobilities of DNA standards.

Figure 12a shows a map of the GDF-8 locus (top line) and targeting construct (second line). The black and stippled boxes represent coding sequences for the pro- and C-terminal regions, respectively. The white boxes represent 5' and 3' untranslated sequences. A probe derived from the region downstream of the 3' homology fragment and upstream of the most distal HindIII site shown hybridizes to an 11.2 kb HindIII fragment in the GDF-8 gene and a 10.4 kb fragment in an homologously targeted gene. Abbreviations: H, HindIII; X, Xba I.

Figure 12b shows a Southern blot analysis of offspring derived from a mating of heterozygous mutant mice. The lanes are as follows: DNA prepared from wild type 129 SV/J mice (lane 1), targeted embryonic stem cells (lane 2), F1 heterozygous mice (lanes 3 and 4), and offspring derived from a mating of these mice (lanes 5-13).

Figure 13 shows the muscle fiber size distribution in mutant and wild type littermates. Figure 13a shows the smallest cross-sectional fiber widths measured for wild type (n = 1761) and mutant (n = 1052) tibialis cranial. Figure 13b shows wild type (n = 900) and mutant (n = 900) gastrocnemius muscles, and fiber sizes were plotted as a percent of total fiber number. Standard deviations were 9 and 10 $\mu$m, respectively, for wild type and mutant tibialis cranial is and 11 and 9 $\mu$m, respectively, for wild type and mutant gastrocnemius muscles. Legend: o-o, wild type; _-_, mutant.

Figure 14a shows the nucleotide and deduced amino acid sequence for baboon GDF-8 (SEQ ID NO:18 and 19, respectively).

Figure 14b shows the nucleotide and deduced amino acid sequence for bovine GDF-8 (SEQ ID NO: 20 and 21, respectively).

Figure 14c shows the nucleotide and deduced amino acid sequence for chicken GDF-8 (SEQ ID NO:22 and 23, respectively).

Figure 14d shows the nucleotide and deduced amino acid sequence for rat GDF-8 (SEQ ID NO:24 and 25, respectively).

Figure 14e shows the nucleotide and deduced amino acid sequence for turkey GDF-8 (SEQ ID NO:26 and 27, respectively).

Figure 14f shows the nucleotide and deduced amino acid sequence for porcine GDF-8 (SEQ ID NO:28 and 29, respectively).

Figure 14g shows the nucleotide and deduced amino acid sequence for ovine GDF-8 (SEQ ID NO:30 and 31, respectively).

Figures 15a and 15b show an alignment between murine, rat, human, porcine, ovine, baboon, bovine, chicken, and turkey GDF-8 amino acid sequences (SEQ ID NO:12, 25, 14, 29, 31, 19, 21, 23 and 27, respectively).

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a growth and differentiation factor, GDF-8 and a polynucleotide sequence encoding GDF-8. GDF-8 is expressed at highest levels in muscle and at lower levels in adipose tissue.

The animals contemplated for use in the practice of the subject invention are those animals generally regarded as useful for the processing of food stuffs, *i.e.* avian such as meat bred and egg laying chicken and turkey, ovine such as lamb, bovine such as beef cattle and milk cows, piscine and porcine. For purposes of the subject invention, these animals are referred to as "transgenic" when such animal has had a heterologous DNA sequence, or one or more additional DNA sequences normally endogenous to the animal (collectively referred to herein as "transgenes") chromosomally integrated into the germ cells of the animal. The transgenic animal (including its progeny) will also have the transgene integrated into the chromosomes of somatic cells.

The TGF-β superfamily consists of multifunctional polypeptides that control proliferation, differentiation, and other functions in many cell types. Many of the peptides have regulatory, both positive and negative, effects on other peptide growth factors. The structural homology between the GDF-8 protein of this invention and the members of the TGF-β family, indicates that GDF-8 is a new member of the family of growth and differentiation factors. Based on the known activities of many of the other members, it can be expected that GDF-8 will also possess biological activities that will make it useful as a diagnostic and therapeutic reagent.

In particular, certain members of this superfamily have expression patterns or possess activities that relate to the function of the nervous system. For example, the inhibins and

activins have been shown to be expressed in the brain (Meunier, *et al., Proc. Natl. Acad. Sci., USA*, 85:247, 1988; Sawchenko, *et al., Nature*, 334:615, 1988), and activin has been shown to be capable of functioning as a nerve cell survival molecule (Schubert, *et al., Nature*, 344:868, 1990). Another family member, namely, GDF-1, is nervous system-specific in its expression pattern (Lee, S.J., *Proc. Natl. Acad. Sci., USA*, 88:4250, 1991), and certain other family members, such as Vgr-1 (Lyons, *et al., Proc. Natl. Acad. Sci., USA*, 86:4554, 1989; Jones, *et al., Development*, 111:531, 1991), OP-1 (Ozkaynak, *et al., J. Biol. Chem.*, 267:25220, 1992), and BMP-4 (Jones, *et al., Development*, 111:531, 1991), are also known to be expressed in the nervous system. Because it is known that skeletal muscle produces a factor or factors that promote the survival of motor neurons (Brown, *Trends Neurosci.*, 7:10, 1984), the expression of GDF-8 in muscle suggests that one activity of GDF-8 may be as a trophic factor for neurons. In this regard, GDF-8 may have applications in the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis or muscular dystrophy, or in maintaining cells or tissues in culture prior to transplantation.

GDF-8 may also have applications in treating disease processes involving muscle, such as in musculodegenerative diseases or in tissue repair due to trauma. In this regard, many other members of the TGF-β family are also important mediators of tissue repair. TGF-β has been shown to have marked effects on the formation of collagen and to cause a striking angiogenic response in the newborn mouse (Roberts, *et al., Proc. Natl. Acad. Sci., USA* 83:4167, 1986). TGF-β has also been shown to inhibit the differentiation of myoblasts in culture (Massague, *et al., Proc. Natl. Acad. Sci., USA* 83:8206, 1986). Moreover, because myoblast cells may be used as a vehicle for delivering genes to muscle for gene therapy, the properties of GDF-8 could be exploited for maintaining cells prior to transplantation or for enhancing the efficiency of the fusion.

The expression of GDF-8 in adipose tissue also raises the possibility of applications for GDF-8 in the treatment of obesity or of disorders related to abnormal proliferation of adipocytes. In this regard, TGF-β has been shown to be a potent inhibitor of adipocyte

differentiation *in vitro* (Ignotz and Massague, *Proc. Natl. Acad. Sci., USA* 82:8530, 1985).

***Polypeptides, Polynucleotides, Vectors and Host Cells***

The invention provides substantially pure GDF-8 polypeptide and isolated polynucleotides that encode GDF-8. The term "substantially pure" as used herein refers to GDF-8 which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. One skilled in the art can purify GDF-8 using standard techniques for protein purification. The substantially pure polypeptide will yield a single major band on a non-reducing polyacrylamide gel. The purity of the GDF-8 polypeptide can also be determined by amino-terminal amino acid sequence analysis. GDF-8 polypeptide includes functional fragments of the polypeptide, as long as the activity of GDF-8 remains. Smaller peptides containing the biological activity of GDF-8 are included in the invention.

The invention provides polynucleotides encoding the GDF-8 protein. These polynucleotides include DNA, cDNA and RNA sequences which encode GDF-8. It is understood that all polynucleotides encoding all or a portion of GDF-8 are also included herein, as long as they encode a polypeptide with GDF-8 activity. Such polynucleotides include naturally occurring, synthetic, and intentionally manipulated polynucleotides. For example, GDF-8 polynucleotide may be subjected to site-directed mutagenesis. The polynucleotide sequence for GDF8 also includes antisense sequences. The polynucleotides of the invention include sequences that are degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the invention as long as the amino acid sequence of GDF-8 polypeptide encoded by the nucleotide sequence is functionally unchanged.

Specifically disclosed herein is a genomic DNA sequence containing a portion of the GDF-8 gene. The sequence contains an open reading frame corresponding to the predicted C-terminal region of the GDF-8 precursor protein. The encoded polypeptide

is predicted to contain two potential proteolytic processing sites (KR and RR). Cleavage of the precursor at the downstream site would generate a mature biologically active C-terminal fragment of 109 and 103 amino acids for murine and human species, respectively, with a predicted molecular weight of approximately 12,400. Also disclosed are full length murine and human GDF-8 cDNA sequences. The murine pre-pro-GDF-8 protein is 376 amino acids in length, which is encoded by a 2676 base pair nucleotide sequence, beginning at nucleotide 104 and extending to a TGA stop codon at nucleotide 1232. The human GDF-8 protein is 375 amino acids and is encoded by a 2743 base pair sequence, with the open reading frame beginning at nucleotide 59 and extending to nucleotide 1184. GDF-8 is also capable of forming dimers, or heterodimers, with an expected molecular weight of approximately 23-30KD (see Example 4). For example, GDF-8 may form heterodimers with other family members, such as GDF-11.

Also provided herein are the biologically active C-terminal fragments of chicken (Figure 2c) and rat (Figure 2d) GDF-8. The full length nucleotide and deduced amino acid sequences for baboon, bovine, chicken, rat, ovine, porcine, and turkey are shown in Figures 14a-g and human and murine are shown in Figure 5. As shown in Figure 3b, alignment of the amino acid sequences of human, murine, rat and chicken GDF-8 indicate that the sequences are 100% identical in the C-terminal biologically active fragment. Figure 15 a and 15b also show the alignment of GDF-8 amino acid sequences for murine, rat, human, baboon, porcine, ovine, bovine, chicken and turkey. Given the extensive conservation of amino acid sequences between species, it would now be routine for one of skill in the art to obtain the GDF-8 nucleic acid and amino acid sequence for GDF-8 from any species, including those provided herein, as well as piscine, for example.

The C-terminal region of GDF-8 following the putative proteolytic processing site shows significant homology to the known members of the TGF-β superfamily. The GDF-8 sequence contains most of the residues that are highly conserved in other family members and in other species(see FIGURES 3a and 3b and 15 a and 15b). Like the TGF-βs and inhibin βs, GDF-8 contains an extra pair of cysteine residues in addition to

the 7 cysteines found in virtually all other family members. Among the known family members, GDF-8 is most homologous to Vgr-1 (45% sequence identity) (see FIGURE 4).

Minor modifications of the recombinant GDF-8 primary amino acid sequence may result in proteins which have substantially equivalent activity as compared to the GDF-8 polypeptide described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein as long as the biological activity of GDF-8 still exists. Further, deletion of one or more amino acids can also result in a modification of the structure of the resultant molecule without significantly altering its biological activity. This can lead to the development of a smaller active molecule which would have broader utility. For example, one can remove amino or carboxy terminal amino acids which are not required for GDF-8 biological activity.

The nucleotide sequence encoding the GDF-8 polypeptide of the invention includes the disclosed sequence and conservative variations thereof. The term "conservative variation" as used herein denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like. The term "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.

DNA sequences of the invention can be obtained by several methods. For example, the DNA can be isolated using hybridization techniques which are well known in the art. These include, but are not limited to: 1) hybridization of genomic or cDNA libraries with probes to detect homologous nucleotide sequences, 2) polymerase chain reaction (PCR) on genomic DNA or cDNA using primers capable of annealing to the DNA sequence of

interest, and 3) antibody screening of expression libraries to detect cloned DNA fragments with shared structural features.

Preferably the GDF-8 polynucleotide of the invention is derived from a mammalian organism, and most preferably from mouse, rat, cow, pig, or human. GDF-8 polynucleotides from chicken, turkey, fish and other species are also included herein. Screening procedures which rely on nucleic acid hybridization make it possible to isolate any gene sequence from any organism, provided the appropriate probe is available. Given the extensive nucleotide and amino acid homology between species, it would be routine for one of skill in the art to obtain polynucleotides encoding GDF-8 from any species. Oligonucleotide probes, which correspond to a part of the sequence encoding the protein in question, can be synthesized chemically. This requires that short, oligopeptide stretches of amino acid sequence must be known. The DNA sequence encoding the protein can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. It is possible to perform a mixed addition reaction when the sequence is degenerate. This includes a heterogeneous mixture of denatured double-stranded DNA. For such screening, hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA. Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present. In other words, by using stringent hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture which is its complete complement (Wallace, *et al., Nucl. Acid Res.* 9:879, 1981).

The development of specific DNA sequences encoding GDF-8 can also be obtained by: 1 ) isolation of double-stranded DNA sequences from the genomic DNA; 2) chemical manufacture of a DNA sequence to provide the necessary codons for the polypeptide of interest; and 3) *in vitro* synthesis of a doublestranded DNA sequence by reverse transcription of mRNA isolated from a eukaryotic donor cell. In the latter case, a

double-stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA.

Of the three above-noted methods for developing specific DNA sequences for use in recombinant procedures, the isolation of genomic DNA isolates is the least common. This is especially true when it is desirable to obtain the microbial expression of mammalian polypeptides due to the presence of introns.

The synthesis of DNA sequences is frequently the method of choice when the entire sequence of amino acid residues of the desired polypeptide product is known. When the entire sequence of amino acid residues of the desired polypeptide is not known, the direct synthesis of DNA sequences is not possible and the method of choice is the synthesis of cDNA sequences. Among the standard procedures for isolating cDNA sequences of interest is the formation of plasmid- or phage-carrying cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction technology, even rare expression products can be cloned. In those cases where significant portions of the amino acid sequence of the polypeptide are known, the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA may be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single-stranded form (Jay, *et al., Nucl. Acid Res.*, 11:2325, 1983).

A cDNA expression library, such as lambda gt11, can be screened indirectly for GDF-8 peptides having at least one epitope, using antibodies specific for GDF-8. Such antibodies can be either polyclonally or monoclonally derived and used to detect expression product indicative of the presence of GDF-8 cDNA.

In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition

(*e.g.*, GC v. AT content), and nucleic acid type (*e.g.*, RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.

An example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2 x SSC/0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C (high stringency conditions). Washing can be carried out using only one of these conditions, *e.g.*, high stringency conditions, or each of the conditions can be used, *e.g.*, for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically.

DNA sequences encoding GDF-8 can be expressed *in vitro* by DNA transfer into a suitable host cell. "Host cells" are cells in which a vector can be propagated and its DNA expressed. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell" is used. Methods of stable transfer, meaning that the foreign DNA is continuously maintained in the host, are known in the art.

In the present invention, the GDF-8 polynucleotide sequences may be inserted into a recombinant expression vector. The term "recombinant expression vector" refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of the GDF-8 genetic sequences. Such expression vectors contain a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host. The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the present invention include, but are not limited

to the T7-based expression vector for expression in bacteria (Rosenberg, *et al.*, *Gene*, 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, *J. Biol. Chem.*, 263:3521, 1988) and baculovirus-derived vectors for expression in insect cells. The DNA segment can be present in the vector operably linked to regulatory elements, for example, a promoter (*e.g.*, T7, metallothionein 1, or polyhedrin promoters).

Polynucleotide sequences encoding GDF-8 can be expressed in either prokaryotes or eukaryotes. Hosts can include microbial, yeast, insect and mammalian organisms. Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art. Such vectors are used to incorporate DNA sequences of the invention. Preferably, the mature C-terminal region of GDF-8 is expressed from a cDNA clone containing the entire coding sequence of GDF-8. Alternatively, the C-terminal portion of GDF-8 can be expressed as a fusion protein with the pro- region of another member of the TGF-β family or co-expressed with another pro-region (see for example, Hammonds, *et al.*, *Molec. Endocrin.*, 5:149, 1991; Gray, A., and Mason, A., *Science*, 247:1328, 1990).

Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as *E. coli*, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the $CaCl_2$ method using procedures well known in the art. Alternatively, $MgCl_2$ or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell if desired.

When the host is a eukaryote, such methods of transfection of DNA as calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be cotransformed with DNA sequences encoding the GDF-8

of the invention, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. (see for example, *Eukaryotic Viral Vectors*, Cold Spring Harbor Laboratory, Gluzman ed., 1982).

Isolation and purification of microbial expressed polypeptide, or fragments thereof, provided by the invention, may be carried out by conventional means including preparative chromatography and immunological separations involving monoclonal or polyclonal antibodies.

***GDF-8 Antibodies and Methods of Use***

The invention includes antibodies immunoreactive with GDF-8 polypeptide or functional fragments thereof. Antibody which consists essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations are provided. Monoclonal antibodies are made from antigen containing fragments of the protein by methods well known to those skilled in the art (Kohler, *et al., Nature*, 256:495, 1975). The term antibody as used in this invention is meant to include intact molecules as well as fragments thereof, such as Fab and $F(ab')_2$, Fv and SCA fragments which are capable of binding an epitopic determinant on GDF-8.

(1) An Fab fragment consists of a monovalent antigen-binding fragment of an antibody molecule, and can be produced by digestion of a whole antibody molecule with the enzyme papain, to yield a fragment consisting of an intact light chain and a portion of a heavy chain.

(2) An Fab' fragment of an antibody molecule can be obtained by treating a whole antibody molecule with pepsin, followed by reduction, to yield a molecule consisting of an intact light chain and a portion of a heavy chain. Two Fab' fragments are obtained per antibody molecule treated in this manner.

(3) An $(Fab')_2$ fragment of an antibody can be obtained by treating a whole antibody molecule with the enzyme pepsin, without subsequent reduction. A $(Fab')_2$ fragment is a dimer of two Fab' fragments, held together by two disulfide bonds.

(4) An Fv fragment is defined as a genetically engineered fragment containing the variable region of a light chain and the variable region of a heavy chain expressed as two chains.

(5) A single chain antibody ("SCA") is a genetically engineered single chain molecule containing the variable region of a light chain and the variable region of a heavy chain, linked by a suitable, flexible polypeptide linker.

As used in this invention, the term "epitope" refers to an antigenic determinant on an antigen, such as a GDF-8 polypeptide, to which the paratope of an antibody, such as an GDF-8-specific antibody, binds. Antigenic determinants usually consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and can have specific three-dimensional structural characteristics, as well as specific charge characteristics.

As is mentioned above, antigens that can be used in producing GDF-8-specific antibodies include GDF-8 polypeptides or GDF-8 polypeptide fragments. The polypeptide or peptide used to immunize an animal can be obtained by standard recombinant, chemical synthetic, or purification methods. As is well known in the art, in order to increase immunogenicity, an antigen can be conjugated to a carrier protein. Commonly used carriers include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid. The coupled peptide is then used to immunize the animal (*e.g.*, a mouse, a rat, or a rabbit). In addition to such carriers, well known adjuvants can be administered with the antigen to facilitate induction of a strong immune response.

The term "cell-proliferative disorder" denotes malignant as well as non-malignant cell populations which often appear to differ from the surrounding tissue both morphologi-

cally and genotypically. Malignant cells (*i.e.* cancer) develop as a result of a multistep process. The GDF-8 polynucleotide that is an antisense molecule or that encodes a dominant negative GDF-8 is useful in treating malignancies of the various organ systems, particularly, for example, cells in muscle or adipose tissue. Essentially, any disorder which is etiologically linked to altered expression of GDF-8 could be considered susceptible to treatment with a GDF-8 agent (*e.g.*, a suppressing or enhancing agent). One such disorder is a malignant cell proliferative disorder, for example.

The invention provides a method for detecting a cell proliferative disorder of muscle or adipose tissue which comprises contacting an anti-GDF-8 antibody with a cell suspected of having a GDF-8 associated disorder and detecting binding to the antibody. The antibody reactive with GDF-8 is labeled with a compound which allows detection of binding to GDF-8. For purposes of the invention, an antibody specific for GDF-8 polypeptide may be used to detect the level of GDF-8 in biological fluids and tissues. Any specimen containing a detectable amount of antigen can be used. A preferred sample of this invention is muscle tissue. The level of GDF-8 in the suspect cell can be compared with the level in a normal cell to determine whether the subject has a GDF-8-associated cell proliferative disorder. Such methods of detection are also useful using nucleic acid hybridization to detect the level of GDF-8 mRNA in a sample or to detect an altered GDF-8 gene. Preferably the subject is human.

The antibodies of the invention can be used in any subject in which it is desirable to administer *in vitro* or *in vivo* immunodiagnosis or immunotherapy. The antibodies of the invention are suited for use, for example, in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier. In addition, the antibodies in these immunoassays can be detectably labeled in various ways. Examples of types of immunoassays which can utilize antibodies of the invention are competitive and non-competitive immunoassays in either a direct or indirect format. Examples of such immunoassays are the radioimmunoassay (RIA) and the sandwich (immunometric) assay. Detection of the antigens using the antibodies of the invention can be done utilizing immunoassays which are run in either the forward, reverse, or simultaneous modes,

including immunohistochemical assays on physiological samples. Those of skill in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

The antibodies of the invention can be bound to many different carriers and used to detect the presence of an antigen comprising the polypeptide of the invention. Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetite. The nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding antibodies, or will be able to ascertain such, using routine experimentation.

There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the present invention include enzymes, radioisotopes, fluorescent compounds, colloidal metals, chemiluminescent compounds, phosphorescent compounds, and bioluminescent compounds. Those of ordinary skill in the art will know of other suitable labels for binding to the antibody, or will be able to ascertain such, using routine experimentation.

Another technique which may also result in greater sensitivity consists of coupling the antibodies to low molecular weight haptens. These haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as biotin, which reacts with avidin, or dinitrophenyi, puridoxal, and fluorescein, which can react with specific antihapten antibodies.

In using the monoclonal antibodies of the invention for the *in vivo* detection of antigen, the detectably labeled antibody is given a dose which is diagnostically effective. The term "diagnostically effective" means that the amount of detectably labeled monoclonal antibody is administered in sufficient quantity to enable detection of the site having the antigen comprising a polypeptide of the invention for which the monoclonal antibodies are specific.

The concentration of detectably labeled monoclonal antibody which is administered should be sufficient such that the binding to those cells having the polypeptide is detectable compared to the background. Further, it is desirable that the detectably labeled monoclonal antibody be rapidly cleared from the circulatory system in order to give the best target-to-background signal ratio.

As a rule, the dosage of detectably labeled monoclonal antibody for *in vivo* diagnosis will vary depending on such factors as age, sex, and extent of disease of the individual. Such dosages may vary, for example, depending on whether multiple injections are given, antigenic burden, and other factors known to those of skill in the art.

For *in vivo* diagnostic imaging, the type of detection instrument available is a major factor in selecting a given radioisotope. The radioisotope chosen must have a type of decay which is detectable for a given type of instrument. Still another important factor in selecting a radioisotope for *in vivo* diagnosis is that deleterious radiation with respect to the host is minimized. Ideally, a radioisotope used for *in vivo* imaging will lack a particle emission, but produce a large number of photons in the 140-250 keV range, which may readily be detected by conventional gamma cameras.

For *in vivo* diagnosis radioisotopes may be bound to immunoglobulin either directly or indirectly by using an intermediate functional group. intermediate functional groups which often are used to bind radioisotopes which exist as metallic ions to immunoglobulins are the bifunctional chelating agents such as diethylenetriaminepentacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) and similar molecules. Typical examples of metallic ions which can be bound to the monoclonal antibodies of the invention are $^{111}In$,$^{97}Ru$,$^{67}Ga$,$^{68}Ga$, $^{72}As$,$^{89}Zr$ and $^{201}Tl$.

The monoclonal antibodies of the invention can also be labeled with a paramagnetic isotope for purposes of *in vivo* diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR). In general, any conventional method for visualizing diagnostic imaging can be utilized. Usually gamma and positron emitting radioisotopes

are used for camera imaging and paramagnetic isotopes for MRI. Elements which are particularly useful in such techniques include $^{157}Gd$,$^{55}Mn$, $^{162}Dy$,$^{52}Cr$, and $^{56}Fe$.

The monoclonal antibodies of the invention can be used *in vitro* and *in vivo* to monitor the course of amelioration of a GDF-8-associated disease in a subject. Thus, for example, by measuring the increase or decrease in the number of cells expressing antigen comprising a polypeptide of the invention or changes in the concentration of such antigen present in various body fluids, it would be possible to determine whether a particular therapeutic regimen aimed at ameliorating the GDF-8-associated disease is effective. The term "ameliorate" denotes a lessening of the detrimental effect of the GDF-8-associated disease in the subject receiving therapy.

***Additional Methods of Treatment and Diagnosis***

The present invention identifies a nucleotide sequence that can be expressed in an altered manner as compared to expression in a normal cell, therefore it is possible to design appropriate therapeutic or diagnostic techniques directed to this sequence. Treatment includes administration of a reagent which modulates activity. The term "modulate" envisions the suppression or expression of GDF-8 when it is over-expressed, or augmentation of GDF-8 expression when it is underexpressed. When a muscle-associated disorder is associated with GDF-8 overexpression, such suppressive reagents as antisense GDF-8 polynucleotide sequence, dominant negative sequences or GDF-8 binding antibody can be introduced into a cell. In addition, an anti-idiotype antibody which binds to a monoclonal antibody which binds GDF-8 of the invention, or an epitope thereof, may also be used in the therapeutic method of the invention. Alternatively, when a cell proliferative disorder is associated with underexpression or expression of a mutant GDF-8 polypeptide, a sense polynucleotide sequence (the DNA coding strand) or GDF-8 polypeptide can be introduced into the cell. Such muscle-associated disorders include cancer, muscular dystrophy, spinal cord injury, traumatic injury, congestive obstructive pulmonary disease (COPD), AIDS or cachecia. One of skill in the art can determine whether or not a particular therapeutic course of treatment is successful by several methods described herein (e.g., muscle fiber analysis or biopsy). Neurodegenerative

disorders are also envisioned as treated by the method of the invention. In addition, the method of the invention can be used in the treatment of obesity or of disorders related to abnormal proliferation of adipocytes. One of skill in the art can determine whether or not a particular therapeutic course of treatment is successful by several methods described herein (*e.g.*, muscle fiber analysis or biopsy; determination of fat content). The present examples demonstrate that the methods of the invention are useful for decreasing fat content, and therefore would be useful in the treatment of obesity and related disorders (e.g., diabetes). Neurodegenerative disorders are also envisioned as treated by the method of the invention.

Thus, where a cell-proliferative disorder is associated with the expression of GDF-8, nucleic acid sequences that interfere with GDF-8 expression at the translational level can be used. This approach utilizes, for example, antisense nucleic acid and ribozymes to block translation of a specific GDF-8 mRNA, either by masking that mRNA with an antisense nucleic acid or by cleaving it with a ribozyme. Such disorders include neurodegenerative diseases, for example. In addition, dominant-negative GDF-8 mutants would be useful to actively interfere with function of "normal" GDF-8.

Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (Weintraub, *Scientific American*, 262:40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule. The antisense nucleic acids interfere with the translation of the mRNA, since the cell will not translate a mRNA that is double-stranded.

Antisense oligomers of about 15 nucleotides are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target GDF-8-producing cell. The use of antisense methods to inhibit the *in vitro* translation of genes is well known in the art (Marcus-Sakura, *Anal. Biochem.*, 172:289, 1988).

Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA in a manner analogous to DNA restriction endonucleases. Through the modification of nucleotide sequences which encode these RNAs, it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, *J. Amer. Med. Assn.*, 260:3030, 1988). A major advantage of this approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.

There are two basic types of ribozymes namely, tetrahymena-type (Hasselhoff, *Nature*, 334:585, 1988) and "hammerhead"-type. Tetrahymena-type ribozymes recognize sequences which are four bases in length, while "hammerhead"-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the greater the likelihood that the sequence will occur exclusively in the target mRNA species. Consequently, hammerhead-type ribozymes are preferable to tetrahymena-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences are preferable to shorter recognition sequences.

In another embodiment of the present invention, a nucleotide sequence encoding a GDF-8 dominant negative protein is provided. For example, a genetic construct that contain such a dominant negative encoding gene may be operably linked to a promoter, such as a tissue-specific promoter. For example, a skeletal muscle specific promoter (*e.g.*, human skeletal muscle α-actin promoter) or developmentally specific promoter (*e.g.*, MyHC 3, which is restricted in skeletal muscle to the embryonic period of development, or an inducible promoter (*e.g.*, the orphan nuclear receptor TIS1).

Such constructs are useful in methods of modulating a subject's skeletal mass. For example, a method include transforming an organism, tissue, organ or cell with a genetic construct encoding a dominant negative GDF-8 protein and suitable promoter in operable linkage and expressing the dominant negative encoding GDF-8 gene, thereby modulating muscle mass by interfering with wild-type GDF-8 activity.

GDF-8 most likely forms dimers, homodimers or heterodimers and may even form heterodimers with other GDF family members, such as GDF-11 (*see* Example 4). Hence, while not wanting to be bound by a particular theory, the dominant negative effect described herein may involve the formation of non-functional homodimers or heterodimers of dominant negative and wild-type GDF-8 monomers. More specifically, it is possible that any non-functional homodimer or any heterodimer formed by the dimerization of wild-type and/or dominant negative GDF-8 monomers produces a dominant effect by: 1) being synthesized but not processed or secreted; 2) inhibiting the secretion of wild type GDF-8; 3) preventing normal proteolytic cleavage of the preprotein thereby producing a nonfunctional GDF-8 molecule; 4) altering the affinity of the non-functional dimer (e.g., homodimeric or heterodimeric GDF-8) to a receptor or generating an antagonistic form of GDF-8 that binds a receptor without activating it; or 5) inhibiting the intracellular processing or secretion of GDF-8 related or TGF-ß family proteins.

Non-functional GDF-8 can function to inhibit the growth regulating actions of GDF-8 on muscle cells that include a dominant negative GDF-8 gene. Deletion or missense dominant negative forms of GDF-8 that retain the ability to form dimers with wild- type GDF-8 protein but do not function as wild-type GDF-8 proteins may be used to inhibit the biological activity of endogenous wild- type GDF-8. For example, in one embodiment, the proteolytic processing site of GDF-8 may be altered (*e.g.*, deleted) resulting in a GDF-8 molecule able to undergo subsequent dimerization with endogenous wild-type GDF-8 but unable to undergo further processing into a mature GDF-8 form. Alternatively, a non-functional GDF-8 can function as a monomeric species to inhibit the growth regulating actions of GDF-8 on muscle cells.

Any genetic recombinant method in the art may be used, for example, recombinant viruses may be engineered to express a dominant negative form of GDF-8 which may be used to inhibit the activity of wild-type GDF-8. Such viruses may be used therapeutically for treatment of diseases resulting from aberrant over-expression or activity of GDF-8 protein, such as in denervation hypertrophy or as a means of

controlling GDF-8 expression when treating disease conditions involving muscle, such as in musculodegenerative diseases or in tissue repair due to trauma or in modulating GDF-8 expression in animal husbandry (*e.g.*, transgenic animals for agricultural purposes).

The invention provides a method for treating a muscle or adipose tissue disorder in a subject. The method includes administering a therapeutically effective amount of a GDF-8 agent to the subject, thereby inhibiting abnormal growth of muscle or adipose tissue. The GDF-8 agent may include a GDF-8 antisense molecule or a dominant negative polypeptide, for example. A "therapeutically effective amount" of a GDF-8 agent is that amount that ameliorates symptoms of the disorder or inhibits GDF-8 induced growth of muscle, for example, as compared with a normal subject.

***Gene Therapy***

The present invention also provides gene therapy for the treatment of cell proliferative or immunologic disorders which are mediated by GDF-8 protein. Such therapy would achieve its therapeutic effect by introduction of the GDF-8 antisense or dominant negative encoding polynucleotide into cells having the proliferative disorder. Delivery of antisense or dominant negative GDF-8 polynucleotide can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system. Especially preferred for therapeutic delivery of antisense or dominant negative sequences is the use of targeted liposomes. In contrast, when it is desirable to enhance GDF-8 production, a "sense" GDF-8 polynucleotide or functional equivalent (*e.g.*, the C-term active region) is introduced into the appropriate cell(s).

Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV).

A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. By inserting a GDF-8 sequence of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target specific. Retroviral vectors can be made target specific by attaching, for example, a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral vector. Those of skill in the art will know of, or can readily ascertain without undue experimentation, specific polynucleotide sequences which can be inserted into the retroviral genome or attached to a viral envelope to allow target specific delivery of the retroviral vector containing the GDF-8 antisense polynucleotide.

Since recombinant retroviruses are defective, they require assistance in order to produce infectious vector particles. This assistance can be provided, for example, by using helper cell lines that contain plasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR. These plasmids are missing a nucleotide sequence which enables the packaging mechanism to recognize an RNA transcript for encapsulation. Helper cell lines which have deletions of the packaging signal include, but are not limited to ψ2, PA317 and PA12, for example. These cell lines produce empty virions, since no genome is packaged. If a retroviral vector is introduced into such cells in which the packaging signal is intact, but the structural genes are replaced by other genes of interest, the vector can be packaged and vector virion produced.

Alternatively, NIH 3T3 or other tissue culture cells can be directly transfected with plasmids encoding the retroviral structural genes gag, pol and env, by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.

Another targeted delivery system for GDF-8 polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are useful as delivery vehicles *in vitro* and *in vivo*. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2-4.0 μm can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, *et al., Trends Biochem. Sci.*, 6:77, 1981). In addition to mammalian cells, liposomes have been used for delivery of polynucleotides in plant, yeast and bacterial cells. in order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes of interest at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (Manning, *et al., Biotechniques*, 6:682, 1988).

The composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidyiglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are diacylphosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated. Illustrative

phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

The targeting of liposomes can be classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific. Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.

The surface of the targeted delivery system may be modified in a variety of ways. In the case of a liposomal targeted delivery system, lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer. Various linking groups can be used for joining the lipid chains to the targeting ligand.

Due to the expression of GDF-8 in muscle and adipose tissue, there are a variety of applications using the polypeptide, polynucleotide, and antibodies of the invention, related to these tissues. Such applications include treatment of cell proliferative disorders involving these and other tissues, such as neural tissue. In addition, GDF-8 may be useful in various gene therapy procedures. In embodiments where GDF-8 polypeptide is administered to a subject, the dosage range is about 0.1 ug/kg to 100 mg/kg; more preferably from about 1 ug/kg to 75 mg/kg and most preferably from about 10 mg/kg to 50 mg/kg.

***Chromosomal Location of GDF-8***

The data in Example 6 shows that the human GDF-8 gene is located on chromosome 2. By comparing the chromosomal location of GDF-8 with the map positions of various human disorders, it should be possible to determine whether mutations in the GDF-8 gene are involved in the etiology of human diseases. For example, an autosomal recessive form of juvenile amyotrophic lateral sclerosis has been shown to map to chromosome 2 (Hentati, *et al., Neurology*, 42 [Suppl.3]:201, 1992). More precise mapping of GDF-8 and analysis of DNA from these patients may indicate that GDF-8 is, in fact, the gene affected in this disease. In addition, GDF-8 is useful for distinguishing chromosome 2 from other chromosomes.

***Transgenic Animals and Methods of Making the same***

Various methods to make the transgenic animals of the subject invention can be employed. Generally speaking, three such methods may be employed. In one such method, an embryo at the pronuclear stage (a "one cell embryo") is harvested from a female and the transgene is microinjected into the embryo, in which case the transgene will be chromosomally integrated into both the germ cells and somatic cells of the resulting mature animal. In another such method, embryonic stem cells are isolated and the transgene incorporated therein by electroporation, plasmid transfection or microinjection, followed by reintroduction of the stem cells into the embryo where they colonize and contribute to the germ line. Methods for microinjection of mammalian species is described in United States Patent No. 4,873,191. In yet another such method, embryonic cells are infected with a retrovirus containing the transgene whereby the germ cells of the embryo have the transgene chromosomally integrated therein. When the animals to be made transgenic are avian, because avian fertilized ova generally go through cell division for the first twenty hours in the oviduct, microinjection into the pronucleus of the fertilized egg is problematic due to the inaccessibility of the pronucleus. Therefore, of the methods to make transgenic animals described generally above, retrovirus infection is preferred for avian species, for example as described in U.S. 5,162,215. If microinjection is to be used with avian species, however, a recently published procedure by Love *et al.*, (Biotechnology, 12, Jan 1994) can be utilized

whereby the embryo is obtained from a sacrificed hen approximately two and one-half hours after the laying of the previous laid egg, the transgene is microinjected into the cytoplasm of the germinal disc and the embryo is cultured in a host shell until maturity. When the animals to be made transgenic are bovine or porcine, microinjection can be hampered by the opacity of the ova thereby making the nuclei difficult to identify by traditional differential interference-contrast microscopy. To overcome this problem, the ova can first be centrifuged to segregate the pronuclei for better visualization.

The "non-human animals" of the invention bovine, porcine, ovine and avian animals (*e.g.*, cow, pig, sheep, chicken, turkey). The "transgenic non-human animals" of the invention are produced by introducing "transgenes" into the germline of the non-human animal. Embryonal target cells at various developmental stages can be used to introduce transgenes. Different methods are used depending on the stage of development of the embryonal target cell. The zygote is the best target for micro-injection. The use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incorporated into the host gene before the first cleavage (Brinster *et al., Proc. Natl. Acad. Sci. USA* 82:4438-4442, 1985). As a consequence, all cells of the transgenic non-human animal will carry the incorporated transgene. This will in general also be reflected in the efficient transmission of the transgene to offspring of the founder since 50% of the germ cells will harbor the transgene.

The term "transgenic" is used to describe an animal which includes exogenous genetic material within all of its cells. A "transgenic" animal can be produced by cross-breeding two chimeric animals which include exogenous genetic material within cells used in reproduction. Twenty-five percent of the resulting offspring will be transgenic *i.e.*, animals which include the exogenous genetic material within all of their cells in both alleles. 50% of the resulting animals will include the exogenous genetic material within one allele and 25% will include no exogenous genetic material.

In the microinjection method useful in the practice of the subject invention, the transgene is digested and purified free from any vector DNA *e.g.* by gel electrophoresis. It is

preferred that the transgene include an operatively associated promoter which interacts with cellular proteins involved in transcription, ultimately resulting in constitutive expression. Promoters useful in this regard include those from cytomegalovirus (CMV), Moloney leukemia virus (MLV), and herpes virus, as well as those from the genes encoding metallothionin, skeletal actin, P-enolpyruvate carboxylase (PEPCK), phosphoglycerate (PGK), DHFR, and thymidine kinase. Promoters for viral long terminal repeats (LTRs) such as Rous Sarcoma Virus can also be employed. When the animals to be made transgenic are avian, preferred promoters include those for the chicken β-globin gene, chicken lysozyme gene, and avian leukosis virus. Constructs useful in plasmid transfection of embryonic stem cells will employ additional regulatory elements well known in the art such as enhancer elements to stimulate transcription, splice acceptors, termination and polyadenylation signals, and ribosome binding sites to permit translation.

Retroviral infection can also be used to introduce transgene into a non-human animal, as described above. The developing non-human embryo can be cultured *in vitro* to the blastocyst stage. During this time, the blastomeres can be targets for retro viral infection (Jaenich, R., Proc. Natl. Acad. Sci USA 73:1260-1264, 1976). Efficient infection of the blastomeres is obtained by enzymatic treatment to remove the zona pellucida (Hogan, *et al.* (1986) in Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). The viral vector system used to introduce the transgene is typically a replication-defective retro virus carrying the transgene (Jahner, *et al., Proc. Natl. Acad. Sci. USA* 82:6927-6931, 1985; Van der Putten, *et al., Proc. Natl. Acad. Sci USA* 82:6148-6152, 1985). Transfection is easily and efficiently obtained by culturing the blastomeres on a monolayer of virus-producing cells (Van der Putten, *supra*; Stewart, *et al., EMBO J.* 6:383-388, 1987). Alternatively, infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele (D. Jahner *et al., Nature* 298:623-628, 1982). Most of the founders will be mosaic for the transgene since incorporation occurs only in a subset of the cells which formed the transgenic nonhuman animal. Further, the founder may contain various retro viral insertions of the transgene at different positions in the genome which generally will segregate in the offspring. In

addition, it is also possible to introduce transgenes into the germ line, albeit with low efficiency, by intrauterine retroviral infection of the midgestation embryo (D. Jahner *et al., supra*).

A third type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells are obtained from pre-implantation embryos cultured *in vitro* and fused with embryos (M. J. Evans *et al. Nature* 292:154-156, 1981; M.O. Bradley *et al., Nature* 309: 255-258, 1984; Gossler, *et al., Proc. Natl. Acad. Sci USA* 83: 9065-9069, 1986; and Robertson *et al., Nature* 322:445-448, 1986). Transgenes can be efficiently introduced into the ES cells by DNA transfection or by retro virus-mediated transduction. Such transformed ES cells can thereafter be combined with blastocysts from a nonhuman animal. The ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal. (For review see Jaenisch, R., *Science* 240: 1468-1474, 1988).

"Transformed" means a cell into which (or into an ancestor of which) has been introduced, by means of recombinant nucleic acid techniques, a heterologous nucleic acid molecule. "Heterologous" refers to a nucleic acid sequence that either originates from another species or is modified from either its original form or the form primarily expressed in the cell.

"Transgene" means any piece of DNA which is inserted by artifice into a cell, and becomes part of the genome of the organism (*i.e.*, either stably integrated or as a stable extrachromosomal element) which develops from that cell. Such a transgene may include a gene which is partly or entirely heterologous (*i.e.*, foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism. Included within this definition is a transgene created by the providing of an RNA sequence which is transcribed into DNA and then incorporated into the genome. The transgenes of the invention include DNA sequences which encode GDF-8, and include GDF-sense, antisense, dominant negative encoding polynucleotides, which may be expressed in a transgenic non-human animal. The term "transgenic" as used herein

additionally includes any organism whose genome has been altered by *in vitro* manipulation of the early embryo or fertilized egg or by any transgenic technology to induce a specific gene knockout. The term "gene knockout" as used herein, refers to the targeted disruption of a gene *in vivo* with complete loss of function that has been achieved by any transgenic technology familiar to those in the art. In one embodiment, transgenic animals having gene knockouts are those in which the target gene has been rendered nonfunctional by an insertion targeted to the gene to be rendered non-functional by homologous recombination. As used herein, the term "transgenic" includes any transgenic technology familiar to those in the art which can produce an organism carrying an introduced transgene or one in which an endogenous gene has been rendered non-functional or "knocked out." An example of a transgene used to "knockout" GDF-8 function in the present Examples is described in Example 8 and FIGURE 12a. Thus, in another embodiment, the invention provides a transgene wherein the entire mature C-terminal region of GDF-8 is deleted.

The transgene to be used in the practice of the subject invention is a DNA sequence comprising a modified GDF-8 coding sequence. In a preferred embodiment, the GDF-8 gene is disrupted by homologous targeting in embryonic stem cells. For example, the entire mature C-terminal region of the GDF-8 gene may be deleted as described in the examples below. Optionally, the GDF-8 disruption or deletion may be accompanied by insertion of or replacement with other DNA sequences, such as a non-functional GDF-8 sequence. In other embodiments, the transgene comprises DNA antisense to the coding sequence for GDF-8. In another embodiment, the transgene comprises DNA encoding an antibody or receptor peptide sequence which is able to bind to GDF-8. The DNA and peptide sequences of GDF-8 are known in the art, the sequences, localization and activity disclosed in WO94/21681 and pending United States patent application 08/033,923, filed on March 19, 1993, incorporated by reference in its entirety. The disclosure of both of these applications are hereby incorporated herein by reference. Where appropriate, DNA sequences that encode proteins having GDF-8 activity but differ in nucleic acid sequence due to the degeneracy of the genetic code may also be used herein, as may truncated forms, allelic variants and interspecies homologues.

The invention also includes animals having heterozygous mutations in GDF-8 or partial inhibition of GDF-8 function or expression. A heterozygote would exhibit an intermediate increase in muscle mass as compared to the homozygote as shown in Table 4 below. In other words, partial loss of function leads to a partial increase in muscle mass. One of skill in the art would readily be able to determine if a particular mutation or if an antisense molecule was able to partially inhibit GDF-8. For example, *in vitro* testing may be desirable initially by comparison with wild-type or untreated GDF-8 (*e.g.*, comparison of northern blots to examine a decrease in expression).

After an embryo has been microinjected, colonized with transfected embryonic stem cells or infected with a retrovirus containing the transgene (except for practice of the subject invention in avian species which is addressed elsewhere herein) the embryo is implanted into the oviduct of a pseudopregnant female. The consequent progeny are tested for incorporation of the transgene by Southern blot analysis of blood samples using transgene specific probes. PCR is particularly useful in this regard. Positive progeny (G0) are crossbred to produce offspring (G1) which are analyzed for transgene expression by Northern blot analysis of tissue samples. To be able to distinguish expression of like-species transgenes from expression of the animals endogenous GDF-8 gene(s), a marker gene fragment can be included in the construct in the 3' untranslated region of the transgene and the Northern probe designed to probe for the marker gene fragment. The serum levels of GDF-8 can also be measured in the transgenic animal to establish appropriate expression. Expression of the GDF-8 transgenes, thereby decreasing the GDF-8 in the tissue and serum levels of the transgenic animals and consequently increasing the muscle tissue content results in the foodstuffs from these animals (*i.e.* eggs, beef, pork, poultry meat, milk, *etc.*) having markedly increased muscle content, and preferably without increased, and more preferably, reduced levels of fat and cholesterol. By practice of the subject invention, a statistically significant increase in muscle content, preferably at least a 2% increase in muscle content (*e.g.*, in chickens), more preferably a 25% increase in muscle content as a percentage of body weight, more preferably greater than 40% increase in muscle content in these foodstuffs can be obtained.

***Additional Methods of Use***

Thus, the present invention includes methods for increasing muscle mass in domesticated animals, characterized by inactivation or deletion of the gene encoding growth and differentiation factor-8 (GDF-8). The domesticated animal is preferably selected from the group consisting of ovine, bovine, porcine, piscine and avian. The animal may be treated with an isolated polynucleotide sequence encoding growth and differentiation factor-8 which polynucleotide sequence is also from a domesticated animal selected from the group consisting of ovine, bovine, porcine, piscine and avian. The present invention includes methods for increasing the muscle mass in domesticated animals characterized by administering to a domesticated animal monoclonal antibodies directed to the GDF-8 polypeptide. The antibody may be an anti-GDF-8, and may be either a monoclonal antibody or a polyclonal antibody.

The invention includes methods comprising using an anti-GDF-8 monoclonal antibody, antisense, or dominant negative mutants as a therapeutic agent to inhibit the growth regulating actions of GDF-8 on muscle cells. Muscle cells are defined to include fetal or adult muscle cells, as well as progenitor cells which are capable of differentiation into muscle. The monoclonal antibody may be a humanized (*e.g.*, either fully or a chimeric) monoclonal antibody, of any species origin, such as murine, ovine, bovine, porcine or avian. Methods of producing antibody molecules with various combinations of "humanized" antibodies are well known in the art and include combining murine variable regions with human constant regions (Cabily, *et al. Proc.Natl.Acad.Sci. USA*, 81:3273, 1984), or by grafting the murine-antibody complementary determining regions (CDRs) onto the human framework (Richmann, *et al., Nature* 332:323, 1988). Other general references which teach methods for creating humanized antibodies include Morrison, *et al., Science,* 229:1202, 1985; Jones, *et al., Nature,* 321:522, 1986; Monroe, *et al., Nature* 312:779, 1985; Oi, *et al., BioTechniques*, 4:214, 1986; European Patent Application No. 302,620; and U.S. Patent No. 5,024,834. Therefore, by humanizing the monoclonal antibodies of the invention for *in vivo* use, an immune response to the antibodies would be greatly reduced.

The monoclonal antibody, GDF-8 polypeptide, or GDF-8 polynucleotide (all "GDF-8 agents") may have the effect of increasing the development of skeletal muscles. In preferred embodiments of the claimed methods, the GDF-8 monoclonal antibody, polypeptide, or polynucleotide is administered to a patient suffering from a disorder selected from the group consisting of muscle wasting disease, neuromuscular disorder, muscle atrophy or aging. The GDF-8 agent may also be administered to a patient suffering from a disorder selected from the group consisting of muscular dystrophy, spinal cord injury, traumatic injury, congestive obstructive pulmonary disease (COPD), AIDS or cachechia. In a preferred embodiment, the GDF-8 agent is administered to a patient with muscle wasting disease or disorder by intravenous, intramuscular or subcutaneous injection; preferably, a monoclonal antibody is administered within a dose range between about 0.1 mg/kg to about 100 mg/kg; more preferably between about 1 ug/kg to 75 mg/kg; most preferably from about 10 mg/kg to 50 mg/kg. The antibody may be administered, for example, by bolus injunction or by slow infusion. Slow infusion over a period of 30 minutes to 2 hours is preferred. The GDF-8 agent may be formulated in a formulation suitable for administration to a patient. Such formulations are known in the art.

The dosage regimen will be determined by the attending physician considering various factors which modify the action of the GDF-8 protein, *e.g.* amount of tissue desired to be formed, the site of tissue damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and the types of agent, such as anti-GDF-8 antibodies, to be used in the composition. Generally, systemic or injectable administration, such as intravenous (IV), intramuscular (IM) or subcutaneous (Sub-Q) injection. Administration will generally be initiated at a dose which is minimally effective, and the dose will be increased over a preselected time course until a positive effect is observed. Subsequently, incremental increases in dosage will be made limiting such incremental increases to such levels that produce a corresponding increase in effect, while taking into account any adverse affects that may appear. The addition of other known growth

factors, such as IGF I (insulin like growth factor I), human, bovine, or chicken growth hormone which may aid in increasing muscle mass, to the final composition, may also affect the dosage. In the embodiment where an anti-GDF-8 antibody is administered, the anti-GDF-8 antibody is generally administered within a dose range of about 0.1 ug/kg to about 100 mg/kg.; more preferably between about 10 mg/kg to 50 mg/kg.

Progress can be monitored by periodic assessment of tissue growth and/or repair. The progress can be monitored, for example, x-rays, histomorphometric determinations and tetracycline labeling.

***Screening for GDF-8 Modulating Compounds***

In another embodiment, the invention provides a method for identifying a compound or molecule that modulates GDF-8 protein activity or gene expression. The method includes incubating components comprising the compound, GDF-8 polypeptide or with a recombinant cell expressing GDF-8 polypeptide, under conditions sufficient to allow the components to interact and determining the effect of the compound on GDF-8 activity or expression. The effect of the compound on GDF-8 activity can be measured by a number of assays, and may include measurements before and after incubating in the presence of the compound. Compounds that affect GDF-8 activity or gene expression include peptides, peptidomimetics, polypeptides, chemical compounds and biologic agents. Assays include Northern blot analysis of GDF-8 mRNA (for gene expression), Western blot analysis (for protein level) and muscle fiber analysis (for protein activity).

The above screening assays may be used for detecting the compounds or molecules that bind to the GDF-8 receptor or GDF-8 polypeptide, in isolating molecules that bind to the GDF-8 gene, for measuring the amount of GDF-8 in a sample, either polypeptide or RNA (mRNA), for identifying molecules that may act as agonists or antagonists, and the like. For example, GDF-8 antagonists are useful for treatment of muscular and adipose tissue disorders (e.g., obesity).

Incubating includes conditions which allow contact between the test compound and GDF-8 polypeptide or with a recombinant cell expressing GDF-8 polypeptide. Contacting includes in solution and in solid phase, or in a cell. The test compound may optionally be a combinatorial library for screening a plurality of compounds. Compounds identified in the method of the invention can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a specific DNA sequence such as PCR, oligomer restriction (Saiki, *et al., Bio/Technology*, 3:1008-1012, 1985), allele-specific oligonucleotide (ASO) probe analysis (Conner, *et al., Proc. Natl. Acad. Sci. USA*, 80:278, 1983), oligonucleotide Landegren, *et al., Science*, 241:1077, 1988), and the like. Molecular techniques for DNA analysis have been reviewed (Landegren, *et al., Science*, 242:229-237, 1988).

All references cited herein are hereby incorporated by reference in their entirety.

The following examples are intended to illustrate but not limit the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be used.

## EXAMPLE 1
## IDENTIFICATION AND ISOLATION OF A NOVEL TGF-β FAMILY MEMBER

To identify a new member of the TGF-β superfamily, degenerate oligonucleotides were designed which corresponded to two conserved regions among the known family members: one region spanning the two tryptophan residues conserved in all family members except MIS and the other region spanning the invariant cysteine residues near the C-terminus. These primers were used for polymerase chain reactions on mouse genomic DNA followed by subcloning the PCR products using restriction sites placed at the 5' ends of the primers, picking individual *E. coli* colonies carrying these subcloned

inserts, and using a combination of random sequencing and hybridization analysis to eliminate known members of the superfamily.

GDF-8 was identified from a mixture of PCR products obtained with the primers

SJL141: 5'-CCGGAATTCGGITGG(G/C/A)A(G/A/T/C)(A/G)A(T/C)TGG(A/G)TI (A/G)TI(T/G)CICC-3' (SEQ ID NO:1)

SJL147:

5'-CCGGAATTC(G/A)CAI(G/C)C(G/A)CA(G/A)CT(GIA/T/C) TCIACI(G/A)(T/C)CAT-3' (SEQ ID NO:2)

PCR using these primers was carried out with 2 μg mouse genomic DNA at 94°C for 1 min, 50°C for 2 min, and 72°C for 2 min for 40 cycles.

PCR products of approximately 280 bp were gel-purified, digested with Eco RI, gel-purified again, and subcloned in the Bluescript vector (Stratagene, San Diego, CA). Bacterial colonies carrying individual subclones were picked into 96 well microtiter plates, and multiple replicas were prepared by plating the cells onto nitrocellulose. The replicate filters were hybridized to probes representing known members of the family, and DNA was prepared from nonhybridizing colonies for sequence analysis.

The primer combination of SJL141 and SJL147, encoding the amino acid sequences GW(H/Q/N/K/D/E)(D/N)W(V/I/M)(V/I/M)(A/S)P (SEQ ID NO:9) and M(V/I/M/T/A)V(D/E)SC(G/A)C (SEQ ID NO:10), respectively, yielded four previously identified sequences (BMP-4, inhibin,βB, GDF-3 and GDF-5) and one novel sequence, which was designated GDF-8, among 110 subclones analyzed.

Human GDF-8 was isolated using the primers:

ACM13: 5'-CGCGGATCCAGAGTCAAGGTGACAGACACAC-3' (SEQ ID NO:3); and

ACM14: 5'-CGCGGATCCTCCTCATGAGCACCCACAGCGGTC-3' (SEQ ID NO:4)

PCR using these primers was carried out with one µg human genomic DNA at 94°C for 1 min, 58°C for 2 min, and 72°C for 2 min for 30 cycles. The PCR product was digested with Bam HI, gel-purified, and subcloned in the Bluescript vector (Stratagene, San Francisco, CA).

## EXAMPLE 2

## EXPRESSION PATTERN AND SEQUENCE OF GDF-8

To determine the expression pattern of GDF-8, RNA samples prepared from a variety of adult tissues were screened by Northern analysis. RNA isolation and Northern analysis were carried out as described previously (Lee, S.J., *Mol. Endocrinol.*, 4:1034, 1990) except that hybridization was carried out in 5X SSPE, 10% dextran sulfate, 50% formamide, 1% SDS, 200 µg/ml salmon DNA, and 0.1% each of bovine serum albumin, ficoll, and polyvinylpyrrolidone. Five micrograms of twice poly A-selected RNA prepared from each tissue (except for muscle, for which only 2 µg RNA was used) were electrophoresed on formaldehyde gels, blotted, and probed with GDF-8. As shown in FIGURE 1, the GDF-8 probe detected a single mRNA species expressed at highest levels in muscle and at significantly lower levels in adipose tissue.

To obtain a larger segment of the GDF-8 gene, a mouse genomic library was screened with a probe derived from the GDF-8 PCR product. The partial sequence of a GDF-8 genomic clone is shown in FIGURE 2a. The sequence contains an open reading frame corresponding to the predicted C-terminal region of the GDF-8 precursor protein. The predicted GDF-8 sequence contains two potential proteolytic processing sites, which are boxed. Cleavage of the precursor at the second of these sites would generate a mature C terminal fragment 109 amino acids in length with a predicted molecular weight of 12,400. The partial sequence of human GDF-8 is shown in FIGURE 2b. Assuming no PCR-induced errors during the isolation of the human clone, the human and mouse amino acid sequences in this region are 100% identical.

The C-terminal region of GDF-8 following the putative proteolytic processing site shows significant homology to the known members of the TGF-β; superfamily (FIGURE 3). FIGURE 3 shows the alignment of the C-terminal sequences of GDF-8 with the corresponding regions of human GDF-1 (Lee, *Proc. Natl. Acad. Sci. USA*, 88:4250-4254, 1991), human BMP-2 and 4 (Wozney, *et al., Science*, 242:1528-1534, 1988), human Vgr-1 (Celeste, *et al. Proc. Natl. Acad. Sci. USA*, 87:9843-9847, 1990), human OP-1 (Ozkaynak, *et al., EMBO J.*, 9:2085-2093, 1990), human BMP-5 (Celeste, *et al., Proc. Natl. Acad. Sci. USA*, 87:9843-9847, 1990), human BMP-3 (Wozney, *et al., Science*, 242:1528-1534, 1988), human MiS (Cate, *et al. Cell*, 45:685-698,1986), human inhibin alpha, βA, and βB (Mason, *et al., Biochem. Biophys. Res. Commun.*, 135:957-964, 1986), human TGF-β1 (Derynck, *et al., Nature*, 316:701 -705, 1985), humanTGF-R2 (deMartin, *et al., EMBO J.*, 6:3673-3677, 1987), and human TGF-β3 (ten Dijke, *et al., Proc. Natl. Acad. Sci. USA*, 85:4715-4719, 1988). The conserved cysteine residues are boxed. Dashes denote gaps introduced in order to maximize the alignment.

GDF-8 contains most of the residues that are highly conserved in other family members, including the seven cysteine residues with their characteristic spacing. Like the TGF-βs and inhibin βs, GDF-8 also contains two additional cysteine residues. In the case of TGF-β2, these two additional cysteine residues are known to form an intramolecular disulfide bond (Daopin, *et al., Science*, 257:369, 1992; Schlunegger and Grutter, *Nature*, 358:430, 1992).

FIGURE 4 shows the amino acid homologies among the different members of the TGF-β superfamily. Numbers represent percent amino acid identities between each pair calculated from the first conserved cysteine to the C terminus. Boxes represent homologies among highly-related members within particular subgroups. In this region, GDF-8 is most homologous to Vgr-1 (45% sequence identity).

## EXAMPLE 3

## ISOLATION OF cDNA CLONES ENCODING MURINE AND HUMAN GDF-8

In order to isolate full-length cDNA clones encoding murine and human GDF-8, cDNA libraries were prepared in the lambda ZAP II vector (Stratagene) using RNA prepared from skeletal muscle. From 5 μg of twice poly A-selected RNA prepared from murine and human muscle, cDNA libraries consisting of 4.4 million and 1.9 million recombinant phage, respectively, were constructed according to the instructions provided by Stratagene. These libraries were screened without amplification. Library screening and characterization of cDNA inserts were carried out as described previously (Lee, *Mol. Endocrinol.*, 4:1034-1040).

From 2.4 x $10^6$ recombinant phage screened from the murine muscle cDNA library, greater than 280 positive phage were identified using a murine GDF-8 probe derived from a genomic clone, as described in Example 1. The entire nucleotide sequence of the longest cDNA insert analyzed is shown in FIGURE 5a and 5b and SEQ ID NO:11. The 2676 base pair sequence contains a single long open reading frame beginning with a methionine codon at nucleotide 104 and extending to a TGA stop codon at nucleotide 1232. Upstream of the putative initiating methionine codon is an in-frame stop codon at nucleotide 23. The predicted pre-pro-GDF-8 protein is 76 amino acids in length. The sequence contains a core of hydrophobic amino acids at the N-terminus suggestive of a signal peptide for secretion (FIGURE 6a), one potential N-glycosylation site at asparagine 72, a putative RXXR proteolytic cleavage site at amino acids 264-267, and a C-terminal region showing significant homology to the known members of the TGF-β superfamily. Cleavage of the precursor protein at the putative RXXR site would generate a mature C-terminal GDF-8 fragment 109 amino acids in length with a predicted molecular weight of approximately 12,400.

From 1.9 x $10^6$ recombinant phage screened from the human muscle cDNA library, 4 positive phage were identified using a human GDF-8 probe derived by polymerase chain reaction on human genomic DNA. The entire nucleotide sequence of the longest cDNA

insert is shown in FIGURE 5c and 5d and SEQ ID NO:13. The 2743 base pair sequence contains a single long open reading frame beginning with a methionine codon at nucleotide 59 and extending to a TGA stop codon at nucleotide 1184. The predicted pre-pro-GDF-8 protein is 375 amino acids in length. The sequence contains a core of hydrophobic amino acids at the N-terminus suggestive of a signal peptide for secretion (FIGURE 6b), one potential N-glycosylation site at asparagine 71, and a putative RX)(R proteolytic cleavage site at amino acids 263-266. FIGURE 7 shows a comparison of the predicted murine (top) and human (bottom) GDF-8 amino acid sequences. Numbers indicate amino acid position relative to the N-terminus. Identities between the two sequences are denoted by a vertical line. Murine and human GDF-8 are approximately 94% identical in the predicted pro-regions and 100% identical following the predicted RXXR cleavage sites.

## EXAMPLE 4

## DIMERIZATION OF GDF-8

To determine whether the processing signals in the GDF-8 sequence are functional and whether GDF-8 forms dimers like other members of the TGF-ß superfamily, the GDF-8 cDNA was stably expressed in CHO cells. The GDF-8 coding sequence was cloned into the pMSXND expression vector (Lee and Nathans, *J. Biol. Chem.*, 263:3521,(1988) and transfected into CHO cells. Following G418 selection, the cells were selected in 0.2 $\mu$M methotrexate, and conditioned medium from resistant cells was concentrated and electrophoresed on SDS gels. Conditioned medium was prepared by Cell Trends, Inc. (Middletown, MD). For preparation of anti-GDF-8 serum, the C-terminal region of GDF-8 (amino acids 268 to 376) was expressed in bacteria using the RSET vector (Invitrogen, San Diego, CA), purified using a nickle chelate column, and injected into rabbits. All immunizations were carried out by Spring Valley Labs (Woodbine, MD). Western analysis using [$^{125}$I]iodoprotein A was carried out as described (Burnette, W.N., *Anal. Biochem.*, 112:195, 1981). Western analysis of conditioned medium prepared from these cells using an antiserum raised against a bacterially-expressed C-terminal fragment of GDF-8 detected two protein species with apparent molecular weights of approximately

52K and 15K under reducing conditions, consistent with unprocessed and processed forms of GDF-8, respectively. No bands were obtained either with preimmune serum or with conditioned medium from CHO cells transfected with an antisense construct. Under non-reducing conditions, the GDF-8 antiserum detected two predominant protein species with apparent molecular weights of approximately 101K and 25K, consistent with dimeric forms of unprocessed and processed GDF-8, respectively. Hence, like other TGF-ß family members, GDF-8 appears to be secreted and proteolytically processed, and the C-terminal region appears to be capable of forming a disulfide-linked dimer.

## EXAMPLE 5

## PREPARATION OF ANTIBODIES AGAINST GDF-8 AND EXPRESSION OF GDF-8 IN MAMMALIAN CELLS

In order to prepare antibodies against GDF-8, GDF-8 antigen was expressed as a fusion protein in bacteria. A portion of murine GDF-8 cDNA spanning amino acids 268-376 (mature region) was inserted into the pRSET vector (Invitrogen) such that the GDF-8 coding sequence was placed in frame with the initiating methionine codon present in the vector; the resulting construct created an open reading frame encoding a fusion protein with a molecular weight of approximately 16,600. The fusion construct was transformed into BL21 (DE3) (pLysS) cells, and expression of the fusion protein was induced by treatment with isopropylthio-β-galactoside as described (Rosenberg, *et al., Gene*, 56:125-135). The fusion protein was then purified by metal chelate chromatography according to the instructions provided by Invitrogen. A Coomassie blue-stained gel of unpurified and purified fusion proteins is shown in FIGURE 8.

The purified fusion protein was used to immunize both rabbits and chickens. Immunization of rabbits was carried out by Spring Valley Labs (Sykesville, MD), and immunization of chickens was carried out by HRP, Inc. (Denver, PA). Western analysis of sera both from immunized rabbits and from immunized chickens demonstrated the presence of antibodies directed against the fusion protein.

To express GDF-8 in mammalian cells, the murine GDF-8 cDNA sequence from nucleotides 48-1303 was cloned in both orientations downstream of the metallothionein I promoter in the pMSXND expression vector; this vector contains processing signals derived from SV40, a dihydrofolate reductase gene, and a gene conferring resistance to the antibiotic G418 (Lee and Nathans, *J. Biol. Chem.*, 263:3521-3527). The resulting constructs were transfected into Chinese hamster ovary cells, and stable tranfectants were selected in the presence of G418. Two milliliters of conditioned media prepared from the G418-resistant cells were dialyzed, lyophilized, electrophoresed under denaturing, reducing conditions, transferred to nitrocellulose, and incubated with anti-GDF-8 antibodies (described above) and [$^{125}$I]iodoproteinA.

As shown in FIGURE 9, the rabbit GDF-8 antibodies (at a 1:500 dilution) detected a protein of approximately the predicted molecular weight for the mature C-terminal fragment of GDF-8 in the conditioned media of cells transfected with a construct in which GDF-8 had been cloned in the correct (sense) orientation with respect to the metallothionein promoter (lane 2); this band was not detected in a similar sample prepared from cells transfected with a control antisense construct (lane 1). Similar results were obtained using antibodies prepared in chickens. Hence, GDF-8 is secreted and proteolytically processed by these transfected mammalian cells.

## EXAMPLE 6

## EXPRESSION PATTERN OF GDF-8

To determine the pattern of GDF-8, 5 μg of twice poly A-selected RNA prepared from a variety of murine tissue sources were subjected to Northern analysis. As shown in FIGURE 10a (and as shown previously in Example 2), the GDF-8 probe detected a single mRNA species present almost exclusively in skeletal muscle among a large number of adult tissues surveyed. On longer exposures of the same blot, significantly lower but detectable levels of GDF-8 mRNA were seen in fat, brain, thymus, heart, and lung. Hence, these results confirm the high degree of specificity of GDF-8 expression in skeletal muscle. GDF-8 mRNA was also detected in mouse embryos at both gestational

ages (day 12.5 and day 18.5 post-coital) examined but not in placentas at various stages of development (FIGURE 10b).

To further analyze the expression pattern of GDF-8, *in situ* hybridization was performed on mouse embryos isolated at various stages of development.

For all in situ hybridization experiments, probes corresponding to the C-terminal region of GDF-8 were excluded in order to avoid possible cross-reactivity with other members of the superfamily. Whole mount in situ hybridization analysis was carried out as described (Wilkinson, D.G., *In Situ Hybridization, A Practical Approach*, pp. 75-83, IRL. Press, Oxford, 1992) except that blocking and antibody incubation steps were carried out as in Knecht *et al.* (Knecht, *et al., Development*, 121:1927, 1955). Alkaline phosphatase reactions were carried out for 3 hours for day 10.5 embryos and overnight for day 9.5 embryos. Hybridization was carried out using digoxigenin- labelled probes spanning nucleotides 8-811 and 1298-2676, which correspond to the pro- region and 3' untranslated regions, respectively. *In situ* hybridization to sections was carried out as described (Wilkinson, *et al., Cell*, 50:79, 1987) using $^{35}$S-labelled probes ranging from approximately 100-650 bases in length and spanning nucleotides 8-793 and 1566-2595. Following hybridization and washing, slides were dipped in NTB-3 photographic emulsion, exposed for 16-19 days, developed and stained with either hematoxylin and eosin or toluidine blue. RNA isolation, poly A selection, and Northern analysis were carried out as described previously (McPherron and Lee, *J. Biol. Chem.*, 268:3444, 1993).

At all stages examined, the expression of GDF-8 mRNA appeared to be restricted to developing skeletal muscle. At early stages, GDF-8 expression was restricted to developing somites. By whole mount *in situ* hybridization analysis, GDF-8 mRNA could first be detected as early as day 9.5 post coitum in approximately one-third of the somites. At this stage of development, hybridization appeared to be restricted to the most mature (9 out of 21 in this example), rostral somites. By day 10.5 p.c., GDF-8 expression was clearly evident in almost every somite (28 out of 33 in this example

shown). Based on *in situ* hybridization analysis of sections prepared from day 10.5 p.c. embryos, the expression of GDF-8 in somites appeared to be localized to the myotome compartment. At later stages of development, GDF-8 expression was detected in a wide range of developing muscles.

GDF-8 continues to be expressed in adult animals as well. By Northern analysis, GDF-8 mRNA expression was seen almost exclusively in skeletal muscle among the different adult tissues examined. A significantly lower though clearly detectable signal was also seen in adipose tissue. Based on Northern analysis of RNA prepared from a large number of different adult skeletal muscles, GDF-8 expression appeared to be widespread although the expression levels varied among individual muscles.

## EXAMPLE 7
## CHROMOSOMAL LOCALIZATION OF GDF-8

In order to map the chromosomal location of GDF-8, DNA samples from human/rodent somatic cell hybrids (Drwinga, *et al.*, *Genomics*, 16:311-413, 1993; Dubois and Naylor, *Genomics*, 16:315-319, 1993) were analyzed by polymerase chain reaction followed by Southern blotting. Polymerase chain reaction was carried out using primer #83, 5'-C-GCGGATCCGTGGATCTAAATGAGAACAGTGAGC-3' (SEQ ID NO: 15) and primer #84, 5'-CGCGAATTCTCAGGTAATGATTGTTTCCGTTGTAGCG-3'(SEQ ID NO:16) for 40 cycles at 94°C for 2 minutes, 60°C for 1 minute, and 72°C for 2 minutes. These primers correspond to nucleotides 119 to 143 (flanked by a Bam H1 recognition sequence), and nucleotides 394 to 418 (flanked by an Eco R1 recognition sequence), respectively, in the human GDF-8 cDNA sequence. PCR products were electrophoresed on agarose gels, blotted, and probed with oligonucleotide #100, 5'-ACACTAAATCTTCAAGAATA-3' (SEQ ID NO:17), which corresponds to a sequence internal to the region flanked by primer #83 and #84. Filters were hybridized in 6 X SSC, 1 X Denhardt's solution, 100μg/ml yeast transfer RNA, and 0.05% sodium pyrophosphate at 50°C.

As shown in FIGURE 11, the human-specific probe detected a band of the predicted size (approximately 320 base pairs) in the positive control sample (total human genomic DNA) and in a single DNA sample from the human/rodent hybrid panel. This positive signal corresponds to human chromosome 2. The human chromosome contained in each of the hybrid cell lines is identified at the top of each of the first 24 lanes (1-22, X, and Y). In the lanes designated M, CHO, and H, the starting DNA template was total genomic DNA from mouse, hamster, and human sources, respectively. In the lane marked B1, no template DNA was used. Numbers at left indicate the mobilities of DNA standards. These data show that the human GDF-8 gene is located on chromosome 2.

## EXAMPLE 8

## GDF-8 TRANSGENIC KNOCKOUT MICE

The GDF-8, we disrupted the GDF-8 gene was disrupted by homologous targeting in embryonic stem cells. To ensure that the resulting mice would be null for GDF-8 function, the entire mature C-terminal region was deleted and replaced by a neo cassette (Figure 12a). A murine 129 SV/J genomic library was prepared in lambda FIX II according to the instructions provided by Stratagene (La Jolla, CA). The structure of the GDF-8 gene was deduced from restriction mapping and partial sequencing of phage clones isolated from this library. Vectors for preparing the targeting construct were kindly provided by Philip Soriano and Kirk Thomas University. R1 ES cells were transfected with the targeting construct, selected with gancyclovir (2 $\mu$M) and G418 (250 $\mu$g/ml), and analyzed by Southern analysis. Homologously targeted clones were injected into C57BL/6 blastocysts and transferred into pseudopregnant females. Germline transmission of the targeted allele was obtained in a total of 9 male chimeras from 5 independently-derived ES clones. Genomic Southern blots were hybridized at 42°C as described above and washed in 0.2X SSC, 0.1% SDS at 42°C.

For whole leg analysis, legs of 14 week old mice were skinned, treated with 0.2 M EDTA in PBS at 4°C for 4 weeks followed by 0.5 M sucrose in PBS at 4°C. For fiber number and size analysis, samples were directly mounted and frozen in isopentane as described (Brumback and Leech, *Color Atlas of Muscle Histochemistry*, pp. 9-33, PSG Publishing

Company, Littleton, MA, 1984). Ten to 30 $\mu$m sections were prepared using a cryostat and stained with hematoxylin and eosin. Muscle fiber numbers were determined from sections taken from the widest part of the tibialis cranialis muscle. Muscle fiber sizes were measured from photographs of sections of tibialis cranialis and gastrocnemius muscles. Fiber type analysis was carried out using the mysosin ATPase assay after pretreatment at pH 4.35 as described (Cumming, *et al., Color Atlas of Muscle Pathology*, pp. 184-185, 1994) and by immunohistochemistry using an antibody directed against type I myosin (MY32, Sigma) and the Vectastain method (Vector Labs); in the immunohistochemical experiments, no staining was seen when the primary antibodies were left out. Carcasses were prepared from shaved mice by removing the all of the internal organs and associated fat and connective tissue. Fat content of carcasses from 4 month old males was determined as described (Leshner, *et al., Physiol. Behavior*, 9:281, 1972).

For protein and DNA analysis, tissue was homogenized in 150 mM NaCl, 100 mM EDTA. Protein concentrations were determined using the Biorad protein assay. DNA was isolated by adding SDS to 1%, treating with 1 mg/ml proteinase K overnight at 55°C, extracting 3 times with phenol and twice with chloroform, and precipitating with ammonium acetate and EtOH. DNA was digested with 2 mg/ml RNase for 1 hour at 37°C, and following proteinase K digestion and phenol and chloroform extractions, the DNA was precipitated twice with ammonium acetate and EtOH.

Homologous targeting of the GDF-8 gene was seen in 13/131 gancyclovir/G418 doubly-resistant ES cell clones. Following injection of these targeted clones into blastocysts, we obtained chimeras from 5 independently-derived ES clones that produced heterozygous pups when crossed to C57BL/6 females (Figure 12b). Genotypic analysis of 678 offspring derived from crosses of F1 heterozygotes showed 170 +/+ (25%), 380 +/- (56%), and 128 -/- (19%). Although the ratio of genotypes was close to the expected ratio of 1:2:1, the smaller than expected number of homozygous mutants appeared to be statistically significant ($p<0.001$).

Homozygous mutants were viable and fertile when crossed to C57BL/6 mice and to each other. Homozygous mutant animals, however, were approximately 30% larger than their heterozygous and wild type littermates (Table 1). The difference between mutant and wild type body weights appeared to be relatively constant irrespective of age and sex in adult animals. Adult mutants also displayed an abnormal body shape, with pronounced shoulders and hips. When the skin was removed from animals that had been sacrificed, it was apparent that the muscles of the mutants were much larger than those of wild type animals. The increase in skeletal muscle mass appeared to be widespread throughout the body. Individual muscles isolated from homozygous mutant animals weighed approximately 2-3 times more than those isolated from wild type littermates (Table 2). Although the magnitude of the weight increase appeared to roughly correlate with the level of GDF-8 expression in the muscles examined. To determine whether the increased muscle mass could account for the entire difference in total body weights between wild type and mutant animals or whether many tissues were generally larger in the mutants, we compared the total body weights to carcass weights. As shown in Table 3, the difference in carcass weights between wild type and mutant animals was comparable to the difference in total body weights. Moreover, because the fat content of mutant and wild type animals was similar, these data are consistent with all of the total body weight difference resulting from an increase in skeletal muscle mass, although we have not formally ruled out the possibility that differences in bone mass might also contribute to the differences in total body mass.

To determine whether the increase in skeletal muscle mass resulted from hyperplasia or from hypertrophy, histologic analysis of several different muscle groups was performed. The mutant muscle appeared grossly normal. No excess connective tissue or fat was seen nor were there any obvious signs of degeneration, such as widely varying fiber sizes (see below) or centrally-placed nuclei. Quantitation of the number of muscle fibers showed that at the widest portion of the tibialis cranialis muscle, the total cell number was 86% higher in mutant animals compared to wild type littermates [mutant = 5470 +/- 121 (n = 3), wild type = 2936 +/- 288 (n = 3); $p < 0.01$]. Consistent with this result was the finding that the amount of DNA extracted from mutant muscle was roughly 50% higher

than from wild type muscle [mutant = 350 $\mu$g (n = 4), wild type = 233 $\mu$g (n = 3) from pooled gastrocnemius, plantaris, triceps brachii, tibialis cranialis, and pectoralis muscles; p = 0.05]. Hence, a large part of the increase in skeletal muscle mass resulted from muscle cell hyperplasia. However, muscle fiber hypertrophy also appeared to contribute to the overall increase in muscle mass. As shown in Figure 13, the mean fiber diameter of the tibialis cranialis muscle and gastrocnemius muscle was 7% and 22% larger, respectively, in mutant animals compared to wild type littermates, suggesting that the cross-sectional area of the fibers was increased by approximately 14% and 49%, respectively. Notably, although the mean fiber diameter was larger in the mutants, the standard deviation in fiber sizes was similar between mutant and wild type muscle, consistent with the absence of muscle degeneration in mutant animals. The increase in fiber size was also consistent with the finding that the protein to DNA ratio (w/w) was slightly increased in mutant compared to wild type muscle [mutant = 871 +/- 111 (n = 4), wild type = 624 +/- 85 (n = 3); $p < 0.05$].

Table 4 shows a comparison between muscle weight (in grams) from wild-type (+/+), heterozyous (+/-) and a homozygous knock-out mice (-/-). The muscle mass is increased in heterozyogous as compared to wild-type animals.

Finally, fiber type analysis of various muscles was carried out to determine whether the number of both type I (slow) and type II (fast) fibers was increased in the mutant animals. In most of the muscles examined, including the tibialis cranialis muscle, the vast majority of muscle fibers were type II in both mutant and wild type animals. Hence, based on the cell counts discussed above, the absolute number of type II fibers were increased in the tibialis cranialis muscle. In the soleus muscle, where the number of type I fibers was sufficiently high that we could attempt to quantitate the ratio of fiber types could be quantiated, the percent of type I fibers was decreased by approximately 33% in mutant compared to wild type muscle [wild type = 39.2 +/- 8.1 (n = 3), mutant = 26.4 +/- 9.3 (n = 4)]; however, the variability in this ratio for both wild type and mutant animals was too high to support any firm conclusions regarding the relative number of fiber types.

## EXAMPLE 9

## ISOLATION OF RAT AND CHICKEN GDF-8

In order to isolate rat and chicken GDF-8 cDNA clones, skeletal muscle cDNA libraries prepared from these species were obtained from Stratagene and screened with a murine GDF-8 probe. Library screening was carried out as described previously (Lee, Mol. Endocrinol., 4:1034-1040) except that final washes were carried out in 2 X SSC at 65°C. Partial sequence analysis of hybridizing clones revealed the presence of open reading frames highly related to murine and human GDF-8. Partial sequences of rat and chicken GDF-8 are shown in Figures 2c and 2d, respectively, and an alignment of the predicated rat and chicken GDF-8 amino acid sequences with those of murine and human GDF-8 are shown in Figure 3b. Full length rat and chicken GDF-8 is shown in Figures 14d and 14c, respectively and sequence alignment between murine, rat, human, baboon, porcine, ovine, bovine, chicken, and turkey sequences is shown in Figures 15a and 15b. All sequences contain an RSRR sequence that is likely to represent the proteolytic processing site. Following this RSRR sequence, the sequences contain a C-terminal region that is 100% conserved among all four species. The absolute conservation of the C-terminal region between species as evolutionarily far apart as humans and chickens, and baboons and turkeys, suggests that this region will be highly conserved in many other species as well.

Similar methodology was used to obtain the nucleotide and amino acid sequences for baboon (SEQ ID NO:18 and 19, respectively; Figure 14a); bovine (SEQ ID NO:20 and 21, respectively; Figure 14b); turkey (SEQ ID NO:26 and 27, respectively; Figure 14e); porcine (SEQ ID NO:28 and 29, respectively; Figure 14f); and ovine (SEQ ID NO:30 and 31, respectively; Figure 14g).

Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: The Johns Hopkins University School of Medicine

(ii) TITLE OF THE INVENTION: GROWTH DIFFERENTIATION FACTOR-8

(iii) NUMBER OF SEQUENCES: 27

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Fish & Richardson P.C.
(B) STREET: 4225 Executive Square, Suite 1400
(C) CITY: La Jolla
(D) STATE: CA
(E) COUNTRY: US
(F) ZIP: 92037

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: Windows95
(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: PCT/US98/-----
(B) FILING DATE: 05-February-1998
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/795,071
(B) FILING DATE: 05-February-1997

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/847,910
(B) FILING DATE: 28-April-1997

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/862,445
(B) FILING DATE: 23-May-1997

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Lisa A. Haile, Ph.D.
(B) REGISTRATION NUMBER: 38,347
(C) REFERENCE/DOCKET NUMBER: 07265/129WO1

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 619/678-5070
(B) TELEFAX: 619/678-5099

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:

(B) CLONE: SJL141

(ix) FEATURE:
(A) NAME/KEY: Modified Base
(B) LOCATION: 1...35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCGGAATTCG GNTGGVANRA YTGGRTNRTN NKCNCC 35

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: SJL147

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...33

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CCGGAATTCR CANSCRCARC TNTCNACNRY CAT 33

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: ACM13

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...32
(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGCGGATCCA GAAGTCAAGG TGACAGACAC AC 32

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: ACM14

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...33
(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
CGCGGATCCT CCTCATGAGC ACCCACAGCG GTC                    33
```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 550 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: mouse GDF-8

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 59...436
(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
TTAAGGTAGG AAGGATTTCA GGCTCTATTT ACATAATTGT TCTTTCCTTT TCACACAG      58

AAT CCC TTT TTA GAA GTC AAG GTG ACA GAC ACA CCC AAG AGG TCC CGG      106
Asn Pro Phe Leu Glu Val Lys Val Thr Asp Thr Pro Lys Arg Ser Arg
  1               5                  10                  15

AGA GAC TTT GGG CTT GAC TGC GAT GAG CAC TCC ACG GAA TCC CGG TGC      154
Arg Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr Glu Ser Arg Cys
            20                  25                  30

TGC CGC TAC CCC CTC ACG GTC GAT TTT GAA GCC TTT GGA TGG GAC TGG      202
Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe Gly Trp Asp Trp
        35                  40                  45

ATT ATC GCA CCC AAA AGA TAT AAG GCC AAT TAC TGC TCA GGA GAG TGT      250
Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys
    50                  55                  60

GAA TTT GTG TTT TTA CAA AAA TAT CCG CAT ACT CAT CTT GTG CAC CAA      298
Glu Phe Val Phe Leu Gln Lys Tyr Pro His Thr His Leu Val His Gln
65                  70                  75                  80

GCA AAC CCC AGA GGC TCA GCA GGC CCT TGC TGC ACT CCG ACA AAA ATG      346
Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Met
                85                  90                  95
```

```
TCT CCC ATT AAT ATG CTA TAT TTT AAT GGC AAA GAA CAA ATA ATA TAT   394
Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr
            100                 105                 110

GGG AAA ATT CCA GCC ATG GTA GTA GAC CGC TGT GGG TGC TCA TGAGCTTTGC 446
Gly Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys Ser
        115                 120                 125

ATTAGGTTAG AAACTTCCCA AGTCATGGAA GGTCTTCCCC TCAATTTCGA AACTGTGAAT     506

TCCTGCAGCC CGGGGGATCC ACTAGTTCTA GAGCGGCCGC CACC                      550
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 126 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Asn Pro Phe Leu Glu Val Lys Val Thr Asp Thr Pro Lys Arg Ser Arg
 1               5                  10                  15
Arg Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr Glu Ser Arg Cys
            20                  25                  30
Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe Gly Trp Asp Trp
        35                  40                  45
Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys
    50                  55                  60
Glu Phe Val Phe Leu Gln Lys Tyr Pro His Thr His Leu Val His Gln
65                  70                  75                  80
Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr Pro Thr Lys Met
                85                  90                  95
Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr
            100                 105                 110
Gly Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys Ser
        115                 120                 125
```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 326 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: human GDF-8

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 3...326
(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
CA AAA AGA TCC AGA AGG GAT TTT GGT CTT GAC TGT GAT GAG CAC TCA        47
   Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His Ser
     1               5                  10                  15

ACA GAA TCA CGA TGC TGT CGT TAC CCT CTA ACT GTG GAT TTT GAA GCT        95
Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala
                 20                  25                  30

TTT GGA TGG GAT TGG ATT ATC GCT CCT AAA AGA TAT AAG GCC AAT TAC       143
Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr
             35                  40                  45


TGC TCT GGA GAG TGT GAA TTT GTA TTT TTA CAA AAA TAT CCT CAT ACT       191
Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His Thr
         50                  55                  60

CAT CTG GTA CAC CAA GCA AAC CCC AGA GGT TCA GCA GGC CCT TGC TGT       239
His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys
     65                  70                  75

ACT CCC ACA AAG ATG TCT CCA ATT AAT ATG CTA TAT TTT AAT GGC AAA       287
Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys
 80                  85                  90                  95

GAA CAA ATA ATA TAT GGG AAA ATT CCA GCG ATG GTA GTA                   326
Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val
                100                 105
```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 108 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```
Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr
 1               5                  10                  15
Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe
            20                  25                  30
Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys
        35                  40                  45
Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His Thr His
    50                  55                  60
Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr
65                  70                  75                  80
Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys Glu
                85                  90                  95
Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val
            100                 105
```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:
(B) CLONE: SJL141

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1...9
(D) OTHER INFORMATION: "Xaa at position 3 = His, Gln, Asn, Lys, Asp, or Glu; Xaa at position 4 = Asp or Asn; Xaa at positions 6 and 7 is Val, Ile, or Met; Xaa at position 8 = Ala or Ser.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9

Gly Trp Xaa Xaa Trp Xaa Xaa Xaa Pro
1 5

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:
(B) CLONE: SJL147

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1...8
(D) OTHER INFORMATION: "Xaa at position 2 = Val, Ile, Met, Thr or Ala; Xaa at position 4 = Asp or Glu; Xaa at position 7 = Gly, or Ala.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Xaa Val Xaa Ser Cys Xaa Cys
1 5

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2676 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: Murine GDF-8

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...2676
(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GTCTCTCGGA CGGTACATGC ACTAATATTT CACTTGGCAT TACTCAAAAG CAAAAAGAAG 60

```
AAATAAGAAC AAGGGAAAAA AAAAGATTGT GCTGATTTTT AAA ATG ATG CAA AAA      115
                                                Met Met Gln Lys
                                                 1

CTG CAA ATG TAT GTT TAT ATT TAC CTG TTC ATG CTG ATT GCT GCT GGC      163
Leu Gln Met Tyr Val Tyr Ile Tyr Leu Phe Met Leu Ile Ala Ala Gly
 5                  10                  15                  20

CCA GTG GAT CTA AAT GAG GGC AGT GAG AGA GAA GAA AAT GTG GAA AAA      211
Pro Val Asp Leu Asn Glu Gly Ser Glu Arg Glu Glu Asn Val Glu Lys
                25                  30                  35


GAG GGG CTG TGT AAT GCA TGT GCG TGG AGA CAA AAC ACG AGG TAC TCC      259
Glu Gly Leu Cys Asn Ala Cys Ala Trp Arg Gln Asn Thr Arg Tyr Ser
            40                  45                  50

AGA ATA GAA GCC ATA AAA ATT CAA ATC CTC AGT AAG CTG CGC CTG GAA      307
Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
        55                  60                  65

ACA GCT CCT AAC ATC AGC AAA GAT GCT ATA AGA CAA CTT CTG CCA AGA      355
Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu Leu Pro Arg
    70                  75                  80

GCG CCT CCA CTC CGG GAA CTG ATC GAT CAG TAC GAC GTC CAG AGG GAT      403
Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val Gln Arg Asp
 85                  90                  95                 100

GAC AGC AGT GAT GGC TCT TTG GAA GAT GAC GAT TAT CAC GCT ACC ACG      451
Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Thr Thr
                105                 110                 115

GAA ACA ATC ATT ACC ATG CCT ACA GAG TCT GAC TTT CTA ATG CAA GCG      499
Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu Met Gln Ala
            120                 125                 130

GAT GGC AAG CCC AAA TGT TGC TTT TTT AAA TTT AGC TCT AAA ATA CAG      547
Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
        135                 140                 145

TAC AAC AAA GTA GTA AAA GCC CAA CTG TGG ATA TAT CTC AGA CCC GTC      595
Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Pro Val
    150                 155                 160

AAG ACT CCT ACA ACA GTG TTT GTG CAA ATC CTG AGA CTC ATC AAA CCC      643
Lys Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180

ATG AAA GAC GGT ACA AGG TAT ACT GGA ATC CGA TCT CTG AAA CTT GAC      691
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
                185                 190                 195

ATG AGC CCA GGC ACT GGT ATT TGG CAG AGT ATT GAT GTG AAG ACA GTG      739
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
            200                 205                 210

TTG CAA AAT TGG CTC AAA CAG CCT GAA TCC AAC TTA GGC ATT GAA ATC      787
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
        215                 220                 225

AAA GCT TTG GAT GAG AAT GGC CAT GAT CTT GCT GTA ACC TTC CCA GGA      835
Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr Phe Pro Gly
    230                 235                 240
```

```
CCA GGA GAA GAT GGG CTG AAT CCC TTT TTA GAA GTC AAG GTG ACA GAC      883
Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Lys Val Thr Asp
245                 250                 255                 260

ACA CCC AAG AGG TCC CGG AGA GAC TTT GGG CTT GAC TGC GAT GAG CAC      931
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
                265                 270                 275

TCC ACG GAA TCC CGG TGC TGC CGC TAC CCC CTC ACG GTC GAT TTT GAA      979
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
            280                 285                 290

GCC TTT GGA TGG GAC TGG ATT ATC GCA CCC AAA AGA TAT AAG GCC AAT     1027
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
        295                 300                 305

TAC TGC TCA GGA GAG TGT GAA TTT GTG TTT TTA CAA AAA TAT CCG CAT     1075
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
    310                 315                 320

ACT CAT CTT GTG CAC CAA GCA AAC CCC AGA GGC TCA GCA GGC CCT TGC     1123
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340

TGC ACT CCG ACA AAA ATG TCT CCC ATT AAT ATG CTA TAT TTT AAT GGC     1171
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
                345                 350                 355

AAA GAA CAA ATA ATA TAT GGG AAA ATT CCA GCC ATG GTA GTA GAC CGC     1219
Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
            360                 365                 370

TGT GGG TGC TCA TGAGCTTTGC ATTAGGTTAG AAACTTCCCA AGTCATGGAA GGTCT  1276
Cys Gly Cys Ser
        375

TCCCCTCAAT TTCGAAACTG TGAATTCAAG CACCACAGGC TGTAGGCCTT GAGTATGCTC  1336
TAGTAACGTA AGCACAAGCT ACAGTGTATG AACTAAAAGA GAGAATAGAT GCAATGGTTG  1396
GCATTCAACC ACCAAAATAA ACCATACTAT AGGATGTTGT ATGATTTCCA GAGTTTTTGA  1456
AATAGATGGA GATCAAATTA CATTTATGTC CATATATGTA TATTACAACT ACAATCTAGG  1516
CAAGGAAGTG AGAGCACATC TTGTGGTCTG CTGAGTTAGG AGGGTATGAT TAAAAGGTAA  1576
AGTCTTATTT CCTAACAGTT TCACTTAATA TTTACAGAAG AATCTATATG TAGCCTTTGT  1636
AAAGTGTAGG ATTGTTATCA TTTAAAAACA TCATGTACAC TTATATTTGT ATTGTATACT  1696
TGGTAAGATA AAATTCCACA AAGTAGGAAT GGGGCCTCAC ATACACATTG CCATTCCTAT  1756
TATAATTGGA CAATCCACCA CGGTGCTAAT GCAGTGCTGA ATGGCTCCTA CTGGACCTCT  1816
CGATAGAACA CTCTACAAAG TACGAGTCTC TCTCTCCCTT CCAGGTGCAT CTCCACACAC  1876
ACAGCACTAA GTGTTCAATG CATTTTCTTT AAGGAAAGAA GAATCTTTTT TTCTAGAGGT  1936
CAACTTTCAG TCAACTCTAG CACAGCGGGA GTGACTGCTG CATCTTAAAA GGCAGCCAAA  1996
CAGTATTCAT TTTTTAATCT AAATTTCAAA ATCACTGTCT GCCTTTATCA CATGGCAATT  2056
TTGTGGTAAA ATAATGGAAA TGACTGGTTC TATCAATATT GTATAAAAGA CTCTGAAACA  2116
ATTACATTTA TATAATATGT ATACAATATT GTTTTGTAAA TAAGTGTCTC CTTTTATATT  2176
TACTTTGGTA TATTTTTACA CTAATGAAAT TTCAAATCAT TAAAGTACAA AGACATGTCA  2236
TGTATCACAA AAAAGGTGAC TGCTTCTATT TCAGAGTGAA TTAGCAGATT CAATAGTGGT  2296
CTTAAAACTC TGTATGTTAA GATTAGAAGG TTATATTACA ATCAATTTAT GTATTTTTTA  2356
CATTATCAAC TTATGGTTTC ATGGTGGCTG TATCTATGAA TGTGGCTCCC AGTCAAATTT  2416
CAATGCCCCA CCATTTTAAA AATTACAAGC ATTACTAAAC ATACCAACAT GTATCTAAAG  2476
AAATACAAAT ATGGTATCTC AATAACAGCT ACTTTTTTAT TTTATAATTT GACAATGAAT  2536
ACATTTCTTT TATTTACTTC AGTTTTATAA ATTGGAACTT TGTTTATCAA ATGTATTGTA  2596
CTCATAGCTA AATGAAATTA TTTCTTACAT AAAAATGTGT AGAAACTATA AATTAAAGTG  2656
TTTTCACATT TTTGAAAGGC                                              2676
```

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 376 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```
Met Met Gln Lys Leu Gln Met Tyr Val Tyr Ile Tyr Leu Phe Met Leu
 1               5                  10                  15
Ile Ala Ala Gly Pro Val Asp Leu Asn Glu Gly Ser Glu Arg Glu Glu
            20                  25                  30
Asn Val Glu Lys Glu Gly Leu Cys Asn Ala Cys Ala Trp Arg Gln Asn
        35                  40                  45
Thr Arg Tyr Ser Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys
    50                  55                  60
Leu Arg Leu Glu Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln
65                  70                  75                  80
Leu Leu Pro Arg Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp
                85                  90                  95
Val Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr
            100                 105                 110
His Ala Thr Thr Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe
        115                 120                 125
Leu Met Gln Ala Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser
    130                 135                 140
Ser Lys Ile Gln Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr
145                 150                 155                 160
Leu Arg Pro Val Lys Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg
                165                 170                 175
Leu Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser
            180                 185                 190
Leu Lys Leu Asp Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp
        195                 200                 205
Val Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu
    210                 215                 220
Gly Ile Glu Ile Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val
225                 230                 235                 240
Thr Phe Pro Gly Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val
                245                 250                 255
Lys Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp
            260                 265                 270
Cys Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr
        275                 280                 285
Val Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg
    290                 295                 300
Tyr Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln
305                 310                 315                 320
Lys Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser
                325                 330                 335
Ala Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu
            340                 345                 350
Tyr Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met
        355                 360                 365
Val Val Asp Arg Cys Gly Cys Ser
    370                 375
```

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2743 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: Human GDF-8

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...2743
(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```
AAGAAAAGTA AAAGGAAGAA ACAAGAACAA GAAAAAAGAT TATATTGATT TTAAAATC          58

ATG CAA AAA CTG CAA CTC TGT GTT TAT ATT TAC CTG TTT ATG CTG ATT          106
Met Gln Lys Leu Gln Leu Cys Val Tyr Ile Tyr Leu Phe Met Leu Ile
  1               5                  10                  15

GTT GCT GGT CCA GTG GAT CTA AAT GAG AAC AGT GAG CAA AAA GAA AAT          154
Val Ala Gly Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn
            20                  25                  30

GTG GAA AAA GAG GGG CTG TGT AAT GCA TGT ACT TGG AGA CAA AAC ACT          202
Val Glu Lys Glu Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr
        35                  40                  45

AAA TCT TCA AGA ATA GAA GCC ATT AAG ATA CAA ATC CTC AGT AAA CTT          250
Lys Ser Ser Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu
    50                  55                  60

CGT CTG GAA ACA GCT CCT AAC ATC AGC AAA GAT GTT ATA AGA CAA CTT          298
Arg Leu Glu Thr Ala Pro Asn Ile Ser Lys Asp Val Ile Arg Gln Leu
65                  70                  75                  80

TTA CCC AAA GCT CCT CCA CTC CGG GAA CTG ATT GAT CAG TAT GAT GTC          346
Leu Pro Lys Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val
                85                  90                  95

CAG AGG GAT GAC AGC AGC GAT GGC TCT TTG GAA GAT GAC GAT TAT CAC          394
Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His
            100                 105                 110

GCT ACA ACG GAA ACA ATC ATT ACC ATG CCT ACA GAG TCT GAT TTT CTA          442
Ala Thr Thr Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu
        115                 120                 125

ATG CAA GTG GAT GGA AAA CCC AAA TGT TGC TTC TTT AAA TTT AGC TCT          490
Met Gln Val Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser
    130                 135                 140

AAA ATA CAA TAC AAT AAA GTA GTA AAG GCC CAA CTA TGG ATA TAT TTG          538
Lys Ile Gln Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu
145                 150                 155                 160

AGA CCC GTC GAG ACT CCT ACA ACA GTG TTT GTG CAA ATC CTG AGA CTC          586
Arg Pro Val Glu Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu
                165                 170                 175

ATC AAA CCT ATG AAA GAC GGT ACA AGG TAT ACT GGA ATC CGA TCT CTG          634
Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu
            180                 185                 190
```

```
AAA CTT GAC ATG AAC CCA GGC ACT GGT ATT TGG CAG AGC ATT GAT GTG          682
Lys Leu Asp Met Asn Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val
        195                 200                 205

AAG ACA GTG TTG CAA AAT TGG CTC AAA CAA CCT GAA TCC AAC TTA GGC          730
Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly
    210                 215                 220

ATT GAA ATA AAA GCT TTA GAT GAG AAT GGT CAT GAT CTT GCT GTA ACC          778
Ile Glu Ile Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr
225                 230                 235                 240

TTC CCA GGA CCA GGA GAA GAT GGG CTG AAT CCG TTT TTA GAG GTC AAG          826
Phe Pro Gly Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Lys
                245                 250                 255

GTA ACA GAC ACA CCA AAA AGA TCC AGA AGG GAT TTT GGT CTT GAC TGT          874
Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys
            260                 265                 270

GAT GAG CAC TCA ACA GAA TCA CGA TGC TGT CGT TAC CCT CTA ACT GTG          922
Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val
        275                 280                 285

GAT TTT GAA GCT TTT GGA TGG GAT TGG ATT ATC GCT CCT AAA AGA TAT          970
Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr
    290                 295                 300

AAG GCC AAT TAC TGC TCT GGA GAG TGT GAA TTT GTA TTT TTA CAA AAA         1018
Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys
305                 310                 315                 320

TAT CCT CAT ACT CAT CTG GTA CAC CAA GCA AAC CCC AGA GGT TCA GCA         1066
Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala
                325                 330                 335

GGC CCT TGC TGT ACT CCC ACA AAG ATG TCT CCA ATT AAT ATG CTA TAT         1114
Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr
            340                 345                 350

TTT AAT GGC AAA GAA CAA ATA ATA TAT GGG AAA ATT CCA GCG ATG GTA         1162
Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val
        355                 360                 365

GTA GAC CGC TGT GGG TGC TCA TGAGATTTAT ATTAAGCGTT CATAACTTCC TAAAAC     1219
Val Asp Arg Cys Gly Cys Ser
    370                 375

ATGGAAGGTT TTCCCCTCAA CAATTTTGAA GCTGTGAAAT TAAGTACCAC AGGCTATAGG      1279
CCTAGAGTAT GCTACAGTCA CTTAAGCATA AGCTACAGTA TGTAAACTAA AAGGGGGAAT      1339
ATATGCAATG GTTGGCATTT AACCATCCAA ACAAATCATA CAAGAAAGTT TTATGATTTC      1399
CAGAGTTTTT GAGCTAGAAG GAGATCAAAT TACATTTATG TTCCTATATA TTACAACATC      1459
GGCGAGGAAA TGAAAGCGAT TCTCCTTGAG TTCTGATGAA TTAAAGGAGT ATGCTTTAAA      1519
GTCTATTTCT TTAAAGTTTT GTTTAATATT TACAGAAAAA TCCACATACA GTATTGGTAA      1579
AATGCAGGAT TGTTATATAC CATCATTCGA ATCATCCTTA AACACTTGAA TTTATATTGT      1639
ATGGTAGTAT ACTTGGTAAG ATAAAATTCC ACAAAAATAG GGATGGTGCA GCATATGCAA      1699
TTTCCATTCC TATTATAATT GACACAGTAC ATTAACAATC CATGCCAACG GTGCTAATAC      1759
GATAGGCTGA ATGTCTGAGG CTACCAGGTT TATCACATAA AAAACATTCA GTAAAATAGT      1819
AAGTTTCTCT TTTCTTCAGG TGCATTTTCC TACACCTCCA AATGAGGAAT GGATTTTCTT      1879
TAATGTAAGA AGAATCATTT TTCTAGAGGT TGGCTTTCAA TTCTGTAGCA TACTTGGAGA      1939
AACTGCATTA TCTTAAAAGG CAGTCAAATG GTGTTTGTTT TTATCAAAAT GTCAAAATAA      1999
CATACTTGGA GAAGTATGTA ATTTTGTCTT TGGAAAATTA CAACACTGCC TTTGCAACAC      2059
TGCAGTTTTT ATGGTAAAAT AATAGAAATG ATCGACTCTA TCAATATTGT ATAAAAAGAC      2119
TGAAACAATG CATTTATATA ATATGTATAC AATATTGTTT TGTAAATAAG TGTCTCCTTT      2179
```

```
TTTATTTACT TTGGTATATT TTTACACTAA GGACATTTCA AATTAAGTAC TAAGGCACAA    2239
AGACATGTCA TGCATCACAG AAAAGCAACT ACTTATATTT CAGAGCAAAT TAGCAGATTA    2299
AATAGTGGTC TTAAAACTCC ATATGTTAAT GATTAGATGG TTATATTACA ATCATTTTAT    2359
ATTTTTTTAC ATGATTAACA TTCACTTATG GATTCATGAT GGCTGTATAA AGTGAATTTG    2419
AAATTTCAAT GGTTTACTGT CATTGTGTTT AAATCTCAAC GTTCCATTAT TTTAATACTT    2479
GCAAAAACAT TACTAAGTAT ACCAAAATAA TTGACTCTAT TATCTGAAAT GAAGAATAAA    2539
CTGATGCTAT CTCAACAATA ACTGTTACTT TTATTTTATA ATTTGATAAT GAATATATTT    2599
CTGCATTTAT TTACTTCTGT TTTGTAAATT GGGATTTTGT TAATCAAATT TATTGTACTA    2659
TGACTAAATG AAATTATTTC TTACATCTAA TTTGTAGAAA CAGTATAAGT TATATTAAAG    2719
TGTTTTCACA TTTTTTTGAA AGAC                                           2743
```

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 375 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

```
Met Gln Lys Leu Gln Leu Cys Val Tyr Ile Tyr Leu Phe Met Leu Ile
 1               5                  10                  15
Val Ala Gly Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn
            20                  25                  30
Val Glu Lys Glu Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr
        35                  40                  45
Lys Ser Ser Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu
    50                  55                  60
Arg Leu Glu Thr Ala Pro Asn Ile Ser Lys Asp Val Ile Arg Gln Leu
65                  70                  75                  80
Leu Pro Lys Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val
                85                  90                  95
Gln Arg Asp Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His
            100                 105                 110
Ala Thr Thr Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu
        115                 120                 125
Met Gln Val Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser
    130                 135                 140
Lys Ile Gln Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu
145                 150                 155                 160
Arg Pro Val Glu Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu
                165                 170                 175
Ile Lys Pro Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu
            180                 185                 190
Lys Leu Asp Met Asn Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val
        195                 200                 205
Lys Thr Val Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly
    210                 215                 220
Ile Glu Ile Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr
225                 230                 235                 240
Phe Pro Gly Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Lys
                245                 250                 255
Val Thr Asp Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys
            260                 265                 270
Asp Glu His Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val
        275                 280                 285
Asp Phe Glu Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr
    290                 295                 300
Lys Ala Asn Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys
305                 310                 315                 320
```

```
Tyr Pro His Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala
                325                 330                 335
Gly Pro Cys Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr
            340                 345                 350
Phe Asn Gly Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val
        355                 360                 365
Val Asp Arg Cys Gly Cys Ser
    370                 375
```

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: #83

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..34
(C) OTHER:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CGCGGATCCG TGGATCTAAA TGAGAACAGT GAGC 34

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: #84

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...37
(C) OTHER:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CGCGAATTCT CAGGTAATGA TTGTTTCCGT TGTAGCG 37

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: #100

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...20
(C) OTHER:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
ACACTAAATC TTCAAGAATA 20

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1055 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: Baboon GDF-8

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...1055
(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```
                                                    ATG CAA AAA            9
                                                    Met Gln Lys
                                                      1

CTG CAA CTC TGT GTT TAT ATT TAC CTG TTT ATG CTG ATT GTT GCT GGT       54
Leu Gln Leu Cys Val Tyr Ile Tyr Leu Phe Met Leu Ile Val Ala Gly
  5                  10                  15                  20

CCA GTG GAT CTA AAT GAG AAC AGT GAG CAA AAA GAA AAT GTG GAA AAA       95
Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn Val Glu Lys
                  25                  30                  35

GAG GGG CTG TGT AAT GCA TGT ACT TGG AGA CAA AAC ACT AAA TCT TCA      140
Glu Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr Lys Ser Ser
              40                  45                  50

AGA ATA GAA GCC ATT AAA ATA CAA ATC CTC AGT AAA CTT CGT CTG GAA      185
Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
          55                  60                  65

ACA GCT CCT AAC ATC AGC AAA GAT GCT ATA AGA CAA CTT TTA CCC AAA      230
Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu Leu Pro Lys
      70                  75                  80

GCG CCT CCA CTC CGG GAA CTG ATT GAT CAG TAT GAT GTC CAG AGG GAT      275
Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val Gln Arg Asp
  85                  90                  95                  100
```

```
GAC AGC AGC GAT GGC TCT TTG GAA GAT GAC GAT TAT CAC GCT ACA ACG      320
Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Thr Thr
                    105                 110                 115

GAA ACA ATC ATT ACC ATG CCT ACA GAG TCT GAT TTT TTA ATG CAA GTG      365
Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu Met Gln Val
            120                 125                 130

GAT GGA AAA CCC AAA TGT TGC TTC TTT AAA TTT AGC TCT AAA ATA CAA      410
Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
        135                 140                 145


TAC AAT AAA GTG GTA AAG GCC CAA CTA TGG ATA TAT TTG AGA CCC GTC      455
Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Pro Val
    150                 155                 160

GAG ACT CCT ACA ACA GTG TTT GTG CAA ATC CTG AGA CTC ATC AAA CCT      500
Glu Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180

ATG AAA GAC GGT ACA AGG TAT ACT GGA ATC CGA TCT CTG AAA CTT GAC      545
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
                185                 190                 195

ATG AAC CCA GGC ACT GGT ATT TGG CAG AGC ATT GAT GTG AAG ACA GTG      590
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
            200                 205                 210

TTG CAA AAT TGG CTC AAA CAA CCT GAA TCC AAC TTA GGC ATT GAA ATA      635
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
        215                 220                 225

AAA GCT TTA GAT GAG AAT GGT CAT GAT CTT GCT GTA ACC TTC CCA GGA      680
Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr Phe Pro Gly
    230                 235                 240

CCA GGA GAA GAT GGG CTG AAT CCC TTT TTA GAG GTC AAG GTA ACA GAC      725
Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Lys Val Thr Asp
245                 250                 255                 260

ACA CCC AAA AGA TCC AGA AGG GAT TTT GGT CTT GAC TGT GAT GAG CAC      770
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
                265                 270                 275

TCA ACA GAA TCG CGA TGC TGT CGT TAC CCT CTA ACT GTG GAT TTT GAA      815
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
            280                 285                 290

GCT CTT GGA TGG GAT TGG ATT ATC GCT CCT AAA AGA TAT AAG GCC AAT      860
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
        295                 300                 305

TAC TGC TCT GGA GAG TGT GAA TTT GTA TTT TTA CAA AAA TAT CCT CAT      905
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
    310                 315                 320

ACT CAT CTG GTA CAC CAA GCA AAC CCC AGA GGT TCA GCA GGC CCT TGC      950
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340

TGT ACT CCC ACA AAG ATG TCT CCA ATT AAT ATG CTA TAT TTT AAT GGC      995
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
                345                 350                 355
```

```
AAA GAA CAA ATA ATA TAT GGG AAA ATT CCA GCC ATG GTA GTA GAC CGC     1040
Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
            360                 365                 370

TGC GGG TGC TCA TGA                                             1055
Cys Gly Cys Ser
        375
```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 376 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
(B) CLONE: Baboon GDF-8

(ix) FEATURE:
(A) NAME/KEY: Protein
(B) LOCATION: 1...376
(D) OTHER:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```
                                                    Met Gln Lys
                                                     1
Leu Gln Leu Cys Val Tyr Ile Tyr Leu Phe Met Leu Ile Val Ala Gly
  5                 10                  15                  20
Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn Val Glu Lys
             25                  30                  35
Glu Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr Lys Ser Ser
         40                  45                  50
Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
     55                  60                  65
Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu Leu Pro Lys
 70                  75                  80
Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val Gln Arg Asp
 85                  90                  95                  100
Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Thr Thr
             105                 110                 115
Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu Met Gln Val
         120                 125                 130
Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
     135                 140                 145
Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Pro Val
 150                 155                 160
Glu Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
             185                 190                 195
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
         200                 205                 210
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
     215                 220                 225
Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr Phe Pro Gly
 230                 235                 240
Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Lys Val Thr Asp
245                 250                 255                 260
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
             265                 270                 275
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
         280                 285                 290
```

```
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
        295                 300                 305
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
    310                 315                 320
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
                345                 350                 355
Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
            360                 365                 370
Cys Gly Cys Ser
        375
```

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1055 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: Bovine GDF-8

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...1055

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

```
                                                    ATG CAA AAA      9
                                                    Met Gln Lys
                                                      1

CTG CAA ATC TCT GTT TAT ATT TAC CTA TTT ATG CTG ATT GTT GCT GGC     54
Leu Gln Ile Ser Val Tyr Ile Tyr Leu Phe Met Leu Ile Val Ala Gly
  5                  10                  15                  20

CCA GTG GAT CTG AAT GAG AAC AGC GAG CAG AAG GAA AAT GTG GAA AAA     95
Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn Val Glu Lys
                25                  30                  35

GAG GGG CTG TGT AAT GCA TGT TTG TGG AGG GAA AAC ACT ACA TCG TCA     140
Glu Gly Leu Cys Asn Ala Cys Leu Trp Arg Glu Asn Thr Thr Ser Ser
            40                  45                  50

AGA CTA GAA GCC ATA AAA ATC CAA ATC CTC AGT AAA CTT CGC CTG GAA     185
Arg Leu Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
        55                  60                  65

ACA GCT CCT AAC ATC AGC AAA GAT GCT ATC AGA CAA CTT TTG CCC AAG     230
Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu Leu Pro Lys
    70                  75                  80

GCT CCT CCA CTC CTG GAA CTG ATT GAT CAG TTC GAT GTC CAG AGA GAT     275
Ala Pro Pro Leu Leu Glu Leu Ile Asp Gln Phe Asp Val Gln Arg Asp
 85                  90                  95                  100

GCC AGC AGT GAC GGC TCC TTG GAA GAC GAT GAC TAC CAC GCC AGG ACG     320
Ala Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Arg Thr
                105                 110                 115
```

```
GAA ACG GTC ATT ACC ATG CCC ACG GAG TCT GAT CTT CTA ACG CAA GTG      365
Glu Thr Val Ile Thr Met Pro Thr Glu Ser Asp Leu Leu Thr Gln Val
            120                 125                 130

GAA GGA AAA CCC AAA TGT TGC TTC TTT AAA TTT AGC TCT AAG ATA CAA      410
Glu Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
        135                 140                 145

TAC AAT AAA CTA GTA AAG GCC CAA CTG TGG ATA TAT CTG AGG CCT GTC      455
Tyr Asn Lys Leu Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Pro Val
    150                 155                 160

AAG ACT CCT GCG ACA GTG TTT GTG CAA ATC CTG AGA CTC ATC AAA CCC      500
Glu Thr Pro Thr Ala Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180

ATG AAA GAC GGT ACA AGG TAT ACT GGA ATC CGA TCT CTG AAA CTT GAC      545
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
                185                 190                 195

ATG AAC CCA GGC ACT GGT ATT TGG CAG AGC ATT GAT GTG AAG ACA GTG      590
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
            200                 205                 210

TTG CAG AAC TGG CTC AAA CAA CCT GAA TCC AAC TTA GGC ATT GAA ATC      635
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
        215                 220                 225

AAA GCT TTA GAT GAG AAT GGC CAT GAT CTT GCT GTA ACC TTC CCA GAA      680
Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr Phe Pro Glu
    230                 235                 240

CCA GGA GAA GAT GGA CTG ACT CCC TTT TTA GAA GTC AAG GTA ACA GAC      725
Pro Gly Glu Asp Gly Leu Thr Pro Phe Leu Glu Val Lys Val Thr Asp
245                 250                 255                 260

ACA CCA AAA AGA TCT AGG AGA GAT TTT GGG CTT GAT TGT GAT GAA CAC      770
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
                265                 270                 275

TCC ACA GAA TCT CGA TGC TGT CGT TAC CCT CTA ACT GTG GAT TTT GAA      815
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
            280                 285                 290

GCT TTT GGA TGG GAT TGG ATT ATT GCA CCT AAA AGA TAT AAG GCC AAT      860
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
        295                 300                 305

TAC TGC TCT GGA GAA TGT GAA TTT GTA TTT TTG CAA AAG TAT CCT CAT      905
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
    310                 315                 320

ACC CAT CTT GTG CAC CAA GCA AAC CCC AGA GGT TCA GCC GGC CCC TGC      950
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340

TGT ACT CCT ACA AAG ATG TCT CCA ATT AAT ATG CTA TAT TTT AAT GGC      995
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
                345                 350                 355

GAA GGA CAA ATA ATA TAC GGG AAG ATT CCA GCC ATG GTA GTA GAT CGC     1040
Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
            360                 365                 370
```

```
TGT GGG TGT TCA TGA                                                    1055
Cys Gly Cys Ser
        375
```

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 119 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```
                                                    Met Gln Lys
                                                     1
Leu Gln Ile Ser Val Tyr Ile Tyr Leu Phe Met Leu Ile Val Ala Gly
  5                  10                  15                  20
Pro Val Asp Leu Asn Glu Asn Ser Glu Gln Lys Glu Asn Val Glu Lys
                25                  30                  35
Glu Gly Leu Cys Asn Ala Cys Leu Trp Arg Glu Asn Thr Thr Ser Ser
            40                  45                  50
Arg Leu Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
        55                  60                  65
Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu Leu Pro Lys
    70                  75                  80
Ala Pro Pro Leu Leu Glu Leu Ile Asp Gln Phe Asp Val Gln Arg Asp
85                  90                  95                  100
Ala Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Arg Thr
                105                 110                 115
Glu Thr Val Ile Thr Met Pro Thr Glu Ser Asp Leu Leu Thr Gln Val
            120                 125                 130
Glu Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
        135                 140                 145
Tyr Asn Lys Leu Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Pro Val
    150                 155                 160
Glu Thr Pro Thr Ala Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
                185                 190                 195
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
            200                 205                 21
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
        215                 220                 225
Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr Phe Pro Glu
    230                 235                 240
Pro Gly Glu Asp Gly Leu Thr Pro Phe Leu Glu Val Lys Val Thr Asp
245                 250                 255                 260
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
                265                 270                 275
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
            280                 285                 290
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
        295                 300                 305
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
    310                 315                 320
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
                345                 350                 355
```

```
Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
            360                 365                 370
Cys Gly Cys Ser
        375
```

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1055 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: Chicken GDF-8

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...1055
(D) OTHER:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```
                                                    ATG CAA AAG      9
                                                    Met Gln Lys
                                                     1

CTG GCA GTC TAT GTT TAT ATT TAC CTG TTC ATG CAG ATC GCG GTT GAT     54
Leu Ala Val Tyr Val Tyr Ile Tyr Leu Phe Met Gln Ile Ala Val Asp
  5                  10                  15                  20

CCG GTG GCT CTG GAT GGC AGT AGT CAG CCC ACA GAG AAC GCT GAA AAA     95
Pro Val Ala Leu Asp Gly Ser Ser Glu Gln Lys Glu Asn Val Glu Lys
                 25                  30                  35

GAC GGA CTG TGC AAT GCT TGT ACG TGG AGA CAG AAT ACA AAA TCC TCC    140
Glu Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr Lys Ser Ser
             40                  45                  50

AGA ATA GAA GCC ATA AAA ATT CAA ATC CTC AGC AAA CTG CGC CTG GAA    185
Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
         55                  60                  65

CAA GCA CCT AAC ATT AGC AGG GAC GTT ATT AAG CAG CTT TTA CCC AAA    230
Gln Ala Pro Asn Ile Ser Arg Asp Val Ile Lys Gln Leu Leu Pro Lys
     70                  75                  80

GCT CCT CCA CTG CAG GAA CTG ATT GAT CAG TAT GAT GTC CAG AGG GAC    275
Ala Pro Pro Leu Gln Glu Leu Ile Asp Gln Tyr Asp Val Gln Arg Asp
 85                  90                  95                 100

GAC AGT AGC GAT GGC TCT TTG GAA GAC GAT GAC TAT CAT GCC ACA ACC    320
Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Thr Thr
                105                 110                 115

GAG ACG ATT ATC ACA ATG CCT ACG GAG TCT GAT TTT CTT GTA CAA ATG    365
Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu Val Gln Met
            120                 125                 130

GAG GGA AAA CCA AAA TGT TGC TTC TTT AAG TTT AGC TCT AAA ATA CAA    410
Glu Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
        135                 140                 145
```

```
TAT AAC AAA GTA GTA AAG GCA CAA TTA TGG ATA TAC TTG AGG CAA GTC      455
Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Gln Val
    150                 155                 160

CAA AAA CCT ACA ACG GTG TTT GTG CAG ATC CTG AGA CTC ATT AAG CCC      500
Gln Lys Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180


ATG AAA GAC GGT ACA AGA TAT ACT GGA ATT CGA TCT TTG AAA CTT GAC      545
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
                185                 190                 195

ATG AAC CCA GGC ACT GGT ATC TGG CAG AGT ATT GAT GTG AAG ACA GTG      590
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
            200                 205                 210

CTG CAA AAT TGG CTC AAA CAG CCT GAA TCC AAT TTA GGC ATC GAA ATA      635
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
        215                 220                 225

AAA GCT TTT GAT GAG ACT GGA CGA GAT CTT GCT GTC ACA TTC CCA GGA      680
Lys Ala Phe Asp Glu Thr Gly Arg Asp Leu Ala Val Thr Phe Pro Gly
    230                 235                 240

CCA GGA GAA GAT GGA TTG AAC CCA TTT TTA GAG GTC AGA GTT ACA GAC      725
Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Arg Val Thr Asp
245                 250                 255                 260

ACA CCG AAA CGG TCC CGC AGA GAT TTT GGC CTT GAC TGT GAT GAG CAC      770
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
                265                 270                 275

TCA ACG GAA TCC CGA TGT TGT CGC TAC CCG CTG ACA GTG GAT TTC GAA      815
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
            280                 285                 290

GCT TTT GGA TGG GAC TGG ATT ATA GCA CCT AAA AGA TAC AAA GCC AAT      860
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
        295                 300                 305

TAC TGC TCC GGA GAA TGC GAA TTT GTG TTT CTA CAG AAA TAC CCG CAC      905
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
    310                 315                 320

ACT CAC CTG GTA CAC CAA GCA AAT CCC AGA GGC TCA GCA GGC CCT TGC      950
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340

TGC ACA CCC ACC AAG ATG TCC CCT ATA AAC ATG CTG TAT TTC AAT GGA      995
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
                345                 350                 355

AAA GAA CAA ATA ATA TAT GGA AAG ATA CCA GCC ATG GTT GTA GAT CGT     1040
Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
            360                 365                 370

TGC GGG TGC TCA TGA                                                1055
Cys Gly Cys Ser
        375
```

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 376 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(vii) IMMEDIATE SOURCE:
(B) CLONE: Chicken GDF-8
(ix) FEATURE:
(A) NAME/KEY: Protein
(B) LOCATION: 1..376
(D) OTHER:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```
                                                    Met Gln Lys
                                                      1
Leu Ala Val Tyr Val Tyr Ile Tyr Leu Phe Met Gln Ile Ala Val Asp
  5                  10                  15                  20
Pro Val Ala Leu Asp Gly Ser Ser Glu Gln Lys Glu Asn Val Glu Lys
                25                  30                  35
Glu Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr Lys Ser Ser
            40                  45                  50
Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
        55                  60                  65
Gln Ala Pro Asn Ile Ser Arg Asp Val Ile Lys Gln Leu Leu Pro Lys
    70                  75                  80
Ala Pro Pro Leu Gln Glu Leu Ile Asp Gln Tyr Asp Val Gln Arg Asp
 85                  90                  95                 100
Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Thr Thr
            105                 110                 11
Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu Val Gln Met
        120                 125                 130
Glu Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
    135                 140                 145
Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Gln Val
150                 155                 160
Gln Lys Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
            185                 190                 195
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
        200                 205                 210
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
    215                 220                 225
Lys Ala Phe Asp Glu Thr Gly Arg Asp Leu Ala Val Thr Phe Pro Gly
230                 235                 240
Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Arg Val Thr Asp
245                 250                 255                 260
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
            265                 270                 275
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
        280                 285                 290
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
    295                 300                 305
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
310                 315                 320
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
            345                 350                 355

Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
        360                 365                 370
```

Cys Gly Cys Ser
375

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1276 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: Rat GDF-8

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...1276
(D) OTHER:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```
                                                    ATG ATT CAA AAA      115
                                                    Met Ile Gln Lys
                                                      1

CCG CAA ATG TAT GTT TAT ATT TAC CTG TTT GTG CTG ATT GCT GCT GGC      163
Pro Gln Met Tyr Val Tyr Ile Tyr Leu Phe Val Leu Ile Ala Ala Gly
  5                  10                  15                  20

CCA GTG GAT CTA AAT GAG GAC AGT GAG AGA GAG GCG AAT GTG GAA AAA      211
Pro Val Asp Leu Asn Glu Asp Ser Glu Arg Glu Ala Asn Val Glu Lys
                 25                  30                  35

GAG GGG CTG TGT AAT GCG TGT GCG TGG AGA CAA AAC ACA AGG TAC TCC      259
Glu Gly Leu Cys Asn Ala Cys Ala Trp Arg Gln Asn Thr Arg Tyr Ser
             40                  45                  50

AGA ATA GAA GCC ATA AAA ATT CAA ATC CTC AGT AAA CTC CGC CTG GAA      307
Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
         55                  60                  65

ACA GCG CCT AAC ATC AGC AAA GAT GCT ATA AGA CAA CTT CTG CCC AGA      355
Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu Leu Pro Arg
     70                  75                  80

GCG CCT CCA CTC CGG GAA CTG ATC GAT CAG TAC GAC GTC CAG AGG GAT      403
Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val Gln Arg Asp
 85                  90                  95                 100

GAC AGC AGT GAC GGC TCT TTG GAA GAT GAC GAT TAT CAC GCT ACC ACG      451
Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Thr Thr
                105                 110                 115

GAA ACA ATC ATT ACC ATG CCT ACC GAG TCT GAC TTT CTA ATG CAA GCG      499
Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu Met Gln Ala
            120                 125                 130

GAT GGA AAG CCC AAA TGT TGC TTT TTT AAA TTT AGC TCT AAA ATA CAG      547
Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
        135                 140                 145
```

```
TAC AAC AAA GTG GTA AAG GCC CAG CTG TGG ATA TAT CTG AGA GCC GTC      595
Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Ala Val
    150                 155                 160

AAG ACT CCT ACA ACA GTG TTT GTG CAA ATC CTG AGA CTC ATC AAA CCC      643
Lys Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180

ATG AAA GAC GGT ACA AGG TAT ACC GGA ATC CGA TCT CTG AAA CTT GAC      691
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
                185                 190                 195

ATG AGC CCA GGC ACT GGT ATT TGG CAG AGT ATT GAT GTG AAG ACA GTG      739
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
            200                 205                 210

TTG CAA AAT TGG CTC AAA CAG CCT GAA TCC AAC TTA GGC ATT GAA ATC      787
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
        215                 220                 225

AAA GCT TTG GAT GAG AAT GGG CAT GAT CTT GCT GTA ACC TTC CCA GGA      835
Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr Phe Pro Gly
    230                 235                 240

CCA GGA GAA GAT GGG CTG AAT CCC TTT TTA GAA GTC AAA GTA ACA GAC      883
Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Lys Val Thr Asp
245                 250                 255                 260

ACA CCC AAG AGG TCC CGG AGA GAC TTT GGG CTT GAC TGC GAT GAA CAC      931
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
                265                 270                 275

TCC ACG GAA TCG CGG TGC TGT CGC TAC CCC CTC ACG GTC GAT TTC GAA      979
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
            280                 285                 290

GCC TTT GGA TGG GAC TGG ATT ATT GCA CCC AAA AGA TAT AAG GCT AAT     1027
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
        295                 300                 305

TAC TGC TCT GGA GAG TGT GAA TTT GTG TTC TTA CAA AAA TAT CCG CAT     1075
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
    310                 315                 320

ACT CAT CTT GTG CAC CAA GCA AAC CCC AGA GGC TCG GCA GGC CCT TGC     1123
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340

TGC ACG CCA ACA AAA ATG TCT CCC ATT AAT ATG CTA TAT TTT AAT GGC     1171
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
                345                 350                 355

AAA GAA CAA ATA ATA TAT GGG AAA ATT CCA GCC ATG GTA GTA GAC CGG     1219
Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
            360                 365                 370

TGT GGG TGC TCG TGA                                                1276
Cys Gly Cys Ser
        375
```

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 376 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
(B) CLONE: Rat GDF-8

(ix) FEATURE:
(A) NAME/KEY: Protein
(B) LOCATION: 1..376
(D) OTHER:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```
                                                    Met Ile Gln Lys
                                                     1
Pro Gln Met Tyr Val Tyr Ile Tyr Leu Phe Val Leu Ile Ala Ala Gly
  5                  10                  15                  20
Pro Val Asp Leu Asn Glu Asp Ser Glu Arg Glu Ala Asn Val Glu Lys
                25                  30                  35
Glu Gly Leu Cys Asn Ala Cys Ala Trp Arg Gln Asn Thr Arg Tyr Ser
            40                  45                  50
Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
        55                  60                  65
Thr Ala Pro Asn Ile Ser Lys Asp Ala Ile Arg Gln Leu Leu Pro Arg
    70                  75                  80
Ala Pro Pro Leu Arg Glu Leu Ile Asp Gln Tyr Asp Val Gln Arg Asp
 85                  90                  95                  100
Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Thr Thr
                105                 110                 115
Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu Met Gln Ala
            120                 125                 130
Asp Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
        135                 140                 145
Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Ala Val
    150                 155                 160
Lys Thr Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
                185                 190                 195
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
            200                 205                 210
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
        215                 220                 225
Lys Ala Leu Asp Glu Asn Gly His Asp Leu Ala Val Thr Phe Pro Gly
    230                 235                 240
Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Lys Val Thr Asp
245                 250                 255                 260
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
                265                 270                 275
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
            280                 285                 290
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
        295                 300                 305
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
    310                 315                 320
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
                345                 350                 355
Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
            360                 365                 370
Cys Gly Cys Ser
        375
```

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1055 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(vii) IMMEDIATE SOURCE:
(B) CLONE: Turkey GDF-8

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1...1055
(D) OTHER:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

```
                                                       ATG CAA AAG          9
                                                       Met Gln Lys
                                                         1

CTA GCA GTC TAT GTT TAT ATT TAC CTG TTC ATG CAG ATT TTA GTT CAT      54
Leu Ala Val Tyr Val Tyr Ile Tyr Leu Phe Met Gln Ile Leu Val His
  5                  10                  15                  20

CCG GTG GCT CTT GAT GGC AGT AGT CAG CCC ACA GAG AAC GCT GAA AAA      95
Pro Val Ala Leu Asp Gly Ser Ser Glu Gln Lys Glu Asn Val Glu Lys
                 25                  30                  35

GAC GGA CTG TGC AAT GCT TGC ACG TGG AGA CAG AAT ACT AAA TCC TCC     140
Glu Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr Lys Ser Ser
             40                  45                  50

AGA ATA GAA GCC ATA AAA ATT CAA ATC CTC AGC AAA CTG CGC CTG GAA     185
Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
         55                  60                  65

CAA GCA CCT AAC ATT AGC AGG GAC GTT ATT AAA CAA CTT TTA CCC AAA     230
Gln Ala Pro Asn Ile Ser Arg Asp Val Ile Lys Gln Leu Leu Pro Lys
     70                  75                  80

GCT CCT CCG CTG CAG GAA CTG ATT GAT CAG TAT GAC GTC CAG AGA GAC     275
Ala Pro Pro Leu Gln Glu Leu Ile Asp Gln Tyr Asp Val Gln Arg Asp
 85                  90                  95                 100

GAC AGT AGC GAT GGC TCT TTG GAA GAC GAT GAC TAT CAT GCC ACA ACC     320
Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Thr Thr
                105                 110                 115

GAA ACG ATT ATC ACA ATG CCT ACG GAG TCT GAT TTT CTT GTA CAA ATG     365
Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu Val Gln Met
            120                 125                 130

GAG GGA AAA CCA AAA TGT TGC TTC TTT AAG TTT AGC TCT AAA ATA CAA     410
Glu Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
        135                 140                 145

TAT AAC AAA GTA GTA AAG GCA CAA TTA TGG ATA TAC TTG AGG CAA GTC     455
Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Gln Val
    150                 155                 160
```

```
CAA AAA CCT ACA ACG GTG TTT GTG CAG ATC CTG AGA CTC ATT AAA CCC      500
Gln Lys Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180

ATG AAA GAC GGT ACA AGA TAT ACT GGA ATT CGA TCT TTG AAA CTT GAC      545
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
                185                 190                 195

ATG AAC CCA GGC ACT GGT ATC TGG CAG AGT ATT GAT GTG AAG ACA GTG      590
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
            200                 205                 210

TTG CAA AAT TGG CTC AAA CAG CCT GAA TCC AAT TTA GGC ATC GAA ATA      635
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
        215                 220                 225

AAA GCT TTT GAT GAG AAT GGA CGA GAT CTT GCT GTA ACA TTC CCA GGA      680
Lys Ala Phe Asp Glu Asn Gly Arg Asp Leu Ala Val Thr Phe Pro Gly
    230                 235                 240

CCA GGT GAA GAT GGA CTG AAC CCA TTT TTA GAG GTC AGA GTT ACA GAC      725
Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Arg Val Thr Asp
245                 250                 255                 260

ACA CCA AAA CGG TCC CGC AGA GAT TTT GGC CTT GAC TGC GAC GAG CAC      770
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
                265                 270                 275

TCA ACG GAA TCT CGA TGT TGT CGC TAC CCG CTG ACA GTG GAT TTT GAA      815
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
            280                 285                 290

GCT TTT GGA TGG GAC TGG ATT ATA GCA CCT AAA AGA TAC AAA GCC AAT      860
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
        295                 300                 305

TAC TGC TCT GGA GAA TGT GAA TTC GTA TTT CTA CAG AAA TAC CCG CAC      905
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
    310                 315                 320

ACT CAC CTG GTA CAC CAA GCA AAT CCA AGA GGC TCA GCA GGC CCT TGC      950
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340

TGC ACA CCC ACC AAG ATG TCC CCT ATA AAC ATG CTG TAT TTC AAT GGA      995
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
                345                 350                 355

AAA GAA CAA ATA ATA TAT GGA AAG ATA CCA GCC ATG GTT GTA GAT CGT     1040
Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
            360                 365                 370

TGC GGG TGC TCA TGA                                                1055
Cys Gly Cys Ser
        375
```

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 376 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
(B) CLONE: Turkey GDF-8

(ix) FEATURE:
(A) NAME/KEY: Protein
(B) LOCATION: 1..376
(D) OTHER:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

```
                                                        Met Gln Lys
                                                         1
Leu Ala Val Tyr Val Tyr Ile Tyr Leu Phe Met Gln Ile Leu Val His
  5                  10                  15                  20
Pro Val Ala Leu Asp Gly Ser Ser Glu Gln Lys Glu Asn Val Glu Lys
             25                  30                  35
Glu Gly Leu Cys Asn Ala Cys Thr Trp Arg Gln Asn Thr Lys Ser Ser
         40                  45                  50
Arg Ile Glu Ala Ile Lys Ile Gln Ile Leu Ser Lys Leu Arg Leu Glu
     55                  60                  65
Gln Ala Pro Asn Ile Ser Arg Asp Val Ile Lys Gln Leu Leu Pro Lys
 70                  75                  80
Ala Pro Pro Leu Gln Glu Leu Ile Asp Gln Tyr Asp Val Gln Arg Asp
 85                  90                  95                  100
Asp Ser Ser Asp Gly Ser Leu Glu Asp Asp Asp Tyr His Ala Thr Thr
             105                 110                 115
Glu Thr Ile Ile Thr Met Pro Thr Glu Ser Asp Phe Leu Val Gln Met
         120                 125                 130
Glu Gly Lys Pro Lys Cys Cys Phe Phe Lys Phe Ser Ser Lys Ile Gln
     135                 140                 145
Tyr Asn Lys Val Val Lys Ala Gln Leu Trp Ile Tyr Leu Arg Gln Val
 150                 155                 160
Gln Lys Pro Thr Thr Val Phe Val Gln Ile Leu Arg Leu Ile Lys Pro
165                 170                 175                 180
Met Lys Asp Gly Thr Arg Tyr Thr Gly Ile Arg Ser Leu Lys Leu Asp
             185                 190                 195
Met Ser Pro Gly Thr Gly Ile Trp Gln Ser Ile Asp Val Lys Thr Val
         200                 205                 210
Leu Gln Asn Trp Leu Lys Gln Pro Glu Ser Asn Leu Gly Ile Glu Ile
     215                 220                 225
Lys Ala Phe Asp Glu Asn Gly Arg Asp Leu Ala Val Thr Phe Pro Gly
 230                 235                 240
Pro Gly Glu Asp Gly Leu Asn Pro Phe Leu Glu Val Arg Val Thr Asp
245                 250                 255                 260
Thr Pro Lys Arg Ser Arg Arg Asp Phe Gly Leu Asp Cys Asp Glu His
             265                 270                 275
Ser Thr Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu
         280                 285                 290
Ala Phe Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn
     295                 300                 305
Tyr Cys Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His
 310                 315                 320
Thr His Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys
325                 330                 335                 340
Cys Thr Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly
             345                 350                 355

Lys Glu Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg
         360                 365                 370
Cys Gly Cys Ser
     375
```

CLAIMS

1. A transgenic non-human animal having a transgene disrupting or interfering with expression of growth differentiation factor-8 (GDF-8) chromosomally integrated into the germ cells of the animal.

2. The transgenic animal of claim 1, wherein the animal is selected from the group of species consisting of avian, bovine, ovine, piscine, murine, and porcine.

3. The transgenic animal of claim 1 where the species is avian.

4. The transgenic animal of claim 1 where the species is bovine.

5. The transgenic animal of claim 1 where the species is porcine.

6. The transgenic animal of claim 1 where the species is ovine.

7. The transgenic animal of claim 1 where the species is piscine.

8. The transgenic animal of claim 1, wherein the transgene comprises GDF-8 antisense polynucleotide(s).

9. The transgenic animal of claim 1, wherein the transgene comprises a gene encoding a dominant negative GDF-8 polypeptide.

10. The transgenic animal of claim 1, wherein the animal is homozygous or heterozygous for GDF-8 polynucleotide.

11. A chicken or turkey egg produced by the transgenic animal of claim 3.

12. Beef obtained from the transgenic animal of claim 4.

13. Milk obtained from the transgenic animal of claim 4.

14. Pork obtained from the transgenic animal of claim 5.

15. Lamb obtained from the transgenic animal of claim 6.

16. Chicken or turkey meat produced by the transgenic animal of claim 3.

17. A method of producing animal food products having increased muscle mass comprising:

a) introducing a transgene disrupting or interfering with expression of growth differentiation factor-8 (GDF-8) into an embryo into germ cells of a pronuclear embryo of the animal;

b) implanting the embryo into the oviduct of a pseudopregnant female thereby allowing the embryo to mature to full term progeny;

c) testing the progeny for presence of the transgene to identify transgene-positive progeny;

d) cross-breeding transgene-positive progeny to obtain further transgene-positive progeny; and

e) processing the progeny to obtain foodstuff.

18. The method of claim 17, wherein the transgene comprises GDF-8 antisense polynucleotides.

19. The method of claim 17, wherein the transgene comprises a gene encoding a dominant negative GDF-8 polypeptide.

20. A method of producing avian food products having reduced cholesterol levels comprising:

a) introducing a transgene disrupting or interfering with expression of growth differentiation factor-8 (GDF-8) into an embryo of an avian animal;

b) culturing the embryo under conditions whereby progeny are hatched;

c) testing the progeny for presence of the transgene to identify transgene-positive progeny;

d) cross-breeding transgene-positive progeny; and

e) processing the progeny to obtain foodstuff.

21. The method of claim 20, wherein the transgene comprises GDF-8 antisense polynucleotides.

22. The method of claim 20, wherein the transgene comprises a gene encoding a dominant negative GDF-8 polypeptide.

23. The transgenic animal of claim 20, wherein the transgene comprises a polynucleotide encoding a truncated GDF-8 polypeptide.

24. A method for increasing the muscle mass in an animal comprising administering to the animal an antibody, or fragment thereof, which binds to GDF-8 polypeptide.

25. The method of claim 24, wherein anti-GDF-8 antibody is administered to a domesticated animal.

26. The method of claim 24, wherein the antibody is a monoclonal antibody or a polyclonal antibody.

27. The method of claim 24, wherein the anti-GDF-8 antibody is administered by intravenous, intramuscular, multiple bolus, or subcutaneous injections.

28. The method of claim 27, wherein the anti-GDF-8 antibody is administered within a dose range of 0.1 ug/kg to 100 mg/kg.

29. The method of claim 27, wherein the antibody is formulated in a formulation suitable for administration by injection into an animal.

30. A method of inhibiting the growth regulating actions of GDF-8 comprising contacting a GDF-8 agent with fetal or adult muscle cells or progenitor cells.

31. The method of claim 30, wherein the agent is selected from the group consisting of a monoclonal antibody, an antisense nucleic acid and a dominant negative encoding nucleic acid sequence or polypeptide.

32. The method of claim 31, wherein the antibody is a humanized monoclonal antibody or a chimeric monoclonal antibody or fragment thereof.

33. The method of claim 30, wherein the agent is administered to a patient suffering from a disorder selected from the group consisting of muscle wasting disease, neuromuscular disorder, muscle atrophy and aging.

34. The method of claim 30, wherein the agent is administered to a patient suffering from a disorder selected from the group consisting of muscular dystrophy, spinal cord injury, traumatic injury, congestive obstructive pulmonary disease (COPD), AIDS and cachechia.

35. The method of claim 30, wherein the agent is administered to a patient with muscle wasting disease or disorder by intravenous, intramuscular or subcutaneous injection.

36. The method of claim 31, wherein the monoclonal antibody is administered within a dose range between about 0.1/kg to about 100 mg/kg.

37. The method of claim 31, wherein the monoclonal antibody is formulated in a formulation suitable for administration to a patient.

38. A method for treating a muscle or adipose tissue disorder in a subject, comprising administering a therapeutically effective amount of a GDF-8 agent to the subject, thereby inhibiting abnormal growth of muscle or adipose tissue.

39. The method as in claim 38, wherein the GDF-8 agent is selected from the group consisting of an antisense polynucleotide, a polynucleotide encoding a dominant negative GDF-8 polypeptide, a GDF-8 antibody and a polynucleotide encoding a truncated GDF-8 polypeptide.

40. The method of claim 38, wherein the disorder is a cancer selected from the group consisting of muscle, connective tissue, or bone.

41. The method of claim 38, wherein the subject has an obesity disorder.

42. A method of inhibiting the growth regulating actions of GDF-8 in a subject comprising administering to the subject, a GDF-8 agent that inhibits the action of GDF-8 in the subject.

43. The method of claim 42, wherein the GDF-8 agent is selected from the group consisting of an antisense polynucleotide, a polynucleotide encoding a dominant negative GDF-8 polypeptide, a GDF-8 antibody and a polynucleotide encoding a truncated GDF-8 polypeptide.

44. A method for identifying a compound that affects GDF-8 activity or gene expression comprising:

a) incubating the compound with GDF-8 polypeptide, or with a recombinant cell expressing GDF-8 under conditions sufficient to allow the components to interact; and

b) determining the effect of the compound on GDF-8 activity or expression.

45. The method of claim 44, wherein the effect is inhibition of GDF-8 activity or expression.

46. The method of claim 44, wherein the effect is stimulation of GDF-8 activity or expression.

47. An isolated polynucleotide encoding a truncated GDF-8 polypeptide wherein the truncation is a loss of the C-terminal active fragment of GDF-8.

48. The isolated polynucleotide of claim 47, wherein the polynucleotide is as shown in FIGURE 12a.




FIG. 1a




Figure 1b

```
1   TTAAGGTAGGAAGGATTTCAGGCTCTATTTACATAATTGTTCTTTCCTTTTCACACAGAA  60
                                                              N
61  TCCCTTTTTAGAAGTCAAGGTGACAGACACACCCAAGAGGTCCCGGAGAGACTTTGGGCT 120
      P  F  L  E  V  K  V  T  D  T  P [K  R] S [R  R] D  F  G  L
121 TGACTGCGATGAGCACTCCACGGAATCCCGGTGCTGCCGCTACCCCCTCACGGTCGATTT 180
      D  C  D  E  H  S  T  E  S  R  C  C  R  Y  P  L  T  V  D  F
181 TGAAGCCTTTGGATGGGACTGGATTATCGCACCCAAAAGATATAAGGCCAATTACTGCTC 240
      E  A  F  G  W  D  W  I  I  A  P  K  R  Y  K  A  N  Y  C  S
241 AGGAGAGTGTGAATTTGTGTTTTTACAAAAATATCCGCATACTCATCTTGTGCACCAAGC 300
      G  E  C  E  F  V  F  L  Q  K  Y  P  H  T  H  L  V  H  Q  A
301 AAACCCCAGAGGCTCAGCAGGCCCTTGCTGCACTCCGACAAAAATGTCTCCCATTAATAT 360
      N  P  R  G  S  A  G  P  C  C  T  P  T  K  M  S  P  I  N  M
361 GCTATATTTTAATGGCAAAGAACAAATAATATATGGGAAAATTCCAGCCATGGTAGTAGA 420
      L  Y  F  N  G  K  E  Q  I  I  Y  G  K  I  P  A  M  V  V  D
421 CCGCTGTGGGTGCTCATGAGCTTTGCATTAGGTTAGAAACTTCCCAAGTCATGGAAGGTC 480
      R  C  G  C  S  *
481 TTCCCCTCAATTTCGAAACTGTGAATTCCTGCAGCCCGGGGGATCCACTAGTTCTAGAGC 540
541 GGCCGCCACC 550
```

FIG.2a

```
1   CAAAAAGATCCAGAAGGGATTTTGGTCTTGACTGTGATGAGCACTCAACAGAATCACGAT  60
    [K  R] S [R  R] D  F  G  L  D  C  D  E  H  S  T  E  S  R  C
61  GCTGTCGTTACCCTCTAACTGTGGATTTTGAAGCTTTTGGATGGGATTGGATTATCGCTC 120
      C  R  Y  P  L  T  V  D  F  E  A  F  G  W  D  W  I  I  A  P
121 CTAAAAGATATAAGGCCAATTACTGCTCTGGAGAGTGTGAATTTGTATTTTTACAAAAAT 180
      K  R  Y  K  A  N  Y  C  S  G  E  C  E  F  V  F  L  Q  K  Y
181 ATCCTCATACTCATCTGGTACACCAAGCAAACCCCAGAGGTTCAGCAGGCCCTTGCTGTA 240
      P  H  T  H  L  V  H  Q  A  N  P  R  G  S  A  G  P  C  C  T
241 CTCCCACAAAGATGTCTCCAATTAATATGCTATATTTTAATGGCAAAGAACAAATAATAT 300
      P  T  K  M  S  P  I  N  M  L  Y  F  N  G  K  E  Q  I  I  Y
301 ATGGGAAAATTCCAGCGATGGTAGTA 326
      G  K  I  P  A  M  V  V
```

FIG.2b

```
GAA GAT GGG CTG AAT CCC TTT TTA GAA GTC AAA GTA ACA GAC ACA CCC AAG AGG TCC CGG
 E   D   G   L   N   P   F   L   E   V   K   V   T   D   T   P   K   R   S   R

AGA GAC TTT GGG CTT GAC TGT GAT GAA CAC TCC ACG GAA TCG CGG TGC TGT CGC TAC CCC
 R   D   F   G   L   D   C   D   E   H   S   T   E   S   R   C   C   R   Y   P

CTC ACG GTC GAT TTC GAA GCC TTT GGA TGG GAC TGG ATT ATT GCA CCC AAA AGA TAT AAG
 L   T   V   D   F   E   A   F   G   W   D   W   I   I   A   P   K   R   Y   K

GCT AAT TAC TGC TCT GGA GAG TGT GAA TTT GTG TTC TTA CAA AAA TAT CCG CAT ACT CAT
 A   N   Y   C   S   G   E   C   E   F   V   F   L   Q   K   Y   P   H   T   H

CTT GTG CAC CAA GCA AAC CCC AGA GGC TCG GCA GGC CCT TGC TGC ACG CCA ACA AAA ATG
 L   V   H   Q   A   N   P   R   G   S   A   G   P   C   C   T   P   T   K   M

TCT CCC ATT AAT ATG CTA TAT TTT AAT GGC AAA GAA CAA ATA ATA TAT GGG AAA ATT CCA
 S   P   I   N   M   L   Y   F   N   G   K   E   Q   I   I   Y   G   K   I   P

GCC ATG GTA GTA GAC CGG TGT GGG TGC TCG TGA GCT TTG CAT TAG CTT TAA AAT TTC CCA
 A   M   V   V   D   R   C   G   C   S

AAT CGT GGA AGG TCT TCC CCT CGA TTT CGA AAC TGT GAA TTT ATG TAC CAC AGG CTG TAG
```

Rat GDF-8

FIG. 2c

```
TTA GTA GTA AAG GCA CAA TTA TGG ATA TAC TTG AGG CAA GTC CAA AAA CCT ACA ACG GTG
 L   V   V   K   A   Q   L   W   I   Y   L   R   Q   V   Q   K   P   T   T   V

TTT GTG CAG ATC CTG AGA CTC ATT AAG CCC ATG AAA GAC GGT ACA AGA TAT ACT GGA ATT
 F   V   Q   I   L   R   L   I   K   P   M   K   D   G   T   R   Y   T   G   I

GGA TCT TTG AAA CTT GAC ATG AAC CCA GGC ACT GGT ATC TGG CAG AGT ATT GAT GTG AAG
 G   S   L   K   L   D   M   N   P   G   T   G   I   W   Q   S   I   D   V   K

ACA GTG CTG CAA AAT TGG CTC AAA CAG CCT GAA TCC AAT TTA GGC ATC GAA ATA AAA GCT
 T   V   L   Q   N   W   L   K   Q   P   E   S   N   L   G   I   E   I   K   A

TTT GAT GAG ACT GGA CGA GAT CTT GCT GTC ACA TTC CCA GGA CCG GGT GAA GAT GGA TTG
 F   D   E   T   G   R   D   L   A   V   T   F   P   G   P   G   E   D   G   L

AAC CCA TTT TTA GAG GTC AGA GTT ACA GAC ACA CCG AAA CGG TCC CGC AGA GAT TTT GGC
 N   P   F   L   E   V   R   V   T   D   T   P   K   R   S   R   R   D   F   G

CTT GAC TGT GAT GAG CAC TCA ACG GAA TCC CGA TGT TGT CGC TAC CCG CTG ACA GTG GAT
 L   D   C   D   E   H   S   T   E   S   R   C   C   R   Y   P   L   T   V   D

TTC GAA GCT TTT GGA TGG GAC TGG ATT ATA GCA CCT AAA AGA TAC AAA GCC AAT TAC TGC
 F   E   A   F   G   W   D   W   I   I   A   P   K   R   Y   K   A   N   Y   C

TCC GGA GAA TGC GAA TTT GTG TTT CTA CAG AAA TAC CCG CAC ACT CAC CTG GTA CAC CAA
 S   G   E   C   E   F   V   F   L   Q   K   Y   P   H   T   H   L   V   H   Q

GCA AAT CCC AGA GGC TCA GCA GGC CCT TGC TGC ACA CCC ACC AAG ATG TCC CCT ATA AAC
 A   N   P   R   G   S   A   G   P   C   C   T   P   T   K   M   S   P   I   N

ATG CTG TAT TTC AAT GGA AAA GAA CAA ATA ATA TAT GGA AAG ATA CCA GCC ATG GTT GTA
 M   L   Y   F   N   G   K   E   Q   I   I   Y   G   K   I   P   A   M   V   V

GAT CGT TGC GGG TGC TCA TGA GGC TGT CGT GAG ATC CAC CAT TCG ATA AAT TGT GGA AGC
 D   R   C   G   C   S

CAC CAA AAA AAA AAG CTA TAT CCC CTC ATC CAT CTT TGA AAC TGT GAA ATT ACG TAC GCT

AGG CAT TGC C
```

Chicken GDF-8

FIG. 2d

```
GDF-8       SRRDFGLDCDEHSTESRCCRYPLTVDF-EAFGWD-WIIAPKRYKANYCSGECEFVFLQKYP----
GDF-1       RPRRDAEPVLGGGPGGACRARRLYVSF-REVGWHRWVIAPRGFLANYCQGQCALPVALSGSGPP
BMP-2       REKRQAKHKQRKRLKSSCKRHPLYVDF-SDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNS---
BMP-4       KRSPKHHSQRARKKNKNCRRHSLYVDF-SDVGWNDWIVAPPGYQAFYCHGDCPFPLADHLNS---
Vgr-1       SRGSGSSDYNGSELKTACKKHELYVSF-QDLGWQDWIIAPKGYAANYCDGECSFPLNAHMNA---
OP-1        LRMANVAENSSSDQRQACKKHELYVSF-RDLGWQDWIIAPEGYAAYYCEGECAFPLNSYMNA---
BMP-5       SRMSSVGDYNTSEQKQACKKHELYVSF-RDLGWQDWIIAPEGYAAFYCDGECSFPLNAHMNA---
BMP-3       EQTLKKARRKQWIEPRNCARRYLKVDF-ADIGWSEWIISPKSFDAYYCSGACQFPMPKSLKPS--
MIS         GPGRAQRSAGATAADGPCALRELSVDL----RAERSVLIPETYQANNCQGVCGWPQSDRNPRY--
Inhibinα    ALRLLQRPPEEPAAHANCHRVALNISF-QELGWERWIVYPPSFIFHYCHGGCGLHIPPNLSLPV-
InhibinβA   HRRRRRGLECDGKV-NICCKKQFFVSF-KDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSL-
InhibinβB   HRIRKRGLECDGRT-NLCCRQQFFIDF-RLIGWNDWIIAPTGYYGNYCEGSCPAYLAGVPGSAS-
TGF-β1      HRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWK-WIHEPKGYHANFCLGPCPYIWSLD------
TGF-β2      KKRALDAAYCFRNVQDNCCLRPLYIDFKRDLGWK-WIHEPKGYNANFCAGACPYLWSSD------
TGF-β3      KKRALDTNYCFRNLEENCCVRPLYIDFRQDLGWK-WVHEPKGYYANFCSGPCPYLRSAD------

GDF-8       -HTHLVHQANPRG-------SAGPCCT--PTKMSPINMLYF-NGKEQIIYGKIPAMVVDRCGCS

GDF-1       ALNHAVLRALMHA--AAPGAADLPCCV--PARLSPISVLFF-DNSDNVVLRQYEDMVVDECGCR
BMP-2       -TNHAIVQTLVNS--VNSKIPKACCV--PTELSAISMLYL-DENEKVVLKNYQDMVVEGCGCR
BMP-4       -TNHAIVQTLVNS--VNSSIPKACCV--PTELSAISMLYL-DEYDKVVLKNYQEMVVEGCGCR
Vgr-1       -TNHAIVQTLVHL--MNPEYVPKPCCA--PTKLNAISVLYF-DDNSNVILKKYRNMVVRACGCH
OP-1        -TNHAIVQTLVHF--INPETVPKPCCA--PTQLNAISVLYF-DDSSNVILKKYRNMVVRACGCH
BMP-5       -TNHAIVQTLVHL--MFPDHVPKPCCA--PTKLNAISVLYF-DDSSNVILKKYRNMVVRSCGCH
BMP-3       --NHATIQSIVRA-VGVVPGIPEPCCV--PEKMSSLSILFF-DENKNVVLKVYPNMTVESCACR
MIS         -GNHVVLLLKMQA--RGAALARPPCCV--PTAYAGKLLISLSEER--ISAHHVPNMVATECGCR
Inhibinα    -PGAPPTPAQPYS----LLPGAQPCCAALPGTMRPLHVRTTSDGGYSFKYETVPNLLTQHCACI
InhibinβA   -SFHSTVINHYRMRGHSPFANLKSCCV--PTKLRPMSMLYY-DDGQNIIKKDIQNMIVEECGCS
InhibinβB   -SFHTAVVNQYRMRGLNPGT-VNSCCI--PTKLSTMSMLYF-DDEYNIVKRDVPNMIVEECGCA
TGF-β1      -TQYSKVLALYNQ--HNPGASAAPCCV--PQALEPLPIVYY-VGRKPKV-EQLSNMIVRSCKCS
TGF-β2      -TQHSRVLSLYNT--INPEASASPCCV--SQDLEPLTILYY-IGKTPKI-EQLSNMIVKSCKCS
TGF-β3      -TTHSTVLGLYNT--LNPEASASPCCV--PQDLEPLTILYY-VGRTPKV-EQLSNMVVKSCKCS
```

FIG.3a



FIG. 3b




FIG 4

```
1    GTCTCTCGGACGGTACATGCACTAATATTTCACTTGGCATTACTCAAAAGCAAAAAGAAG   60
61   AAATAAGAACAAGGGAAAAAAAAAAGATTGTGCTGATTTTTAAAATGATGCAAAAACTGCA  120
                                                 M  M  Q  K  L  Q
121  AATGTATGTTTATATTTACCTGTTCATGCTGATTGCTGCTGGCCCAGTGGATCTAAATGA  180
      M  Y  V  Y  I  Y  L  F  M  L  I  A  A  G  P  V  D  L  N  E
181  GGGCAGTGAGAGAGAAGAAAATGTGGAAAAAGAGGGGCTGTGTAATGCATGTGCGTGGAG  240
      G  S  E  R  E  E  N  V  E  K  E  G  L  C  N  A  C  A  W  R
241  ACAAAACACGAGGTACTCCAGAATAGAAGCCATAAAAATTCAAATCCTCAGTAAGCTGCG  300
      Q  N  T  R  Y  S  R  I  E  A  I  K  I  Q  I  L  S  K  L  R
301  CCTGGAAACAGCTCCTAACATCAGCAAAGATGCTATAAGACAACTTCTGCCAAGAGCGCC  360
      L  E  T  A  P  [N  I  S]  K  D  A  I  R  Q  L  L  P  R  A  P
361  TCCACTCCGGGAACTGATCGATCAGTACGACGTCCAGAGGGATGACAGCAGTGATGGCTC  420
      P  L  R  E  L  I  D  Q  Y  D  V  Q  R  D  D  S  S  D  G  S
421  TTTGGAAGATGACGATTATCACGCTACCACGGAAACAATCATTACCATGCCTACAGAGTC  480
      L  E  D  D  D  Y  H  A  T  T  E  T  I  I  T  M  P  T  E  S
481  TGACTTTCTAATGCAAGCGGATGGCAAGCCCAAATGTTGCTTTTTTAAATTTAGCTCTAA  540
      D  F  L  M  Q  A  D  G  K  P  K  C  C  F  F  K  F  S  S  K
541  AATACAGTACAACAAAGTAGTAAAAGCCCAACTGTGGATATATCTCAGACCCGTCAAGAC  600
      I  Q  Y  N  K  V  V  K  A  Q  L  W  I  Y  L  R  P  V  K  T
601  TCCTACAACAGTGTTTGTGCAAATCCTGAGACTCATCAAACCCATGAAAGACGGTACAAG  660
      P  T  T  V  F  V  Q  I  L  R  L  I  K  P  M  K  D  G  T  R
661  GTATACTGGAATCCGATCTCTGAAACTTGACATGAGCCCAGGCACTGGTATTTGGCAGAG  720
      Y  T  G  I  R  S  L  K  L  D  M  S  P  G  T  G  I  W  Q  S
721  TATTGATGTGAAGACAGTGTTGCAAAATTGGCTCAAACAGCCTGAATCCAACTTAGGCAT  780
      I  D  V  K  T  V  L  Q  N  W  L  K  Q  P  E  S  N  L  G  I
781  TGAAATCAAAGCTTTGGATGAGAATGGCCATGATCTTGCTGTAACCTTCCCAGGACCAGG  840
      E  I  K  A  L  D  E  N  G  H  D  L  A  V  T  F  P  G  P  G
841  AGAAGATGGGCTGAATCCCTTTTTAGAAGTCAAGGTGACAGACACACCCAAGAGGTCCCG  900
      E  D  G  L  N  P  F  L  E  V  K  V  T  D  T  P  K  [R  S  R
901  GAGAGACTTTGGGCTTGACTGCGATGAGCACTCCACGGAATCCCGGTGCTGCCGCTACCC  960
     R]  D  F  G  L  D  C  D  E  H  S  T  E  S  R  C  C  R  Y  P
961  CCTCACGGTCGATTTTGAAGCCTTTGGATGGGACTGGATTATCGCACCCAAAAGATATAA 1020
      L  T  V  D  F  E  A  F  G  W  D  W  I  I  A  P  K  R  Y  K
1021 GGCCAATTACTGCTCAGGAGAGTGTGAATTTGTGTTTTTACAAAAATATCCGCATACTCA 1080
      A  N  Y  C  S  G  E  C  E  F  V  F  L  Q  K  Y  P  H  T  H
1081 TCTTGTGCACCAAGCAAACCCCAGAGGCTCAGCAGGCCCTTGCTGCACTCCGACAAAAAT 1140
      L  V  H  Q  A  N  P  R  G  S  A  G  P  C  C  T  P  T  K  M
1141 GTCTCCCATTAATATGCTATATTTTAATGGCAAAGAACAAATAATATATGGGAAAATTCC 1200
      S  P  I  N  M  L  Y  F  N  G  K  E  Q  I  I  Y  G  K  I  P
1201 AGCCATGGTAGTAGACCGCTGTGGGTGCTCATGAGCTTTGCATTAGGTTAGAAACTTCCC 1260
      A  M  V  V  D  R  C  G  C  S  *
```

FIG.5a

```
1261  AAGTCATGGAAGGTCTTCCCCTCAATTTCGAAACTGTGAATTCAAGCACCACAGGCTGTA  1320
1321  GGCCTTGAGTATGCTCTAGTAACGTAAGCACAAGCTACAGTGTATGAACTAAAAGAGAGA  1380
1381  ATAGATGCAATGGTTGGCATTCAACCACCAAAATAAACCATACTATAGGATGTTGTATGA  1440
1441  TTTCCAGAGTTTTTGAAATAGATGGAGATCAAATTACATTTATGTCCATATATGTATATT  1500
1501  ACAACTACAATCTAGGCAAGGAAGTGAGAGCACATCTTGTGGTCTGCTGAGTTAGGAGGG  1560
1561  TATGATTAAAAGGTAAAGTCTTATTTCCTAACAGTTTCACTTAATATTTACAGAAGAATC  1620
1621  TATATGTAGCCTTTGTAAAGTGTAGGATTGTTATCATTTAAAAACATCATGTACACTTAT  1680
1681  ATTTGTATTGTATACTTGGTAAGATAAAATTCCACAAAGTAGGAATGGGGCCTCACATAC  1740
1741  ACATTGCCATTCCTATTATAATTGGACAATCCACCACGGTGCTAATGCAGTGCTGAATGG  1800
1801  CTCCTACTGGACCTCTCGATAGAACACTCTACAAAGTACGAGTCTCTCTCTCCCTTCCAG  1860
1861  GTGCATCTCCACACACACAGCACTAAGTGTTCAATGCATTTTCTTTAAGGAAAGAAGAAT  1920
1921  CTTTTTTTCTAGAGGTCAACTTTCAGTCAACTCTAGCACAGCGGGAGTGACTGCTGCATC  1980
1981  TTAAAAGGCAGCCAAACAGTATTCATTTTTTAATCTAAATTTCAAAATCACTGTCTGCCT  2040
2041  TTATCACATGGCAATTTTGTGGTAAAATAATGGAAATGACTGGTTCTATCAATATTGTAT  2100
2101  AAAAGACTCTGAAACAATTACATTTATATAATATGTATACAATATTGTTTTGTAAATAAG  2160
2161  TGTCTCCTTTTATATTTACTTTGGTATATTTTTACACTAATGAAATTTCAAATCATTAAA  2220
2221  GTACAAAGACATGTCATGTATCACAAAAAAGGTGACTGCTTCTATTTCAGAGTGAATTAG  2280
2281  CAGATTCAATAGTGGTCTTAAAACTCTGTATGTTAAGATTAGAAGGTTATATTACAATCA  2340
2341  ATTTATGTATTTTTTACATTATCAACTTATGGTTTCATGGTGGCTGTATCTATGAATGTG  2400
2401  GCTCCCAGTCAAATTTCAATGCCCCACCATTTTAAAAATTACAAGCATTACTAAACATAC  2460
2461  CAACATGTATCTAAAGAAATACAAATATGGTATCTCAATAACAGCTACTTTTTTATTTTA  2520
2521  TAATTTGACAATGAATACATTTCTTTTATTTACTTCAGTTTTATAAATTGGAACTTTGTT  2580
2581  TATCAAATGTATTGTACTCATAGCTAAATGAAATTATTTCTTACATAAAAATGTGTAGAA  2640
2641  ACTATAAATTAAAGTGTTTTCACATTTTTGAAAGGC  2676
```

FIG.5b

```
   1 AAGAAAAGTAAAAGGAAGAAACAAGAACAAGAAAAAAGATTATATTGATTTTAAAATCAT   60
                                                             M
  61 GCAAAAACTGCAACTCTGTGTTTATATTTACCTGTTTATGCTGATTGTTGCTGGTCCAGT  120
       Q  K  L  Q  L  C  V  Y  I  Y  L  F  M  L  I  V  A  G  P  V
 121 GGATCTAAATGAGAACAGTGAGCAAAAAGAAAATGTGGAAAAAGAGGGGCTGTGTAATGC  180
       D  L  N  E  N  S  E  Q  K  E  N  V  E  K  E  G  L  C  N  A
 181 ATGTACTTGGAGACAAAACACTAAATCTTCAAGAATAGAAGCCATTAAGATACAAATCCT  240
       C  T  W  R  Q  N  T  K  S  S  R  I  E  A  I  K  I  Q  I  L
 241 CAGTAAACTTCGTCTGGAAACAGCTCCTAACATCAGCAAAGATGTTATAAGACAACTTTT  300
       S  K  L  R  L  E  T  A  P  N  I  S  K  D  V  I  R  Q  L  L
 301 ACCCAAAGCTCCTCCACTCCGGGAACTGATTGATCAGTATGATGTCCAGAGGGATGACAG  360
       P  K  A  P  P  L  R  E  L  I  D  Q  Y  D  V  Q  R  D  D  S
 361 CAGCGATGGCTCTTTGGAAGATGACGATTATCACGCTACAACGGAAACAATCATTACCAT  420
       S  D  G  S  L  E  D  D  D  Y  H  A  T  T  E  T  I  I  T  M
 421 GCCTACAGAGTCTGATTTTCTAATGCAAGTGGATGGAAAACCCAAATGTTGCTTCTTTAA  480
       P  T  E  S  D  F  L  M  Q  V  D  G  K  P  K  C  C  F  F  K
 481 ATTTAGCTCTAAAATACAATACAATAAAGTAGTAAAGGCCCAACTATGGATATATTTGAG  540
       F  S  S  K  I  Q  Y  N  K  V  V  K  A  Q  L  W  I  Y  L  R
 541 ACCCGTCGAGACTCCTACAACAGTGTTTGTGCAAATCCTGAGACTCATCAAACCTATGAA  600
       P  V  E  T  P  T  T  V  F  V  Q  I  L  R  L  I  K  P  M  K
 601 AGACGGTACAAGGTATACTGGAATCCGATCTCTGAAACTTGACATGAACCCAGGCACTGG  660
       D  G  T  R  Y  T  G  I  R  S  L  K  L  D  M  N  P  G  T  G
 661 TATTTGGCAGAGCATTGATGTGAAGACAGTGTTGCAAAATTGGCTCAAACAACCTGAATC  720
       I  W  Q  S  I  D  V  K  T  V  L  Q  N  W  L  K  Q  P  E  S
 721 CAACTTAGGCATTGAAATAAAAGCTTTAGATGAGAATGGTCATGATCTTGCTGTAACCTT  780
       N  L  G  I  E  I  K  A  L  D  E  N  G  H  D  L  A  V  T  F
 781 CCCAGGACCAGGAGAAGATGGGCTGAATCCGTTTTTAGAGGTCAAGGTAACAGACACACC  840
       P  G  P  G  E  D  G  L  N  P  F  L  E  V  K  V  T  D  T  P
 841 AAAAAGATCCAGAAGGGATTTTGGTCTTGACTGTGATGAGCACTCAACAGAATCACGATG  900
       K  R  S  R  R  D  F  G  L  D  C  D  E  H  S  T  E  S  R  C
 901 CTGTCGTTACCCTCTAACTGTGGATTTTGAAGCTTTTGGATGGGATTGGATTATCGCTCC  960
       C  R  Y  P  L  T  V  D  F  E  A  F  G  W  D  W  I  I  A  P
 961 TAAAAGATATAAGGCCAATTACTGCTCTGGAGAGTGTGAATTTGTATTTTTACAAAAATA 1020
       K  R  Y  K  A  N  Y  C  S  G  E  C  E  F  V  F  L  Q  K  Y
1021 TCCTCATACTCATCTGGTACACCAAGCAAACCCCAGAGGTTCAGCAGGCCCTTGCTGTAC 1080
       P  H  T  H  L  V  H  Q  A  N  P  R  G  S  A  G  P  C  C  T
1081 TCCCACAAAGATGTCTCCAATTAATATGCTATATTTTAATGGCAAAGAACAAATAATATA 1140
       P  T  K  M  S  P  I  N  M  L  Y  F  N  G  K  E  Q  I  I  Y
1141 TGGGAAAATTCCAGCGATGGTAGTAGACCGCTGTGGGTGCTCATGAGATTTATATTAAGC 1200
       G  K  I  P  A  M  V  V  D  R  C  G  C  S  *
```

FIG.5c

```
1201  GTTCATAACTTCCTAAAACATGGAAGGTTTTCCCCTCAACAATTTTGAAGCTGTGAAATT  1260
1261  AAGTACCACAGGCTATAGGCCTAGAGTATGCTACAGTCACTTAAGCATAAGCTACAGTAT  1320
1321  GTAAACTAAAAGGGGGAATATATGCAATGGTTGGCATTTAACCATCCAAACAAATCATAC  1380
1381  AAGAAAGTTTTATGATTTCCAGAGTTTTTGAGCTAGAAGGAGATCAAATTACATTTATGT  1440
1441  TCCTATATATTACAACATCGGCGAGGAAATGAAAGCGATTCTCCTTGAGTTCTGATGAAT  1500
1501  TAAAGGAGTATGCTTTAAAGTCTATTTCTTTAAAGTTTTGTTTAATATTTACAGAAAAAT  1560
1561  CCACATACAGTATTGGTAAAATGCAGGATTGTTATATACCATCATTCGAATCATCCTTAA  1620
1621  ACACTTGAATTTATATTGTATGGTAGTATACTTGGTAAGATAAAATTCCACAAAAATAGG  1680
1681  GATGGTGCAGCATATGCAATTTCCATTCCTATTATAATTGACACAGTACATTAACAATCC  1740
1741  ATGCCAACGGTGCTAATACGATAGGCTGAATGTCTGAGGCTACCAGGTTTATCACATAAA  1800
1801  AAACATTCAGTAAAATAGTAAGTTTCTCTTTTCTTCAGGTGCATTTTCCTACACCTCCAA  1860
1861  ATGAGGAATGGATTTTCTTTAATGTAAGAAGAATCATTTTTCTAGAGGTTGGCTTTCAAT  1920
1921  TCTGTAGCATACTTGGAGAAACTGCATTATCTTAAAAGGCAGTCAAATGGTGTTTGTTTT  1980
1981  TATCAAAATGTCAAAATAACATACTTGGAGAAGTATGTAATTTTGTCTTTGGAAAATTAC  2040
2041  AACACTGCCTTTGCAACACTGCAGTTTTTATGGTAAAATAATAGAAATGATCGACTCTAT  2100
2101  CAATATTGTATAAAAAGACTGAAACAATGCATTTATATAATATGTATACAATATTGTTTT  2160
2161  GTAAATAAGTGTCTCCTTTTTTATTTACTTTGGTATATTTTTACACTAAGGACATTTCAA  2220
2221  ATTAAGTACTAAGGCACAAAGACATGTCATGCATCACAGAAAAGCAACTACTTATATTTC  2280
2281  AGAGCAAATTAGCAGATTAAATAGTGGTCTTAAAACTCCATATGTTAATGATTAGATGGT  2340
2341  TATATTACAATCATTTTATATTTTTTTACATGATTAACATTCACTTATGGATTCATGATG  2400
2401  GCTGTATAAAGTGAATTTGAAATTTCAATGGTTTACTGTCATTGTGTTTAAATCTCAACG  2460
2461  TTCCATTATTTTAATACTTGCAAAAACATTACTAAGTATACCAAAATAATTGACTCTATT  2520
2521  ATCTGAAATGAAGAATAAACTGATGCTATCTCAACAATAACTGTTACTTTTATTTTATAA  2580
2581  TTTGATAATGAATATATTTCTGCATTTATTTACTTCTGTTTTGTAAATTGGGATTTTGTT  2640
2641  AATCAAATTTATTGTACTATGACTAAATGAAATTATTTCTTACATCTAATTTGTAGAAAC  2700
2701  AGTATAAGTTATATTAAAGTGTTTTCACATTTTTTTGAAAGAC  2743
```

FIG.5d




FIG. 6a




FIG. 6b

```
1   MMQKLQMYVYIYLFMLIAAGPVDLNEGSEREENVEKEGLCNACAWRQNTR  50
    ||||| |||||||||| |||||||| || |||||||||||| |||||
1   MQKLQLCVYIYLFMLIVAGPVDLNENSEQKENVEKEGLCNACTWRQNTK  49

51  YSRIEAIKIQILSKLRLETAPNISKDAIRQLLPRAPPLRELIDQYDVQRD  100
    |||||||||||||||||||||||||| |||||| ||||||||||||||||
50  SSRIEAIKIQILSKLRLETAPNISKDVIRQLLPKAPPLRELIDQYDVQRD  99

101 DSSDGSLEDDDYHATTETIITMPTESDFLMQADGKPKCCFFKFSSKIQYN  150
    |||||||||||||||||||||||||||||||| ||||||||||||||||||
100 DSSDGSLEDDDYHATTETIITMPTESDFLMQVDGKPKCCFFKFSSKIQYN  149

151 KVVKAQLWIYLRPVKTPTTVFVQILRLIKPMKDGTRYTGIRSLKLDMSPG  200
    |||||||||||||| |||||||||||||||||||||||||||||| ||
150 KVVKAQLWIYLRPVETPTTVFVQILRLIKPMKDGTRYTGIRSLKLDMNPG  199

201 TGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVTFPGPGEDGL  250
    ||||||||||||||||||||||||||||||||||||||||||||||||||
200 TGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVTFPGPGEDGL  249

251 NPFLEVKVTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWII  300
    ||||||||||||||||||||||||||||||||||||||||||||||||||
250 NPFLEVKVTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWII  299

301 APKRYKANYCSGECEFVFLQKYPHTHLVHQANPRGSAGPCCTPTKMSPIN  350
    ||||||||||||||||||||||||||||||||||||||||||||||||||
300 APKRYKANYCSGECEFVFLQKYPHTHLVHQANPRGSAGPCCTPTKMSPIN  349

351 MLYFNGKEQIIYGKIPAMVVDRCGCS  376
    |||||||||||||||||||||||||
350 MLYFNGKEQIIYGKIPAMVVDRCGCS  375
```

FIG.7


TOTAL
SOLUBLE
INSOLUBLE (LOAD)
PELLET
FLOW-THROUGH
WASH pH8
WASH pH6.3
FRACTION 1
FRACTION 2
FRACTION 3
FRACTION 4
FRACTION 5
FRACTION 6
pH5.9
-18.5
-27.5
-32.5
-49.5
-106
-80

FIG.8




FIG. 9




FIG.10A




FIG. 10b


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M CHO H B1
1018
506/517
396
344
298

FIG.11


X
H
H
X
X
X
H
TK
neo
TK
H
H
H
X
X
X
X
11.2 kb
wild type
10.4 kb
targeted
1 kb
probe

Figure 12a




Figure 12b




Figur 3a
bottom




Figure 13b
bottom

FIGURE 14a

```
1/1                                                                 31/11
ATG CAA AAA CTG CAA CTC TGT GTT TAT ATT TAC CTG TTT ATG CTG ATT GTT GCT GGT CCA
M   Q   K   L   Q   L   C   V   Y   I   Y   L   F   M   L   I   V   A   G   P
61/21                                                               91/31
GTG GAT CTA AAT GAG AAC AGT GAG CAA AAA GAA AAT GTG GAA AAA GAG GGG CTG TGT AAT
V   D   L   N   E   N   S   E   Q   K   E   N   V   E   K   E   G   L   C   N
121/41                                                              151/51
GCA TGT ACT TGG AGA CAA AAC ACT AAA TCT TCA AGA ATA GAA GCC ATT AAA ATA CAA ATC
A   C   T   W   R   Q   N   T   K   S   S   R   I   E   A   I   K   I   Q   I
181/61                                                              211/71
CTC AGT AAA CTT CGT CTG GAA ACA GCT CCT AAC ATC AGC AAA GAT GCT ATA AGA CAA CTT
L   S   K   L   R   L   E   T   A   P   N   I   S   K   D   A   I   R   Q   L
241/81                                                              271/91
TTA CCC AAA GCT CCT CCA CTC CGG GAA CTG ATT GAT CAG TAT GAT GTC CAG AGG GAT GAC
L   P   K   A   P   P   L   R   E   L   I   D   Q   Y   D   V   Q   R   D   D
301/101                                                             331/111
AGC AGC GAT GGC TCT TTG GAA GAT GAC GAT TAT CAC GCT ACA ACG GAA ACA ATC ATT ACC
S   S   D   G   S   L   E   D   D   D   Y   H   A   T   T   E   T   I   I   T
361/121                                                             391/131
ATG CCT ACA GAG TCT GAT TTT TTA ATG CAA GTG GAT GGA AAA CCC AAA TGT TGC TTC TTT
M   P   T   E   S   D   F   L   M   Q   V   D   G   K   P   K   C   C   F   F
421/141                                                             451/151
AAA TTT AGC TCT AAA ATA CAA TAC AAT AAA GTG GTA AAG GCC CAA CTA TGG ATA TAT TTG
K   F   S   S   K   I   Q   Y   N   K   V   V   K   A   Q   L   W   I   Y   L
481/161                                                             511/171
AGA CCC GTC GAG ACT CCT ACA ACA GTG TTT GTG CAA ATC CTG AGA CTC ATC AAA CCT ATG
R   P   V   E   T   P   T   T   V   F   V   Q   I   L   R   L   I   K   P   M
541/181                                                             571/191
AAA GAC GGT ACA AGG TAT ACT GGA ATC CGA TCT CTG AAA CTT GAC ATG AAC CCA GGC ACT
K   D   G   T   R   Y   T   G   I   R   S   L   K   L   D   M   N   P   G   T
601/201                                                             631/211
GGT ATT TGG CAG AGC ATT GAT GTG AAG ACA GTG TTG CAA AAT TGG CTC AAA CAA CCT GAA
G   I   W   Q   S   I   D   V   K   T   V   L   Q   N   W   L   K   Q   P   E
661/221                                                             691/231
TCC AAC TTA GGC ATT GAA ATA AAA GCT TTA GAT GAG AAT GGT CAT GAT CTT GCT GTA ACC
S   N   L   G   I   E   I   K   A   L   D   E   N   G   H   D   L   A   V   T
721/241                                                             751/251
TTC CCA GGA CCA GGA GAA GAT GGG CTG AAT CCC TTT TTA GAG GTC AAG GTA ACA GAC ACA
F   P   G   P   G   E   D   G   L   N   P   F   L   E   V   K   V   T   D   T
781/261                                                             811/271
CCA AAA AGA TCC AGA AGG GAT TTT GGT CTT GAC TGT GAT GAG CAC TCA ACA GAA TCG CGA
P   K   R   S   R   R   D   F   G   L   D   C   D   E   H   S   T   E   S   R
841/281                                                             871/291
TGC TGT CGT TAC CCT CTA ACT GTG GAT TTT GAA GCT CTT GGA TGG GAT TGG ATT ATC GCT
C   C   R   Y   P   L   T   V   D   F   E   A   L   G   W   D   W   I   I   A
901/301                                                             931/311
CCT AAA AGA TAT AAG GCC AAT TAC TGC TCT GGA GAG TGT GAA TTT GTA TTT TTA CAA AAA
P   K   R   Y   K   A   N   Y   C   S   G   E   C   E   F   V   F   L   Q   K
961/321                                                             991/331
TAT CCT CAT ACT CAT CTG GTA CAC CAA GCA AAC CCC AGA GGT TCA GCA GGC CCT TGC TGT
Y   P   H   T   H   L   V   H   Q   A   N   P   R   G   S   A   G   P   C   C
1021/341                                                            1051/351
ACT CCC ACA AAG ATG TCT CCA ATT AAT ATG CTA TAT TTT AAT GGC AAA GAA CAA ATA ATA
T   P   T   K   M   S   P   I   N   M   L   Y   F   N   G   K   E   Q   I   I
1081/361                                                            1111/371
TAT GGG AAA ATT CCA GCC ATG GTA GTA GAC CGC TGC GGG TGC TCA TGA
Y   G   K   I   P   A   M   V   V   D   R   C   G   C   S   *
```

Baboon GDF-8

FIGURE 14b

```
1/1                                                 31/11
ATG CAA AAA CTG CAA ATC TCT GTT TAT ATT TAC CTA TTT ATG CTG ATT GTT GCT GGC CCA
M   Q   K   L   Q   I   S   V   Y   I   Y   L   F   M   L   I   V   A   G   P
61/21                                               91/31
GTG GAT CTG AAT GAG AAC AGC GAG CAG AAG GAA AAT GTG GAA AAA GAG GGG CTG TGT AAT
V   D   L   N   E   N   S   E   Q   K   E   N   V   E   K   E   G   L   C   N
121/41                                              151/51
GCA TGT TTG TGG AGG GAA AAC ACT ACA TCC TCA AGA CTA GAA GCC ATA AAA ATC CAA ATC
A   C   L   W   R   E   N   T   T   S   S   R   L   E   A   I   K   I   Q   I
181/61                                              211/71
CTC AGT AAA CTT CGC CTG GAA ACA GCT CCT AAC ATC AGC AAA GAT GCT ATC AGA CAA CTT
L   S   K   L   R   L   E   T   A   P   N   I   S   K   D   A   I   R   Q   L
241/81                                              271/91
TTG CCC AAG GCT CCT CCA CTC CTG GAA CTG ATT GAT CAG TTC GAT GTC CAG AGA GAT GCC
L   P   K   A   P   P   L   L   E   L   I   D   Q   F   D   V   Q   R   D   A
301/101                                             331/111
AGC AGT GAC GGC TCC TTG GAA GAC GAT GAC TAC CAC GCC AGG ACG GAA ACG GTC ATT ACC
S   S   D   G   S   L   E   D   D   D   Y   H   A   R   T   E   T   V   I   T
361/121                                             391/131
ATG CCC ACG GAG TCT GAT CTT CTA ACG CAA GTG GAA GGA AAA CCC AAA TGT TGC TTC TTT
M   P   T   E   S   D   L   L   T   Q   V   E   G   K   P   K   C   C   F   F
421/141                                             451/151
AAA TTT AGC TCT AAG ATA CAA TAC AAT AAA CTA GTA AAG GCC CAA CTG TGG ATA TAT CTG
K   F   S   S   K   I   Q   Y   N   K   L   V   K   A   Q   L   W   I   Y   L
481/161                                             511/171
AGG CCT GTC AAG ACT CCT GGG ACA GTG TTT GTG CAA ATC CTG AGA CTC ATC AAA CCC ATG
R   P   V   K   T   P   A   T   V   F   V   Q   I   L   R   L   I   K   P   M
541/181                                             571/191
AAA GAC GGT ACA AGG TAT ACT GGA ATC CGA TCT CTG AAA CTT GAC ATG AAC CCA GGC ACT
K   D   G   T   R   Y   T   G   I   R   S   L   K   L   D   M   N   P   G   T
601/201                                             631/211
GGT ATT TGG CAG AGC ATT GAT GTG AAG ACA GTG TTG CAG AAC TGG CTC AAA CAA CCT GAA
G   I   W   Q   S   I   D   V   K   T   V   L   Q   N   W   L   K   Q   P   E
661/221                                             691/231
TCC AAC TTA GGC ATT GAA ATC AAA GCT TTA GAT GAG AAT GGC CAT GAT CTT GCT GTA ACC
S   N   L   G   I   E   I   K   A   L   D   E   N   G   H   D   L   A   V   T
721/241                                             751/251
TTC CCA GAA CCA GGA GAA GAT GGA CTG ACT CCT TTT TTA GAA GTC AAG GTA ACA GAC ACA
F   P   E   P   G   E   D   G   L   T   P   F   L   E   V   K   V   T   D   T
781/261                                             811/271
CCA AAA AGA TCT AGG AGA GAT TTT GGG CTT GAT TGT GAT GAA CAC TCC ACA GAA TCT CGA
P   K   R   S   R   R   D   F   G   L   D   C   D   E   H   S   T   E   S   R
841/281                                             871/291
TGC TGT CGT TAC CCT CTA ACT GTG GAT TTT GAA GCT TTT GGA TGG GAT TGG ATT ATT GCA
C   C   R   Y   P   L   T   V   D   F   E   A   F   G   W   D   W   I   I   A
901/301                                             931/311
CCT AAA AGA TAT AAG GCC AAT TAC TGC TCT GGA GAA TGT GAA TTT GTA TTT TTG CAA AAG
P   K   R   Y   K   A   N   Y   C   S   G   E   C   E   F   V   F   L   Q   K
961/321                                             991/331
TAT CCT CAT ACC CAT CTT GTG CAC CAA GCA AAC CCC AGA GGT TCA GCC GGC CCC TGC TGT
Y   P   H   T   H   L   V   H   Q   A   N   P   R   G   S   A   G   P   C   C
1021/341                                            1051/351
ACT CCT ACA AAG ATG TCT CCA ATT AAT ATG CTA TAT TTT AAT GGC GAA GGA CAA ATA ATA
T   P   T   K   M   S   P   I   N   M   L   Y   F   N   G   E   G   Q   I   I
1081/361                                            1111/371
TAC GGG AAG ATT CCA GCC ATG GTA GTA GAT CGC TGT GGG TGT TCA TGA
Y   G   K   I   P   A   M   V   V   D   R   C   G   C   S   *
```

Bovine GDF-8

FIGURE 14c

```
1/1                                                                 31/11
ATG CAA AAG CTA GCA GTC TAT GTT TAT ATT TAC CTG TTC ATG CAG ATC GCG GTT GAT CCG
M   Q   K   L   A   V   Y   V   Y   I   Y   L   F   M   Q   I   A   V   D   P
61/21                                                               91/31
GTG GCT CTG GAT GGC AGT AGT CAG CGC ACA GAG AAC GCT GAA AAA GAC GGA CTG TGC AAT
V   A   L   D   G   S   S   Q   P   T   E   N   A   E   K   D   G   L   C   N
121/41                                                              151/51
GCT TGT ACG TGG AGA CAG AAT ACA AAA TCC TCC AGA ATA GAA GCC ATA AAA ATT CAA ATC
A   C   T   W   R   Q   N   T   K   S   S   R   I   E   A   I   K   I   Q   I
181/61                                                              211/71
CTC AGC AAA CTG CGC CTG GAA CAA GCA CCT AAC ATT AGC AGG GAC GTT ATT AAG CAG CTT
L   S   K   L   R   L   E   Q   A   P   N   I   S   R   D   V   I   K   Q   L
241/81                                                              271/91
TTA CCC AAA GCT CCT CCA CTG CAG GAA CTG ATT GAT CAG TAT GAT GTC CAG AGG GAC GAC
L   P   K   A   P   P   L   Q   E   L   I   D   Q   Y   D   V   Q   R   D   D
301/101                                                             331/111
AGT AGC GAT GGC TCT TTG GAA GAC GAT GAC TAT CAT GCC ACA ACC GAG ACG ATT ATC ACA
S   S   D   G   S   L   E   D   D   D   Y   H   A   T   T   E   T   I   I   T
361/121                                                             391/131
ATG CCT ACG GAG TCT GAT TTT CTT GTA CAA ATG GAG GGA AAA CCA AAA TGT TGC TTC TTT
M   P   T   E   S   D   F   L   V   Q   M   E   G   K   P   K   C   C   F   F
421/141                                                             451/151
AAG TTT AGC TCT AAA ATA CAA TAT AAC AAA GTA GTA AAG GCA CAA TTA TGG ATA TAC TTG
K   F   S   S   K   I   Q   Y   N   K   V   V   K   A   Q   L   W   I   Y   L
481/161                                                             511/171
AGG CAA CTC CAA AAA CCT ACA ACG GTG TTT GTG CAG ATC CTG AGA CTC ATT AAG CCC ATG
R   Q   V   Q   K   P   T   T   V   F   V   Q   I   L   R   L   I   K   P   M
541/181                                                             571/191
AAA GAC GGT ACA AGA TAT ACT GGA ATT CGA TCT TTG AAA CTT GAC ATG AAC CCA GGC ACT
K   D   G   T   R   Y   T   G   I   R   S   L   K   L   D   M   N   P   G   T
601/201                                                             631/211
GGT ATC TGG CAG AGT ATT GAT GTG AAG ACA GTG CTG CAA AAT TGG CTC AAA CAG CCT GAA
G   I   W   Q   S   I   D   V   K   T   V   L   Q   N   W   L   K   Q   P   E
661/221                                                             691/231
TCC AAT TTA GGC ATC GAA ATA AAA GCT TTT GAT GAG ACT GGA CGA GAT CTT GCT GTC ACA
S   N   L   G   I   E   I   K   A   F   D   E   T   G   R   D   L   A   V   T
721/241                                                             751/251
TTC CCA GGA CCG GGT GAA GAT GGA TTG AAC CCA TTT TTA GAG GTC AGA GTT ACA GAC ACA
F   P   G   P   G   E   D   G   L   N   P   F   L   E   V   R   V   T   D   T
781/261                                                             811/271
CCG AAA CGG TCC CGC AGA GAT TTT GGC CTT GAC TGT GAT GAG CAT TCA ACG GAA TCC CGA
P   K   R   S   R   R   D   F   G   L   D   C   D   E   H   S   T   E   S   R
841/281                                                             871/291
TGT TGT CGC TAC CCG CTG ACA GTG GAT TTC GAA GCT TTT GGA TGG GAC TGG ATT ATA GCA
C   C   R   Y   P   L   T   V   D   F   E   A   F   G   W   D   W   I   I   A
901/301                                                             931/311
CCT AAA AGA TAC AAA GCC AAT TAC TGC TCC GGA GAA TGC GAA TTT GTG TTT CTA CAG AAA
P   K   R   Y   K   A   N   Y   C   S   G   E   C   E   F   V   F   L   Q   K
961/321                                                             991/331
TAC CCG CAC ACT CAC CTG GTA CAC CAA GCA AAT CCC AGA GGC TCA GCA GGC CCT TGC TGC
Y   P   H   T   H   L   V   H   Q   A   N   P   R   G   S   A   G   P   C   C
1021/341                                                            1051/351
ACA CCC ACC AAG ATG TCC CCT ATA AAC ATG CTG TAT TTC AAT GGA AAA GAA CAA ATA ATA
T   P   T   K   M   S   P   I   N   M   L   Y   F   N   G   K   E   Q   I   I
1081/361                                                            1111/371
TAT GGA AAG ATA CCA GCC ATG GTT GTA GAT CGT TGC GGG TGC TCA TGA
Y   G   K   I   P   A   M   V   V   D   R   C   G   C   S   *
```

Chicken GDF-8

FIGURE 14d

```
1/1                                                 31/11
ATG ATT CAA AAA CCG CAA ATG TAT GTT TAT ATT TAC CTG TTT GTG CTG ATT GCT GCT GGC
M   I   Q   K   P   Q   M   Y   V   Y   I   Y   L   F   V   L   I   A   A   G
61/21                                               91/31
CCA GTG GAT CTA AAT GAG GAC AGT GAG AGA GAG GCG AAT GTG GAA AAA GAG GGG CTG TGT
P   V   D   L   N   E   D   S   E   R   E   A   N   V   E   K   E   G   L   C
121/41                                              151/51
AAT GGG TGT GGC TGG AGA CAA AAC ACA AGG TAC TGC AGA ATA GAA GCC ATA AAA ATT CAA
N   A   C   A   W   R   Q   N   T   R   Y   S   R   I   E   A   I   K   I   Q
181/61                                              211/71
ATC CTC AGT AAA CTC AGC CTG GAA ACA GCG CCT AAC ATC AGC AAA GAT GCT ATA AGA CAA
I   L   S   K   L   R   L   E   T   A   P   N   I   S   K   D   A   I   R   Q
241/81                                              271/91
CTT CTG CCC AGA GGG CCT CCA CTG CGG GAA CTG ATC GAT CAG TAC GAC GTC CAG AGG GAT
L   L   P   R   A   P   P   L   R   E   L   I   D   Q   Y   D   V   Q   R   D
301/101                                             331/111
GAC AGC AGT GAC GGC TCT TTG GAA GAT GAC GAT TAT CAC GCT ACC ACG GAA ACA ATC ATT
D   S   S   D   G   S   L   E   D   D   D   Y   H   A   T   T   E   T   I   I
361/121                                             391/131
ACC ATG CCT ACC GAG TCT GAC TTT CTA ATG CAA GCG GAT GGA AAG CCC AAA TGT TGC TTT
T   M   P   T   E   S   D   F   L   M   Q   A   D   G   K   P   K   C   C   F
421/141                                             451/151
TTT AAA TTT AGC TCT AAA ATA CAG TAC AAC AAA GTG GTA AAG GCC CAG CTG TGG ATA TAT
F   K   F   S   S   K   I   Q   Y   N   K   V   V   K   A   Q   L   W   I   Y
481/161                                             511/171
CTG AGA GCC GTC AAG ACT GGT AGA AGA GTG TTT GTG CAA ATC GCG AGA CTC ATC AAA CCC
L   R   A   V   K   T   P   T   T   V   F   V   Q   I   A   R   L   I   K   P
541/181                                             571/191
ATG AAA GAC GGT ACA AGG TAT ACC GGA ATC CGA TCT CTG AAA CTT GAC ATG AGC CCA GGC
M   K   D   G   T   R   Y   T   G   I   R   S   L   K   L   D   M   S   P   G
601/201                                             631/211
ACT GGT ATT TGG CAG AGT ATT GAT GTG AAG ACA GTG TTG CAA AAT TGG CTC AAA CAG CCT
T   G   I   W   Q   S   I   D   V   K   T   V   L   Q   N   W   L   K   Q   P
661/221                                             691/231
GAA TCC AAC TTA GGC ATT GAA ATC AAA GCT TTG GAT GAG AAT GGG CAT GAT CTT GCT GTA
E   S   N   L   G   I   E   I   K   A   L   D   E   N   G   H   D   L   A   V
721/241                                             751/251
ACC TTC CCA GGA CCA GGA GAA GAT GGG CTG AAT CCC TTT TTA GAA GTC AAA GTA ACA GAC
T   F   P   G   P   G   E   D   G   L   N   P   F   L   E   V   K   V   T   D
781/261                                             811/271
ACA CCC AAG AGG TCC CGG AGA GAC TTT GGG CTT GAC TGT GAT GAA CAC TCC ACG GAA TCG
T   P   K   R   S   R   R   D   F   G   L   D   C   D   E   H   S   T   E   S
841/281                                             871/291
CGG TGC TGT CGC TAC CCC CTC ACG GTC GAT TTC GAA GCC TTT GGA TGG GAC TGG ATT ATT
R   C   C   R   Y   P   L   T   V   D   F   E   A   F   G   W   D   W   I   I
901/301                                             931/311
GCA CCC AAA AGA TAT AAG GCT AAT TAC TGC TCT GGA GAG TGT GAA TTT GTG TTC TTA CAA
A   P   K   R   Y   K   A   N   Y   C   S   G   E   C   E   F   V   F   L   Q
961/321                                             991/331
AAA TAT CCG CAT ACT CAT CTT GTG CAC CAA GCA AAC CCC AGA GGC TCG GCA GGC CCT TGC
K   Y   P   H   T   H   L   V   H   Q   A   N   P   R   G   S   A   G   P   C
1021/341                                            1051/351
TGC ACG CCA ACA AAA ATG TCT CCC ATT AAT ATG CTA TAT TTT AAT GGC AAA GAA CAA ATA
C   T   P   T   K   M   S   P   I   N   M   L   Y   F   N   G   K   E   Q   I
1081/361                                            1111/371
ATA TAT GGC AAA ATT CCA GCC ATG GTA GTA GAC CGG TGT GGG TGC TCG TGA
I   Y   G   K   I   P   A   M   V   V   D   R   C   G   C   S   *
```

Rat GDF-8

FIGURE 14e

```
1/1                                                                31/11
ATG CAA AAG CTA GCA GTC TAT GTT TAT ATT TAC CTG TTC ATG CAG ATT TTA GTT CAT CCG
M   Q   K   L   A   V   Y   V   Y   I   Y   L   F   M   Q   I   L   V   H   P
61/21                                                              91/31
GTG GCT CTT GAT GGC AGT AGT CAG CCC ACA GAG AAC GCT GAA AAA GAC GGA CTG TGC AAT
V   A   L   D   G   S   S   Q   P   T   E   N   A   E   K   D   G   L   C   N
121/41                                                             151/51
GCT TGC ACG TGG AGA CAG AAT ACT AAA TCC TCC AGA ATA GAA GCC ATA AAA ATT CAA ATC
A   C   T   W   R   Q   N   T   K   S   S   R   I   E   A   I   K   I   Q   I
181/61                                                             211/71
CTC AGC AAA CTG CGC CTG GAA CAA GCA CCT AAC ATT AGC AGG GAC GTT ATT AAA CAA CTT
L   S   K   L   R   L   E   Q   A   P   N   I   S   R   D   V   I   K   Q   L
241/81                                                             271/91
TTA CCC AAA GCT CCT CCG CTG CAG GAA CTG ATT GAT CAG TAT GAC GTC CAG AGA GAC GAC
L   P   K   A   P   P   L   Q   E   L   I   D   Q   Y   D   V   Q   R   D   D
301/101                                                            331/111
AGT AGC GAT GGC TCT TTG GAA GAC GAT GAC TAT CAT GCC ACA ACC GAA ACG ATT ATC ACA
S   S   D   G   S   L   E   D   D   D   Y   H   A   T   T   E   T   I   I   T
361/121                                                            391/131
ATG CCT ACG GAG TCT GAT TTT CTT GTA CAA ATG GAG GGA AAA CCA AAA TGT TGC TTC TTT
M   P   T   E   S   D   F   L   V   Q   M   E   G   K   P   K   C   C   F   F
421/141                                                            451/151
AAG TTT AGC TCT AAA ATA CAA TAT AAC AAA GTA GTA AAG GCA CAA TTA TGG ATA TAC TTG
K   F   S   S   K   I   Q   Y   N   K   V   V   K   A   Q   L   W   I   Y   L
481/161                                                            511/171
AGG CAA CCC CAA AAA CCT ACA ACG GTG TTT GTG CAG ATC CTG AGA CTC ATT AAA CCC ATG
R   Q   P   Q   K   P   T   T   V   F   V   Q   I   L   R   L   I   K   P   M
541/181                                                            571/191
AAA GAC GGT ACA AGA TAT ACT GGA ATT CGA TCT TTG AAA CTT GAC ATG AAC CCA GGC ACT
K   D   G   T   R   Y   T   G   I   R   S   L   K   L   D   M   N   P   G   T
601/201                                                            631/211
GGT ATC TGG CAG AGT ATT GAT GTG AAG ACA GTG TTG CAA AAT TGG CTC AAA CAG CCT GAA
G   I   W   Q   S   I   D   V   K   T   V   L   Q   N   W   L   K   Q   P   E
661/221                                                            691/231
TCC AAT TTA GGC ATC GAA ATA AAA GCT TTT GAT GAG AAT GGA CGA GAT CTT GCT GTA ACA
S   N   L   G   I   E   I   K   A   F   D   E   N   G   R   D   L   A   V   T
721/241                                                            751/251
TTC CCA GGA CCA GGT GAA GAT GGA CTG AAC CCA TTT TTA GAC GTC AGA GTT ACA CAC ACA
F   P   G   P   G   E   D   G   L   N   P   F   L   E   V   R   V   T   D   T
781/261                                                            811/271
GGT AAA CGG TCC CGC AGA GAT TTT GGC CTT GAT TGC GAC GAG CAC TCA ACG GAA TCT CGA
G   K   R   S   R   R   D   F   G   L   D   C   D   E   H   S   T   E   S   R
841/281                                                            871/291
TGT TGT CGC TAC CCG CTG ACA GTG GAT TTT GAA GCT TTT GGA TGG GAC TGG ATT ATA GCA
C   C   R   Y   P   L   T   V   D   F   E   A   F   G   W   D   W   I   I   A
901/301                                                            931/311
CCT AAA AGA TAC AAA GCC AAT TAC TGC TCT GGA GAA TGT GAA TTC GTA TTT CTA CAG AAA
P   K   R   Y   K   A   N   Y   C   S   G   E   C   E   F   V   F   L   Q   K
961/321                                                            991/331
TAC CCG CAC ACT CAC CTG GTA CAC CAA GCA AAT CCA AGA GGC TCA GCA GGC CCT TGC TGC
Y   P   H   T   H   L   V   H   Q   A   N   P   R   G   S   A   G   P   C   C
1021/341                                                           1051/351
ACA CCC ACC AAG ATG TCC CCT ATA AAC ATG CTC TAT TTC AAT GGA AAA GAA CAA ATA ATA
T   P   T   K   M   S   P   I   N   M   L   Y   F   N   G   K   E   Q   I   I
1081/361                                                           1111/371
TAT GGA AAG ATA CCA GCC ATG GTT GTA GAT CGT TGC GGC TGC TCA TGA
Y   G   K   I   P   A   M   V   V   D   R   C   G   C   S   *
```

Turkey GDF-8

```
1/1
ATG CAA AAA CTG CAA ATC TAT    TAT ATT TAC CTG TTT ATG CTG ATT GTT GCT GGT CCC
M   Q   K   L   Q   I   Y   V   Y   I   Y   L   F   M   L   I   V   A   G   P
61/21                                                 91/31
GTG GAT CTG AAT GAG AAC AGC GAG CAA AAG GAA AAT GTG GAA AAA GAG GGG CTG TGT AAT
V   D   L   N   E   N   S   E   Q   K   E   N   V   E   K   E   G   L   C   N
121/41                                                151/51
GCA TGT ATG TGG AGA CAA AAC ACT AAA TCT TCA AGA CTA GAA GCC ATA AAA ATT CAA ATC
A   C   M   W   R   Q   N   T   K   S   S   R   L   E   A   I   K   I   Q   I
181/61                                                211/71
CTC AGT AAA CTT CGC CTG GAA ACA GCT CCT AAC ATT AGC AAA GAT GCT ATA AGA CAA CTT
L   S   K   L   R   L   E   T   A   P   N   I   S   K   D   A   I   R   Q   L
241/81                                                271/91
TTG CCC AAA GCT CCT CCA CTC CGG GAA CTG ATT GAT CAG TAC GAT GTC CAG AGA GAT GAC
L   P   K   A   P   P   L   R   E   L   I   D   Q   Y   D   V   Q   R   D   D
301/101                                               331/111
AGC AGT GAT GGC TCC TTG GAA GAT GAT GAT TAT CAC GCT ACG ACG GAA ACG ATC ATT ACC
S   S   D   G   S   L   E   D   D   D   Y   H   A   T   T   E   T   I   I   T
361/121                                               391/131
ATG CCT ACA GAG TCT GAT CTT CTA ATG CAA GTG GAA GGA AAA CCC AAA TGC TGC TTC TTT
M   P   T   E   S   D   L   L   M   Q   V   E   G   K   P   K   C   C   F   F
421/141                                               451/151
AAA TTT AGC TCT AAA ATA CAA TAC AAT AAA GTA GTA AAG GCC CAA CTG TGG ATA TAT CTG
K   F   S   S   K   I   Q   Y   N   K   V   V   K   A   Q   L   W   I   Y   L
481/161                                               511/171
AGA CCC GTC AAG ACT CCT ACA ACA GTG TTT GTG CAA ATC CTG AGA CTC ATC AAA CCC ATG
R   P   V   K   T   P   T   T   V   F   V   Q   I   L   R   L   I   K   P   M
541/181                                               571/191
AAA GAC GGT ACA AGG TAT ACT GGA ATC CGA TCT CTG AAA CTT GAC ATG AAC CCA GGC ACT
K   D   G   T   R   Y   T   G   I   R   S   L   K   L   D   M   N   P   G   T
601/201                                               631/211
GGT ATT TGG CAG AGC ATT GAT GTG AAG ACA GTG TTG CAA AAT TGG CTC AAA CAA CCT GAA
G   I   W   Q   S   I   D   V   K   T   V   L   Q   N   W   L   K   Q   P   E
661/221                                               691/231
TCC AAC TTA GGC ATT GAA ATC AAA GCT TTA GAT GAG AAT GGT CAT GAT CTT GCT GTA ACC
S   N   L   G   I   E   I   K   A   L   D   E   N   G   H   D   L   A   V   T
721/241                                               751/251
TTC CCA GGA CCA GGA GAA GAT GGG CTG AAT CCC TTT TTA GAA GTC AAG GTA ACA GAC ACA
F   P   G   P   G   E   D   G   L   N   P   F   L   E   V   K   V   T   D   T
781/261                                               811/271
CCA AAA AGA TCC AGG AGA GAT TTT GGA CTC GAC TGT GAT GAG CAC TCA ACA GAA TCT CGA
P   K   R   S   R   R   D   F   G   L   D   C   D   E   H   S   T   E   S   R
841/281                                               871/291
TGC TGT CGT TAC CCT CTA ACT GTG GAT TTT GAA GCT TTT GGA TGG GAC TGG ATT ATT GCA
C   C   R   Y   P   L   T   V   D   F   E   A   F   G   W   D   W   I   I   A
901/301                                               931/311
CCC AAA AGA TAT AAG GCC AAT TAC TGC TCT GGA GAG TGT GAA TTT GTA TTT TTA CAA AAA
P   K   R   Y   K   A   N   Y   C   S   G   E   C   E   F   V   F   L   Q   K
961/321                                               991/331
TAC CCT CAC ACT CAT CTT GTG CAC CAA GCA AAC CCC AGA GGT TCA GCA GGC CCC TGC TGT
Y   P   H   T   H   L   V   H   Q   A   N   P   R   G   S   A   G   P   C   C
1021/341                                              1051/351
ACT CCC ACA AAG ATG TCT CCA ATC AAT ATG CTA TAT TTT AAT GGC AAA GAA CAA ATA ATA
T   P   T   K   M   S   P   I   N   M   L   Y   F   N   G   K   E   Q   I   I
1081/361                                              1111/371
TAT GGG AAA ATT CCA GCC ATG GTA GTA GAT CGC TGT GGG TGC TCA TGA
Y   G   K   I   P   A   M   V   V   D   R   C   G   C   S   *
```

Porcine GDF-8

FIGURE 14F

```
1/1                                                                 31/11
ATG CAA AAA CTG CAA ATC TTT GTT TAT ATT TAC CTA TTT ATG CTG CTT GTT GCT GGC CCA
M   Q   K   L   Q   I   F   V   Y   I   Y   L   F   M   L   L   V   A   G   P
61/21                                                               91/31
GTG GAT CTG AAT GAG AAC AGC GAG CAG AAG GAA AAT GTG GAA AAA AAG GGG CTG TGT AAT
V   D   L   N   E   N   S   E   Q   K   E   N   V   E   K   K   G   L   C   N
121/41                                                              151/51
GCA TGC TTG TGG AGA CAA AAC AAT AAA TCC TCA AGA CTA GAA GCC ATA AAA ATC CAA ATC
A   C   L   W   R   Q   N   N   K   S   S   R   L   E   A   I   K   I   Q   I
181/61                                                              211/71
CTC AGT AAG CTT CGC CTG GAA ACA GCT CCT AAC ATC AGC AAA GAT GCT ATA AGA CAA CTT
L   S   K   L   R   L   E   T   A   P   N   I   S   K   D   A   I   R   Q   L
241/81                                                              271/91
TTG CCC AAG GCT CCT CCA CTC CGG GAA CTG ATT GAT CAG TAC GAT GTC CAG AGA GAT GAC
L   P   K   A   P   P   L   R   E   L   I   D   Q   Y   D   V   Q   R   D   D
301/101                                                             331/111
AGC AGC GAC GGC TCC TTG GAA GAC GAT GAC TAC CAC GTT ACG ACG GAA ACG GTC ATT ACC
S   S   D   G   S   L   E   D   D   D   Y   H   V   T   T   E   T   V   I   T
361/121                                                             391/131
ATG CCC ACG GAG TCT GAT CTT CTA GCA GAA GTG CAA GAA AAA CCC AAA TGT TGC TTC TTT
M   P   T   E   S   D   L   L   A   E   V   Q   E   K   P   K   C   C   F   F
421/141                                                             451/151
AAA TTT AGC TCT AAG ATA CAA CAC AAT AAA GTA GTA AAG GCC CAA CTG TGG ATA TAT CTG
K   F   S   S   K   I   Q   H   N   K   V   V   K   A   Q   L   W   I   Y   L
481/161                                                             511/171
AGA CCT GTC AAG ACT CCT ACA ACA GTG TTT GTG CAA ATC CTG AGA CTC ATC AAA CGC ATG
R   P   V   K   T   P   T   T   V   F   V   Q   I   L   R   L   I   K   P   M
541/181                                                             571/191
AAA GAC GGT ACA AGG TAT ACT GGA ATC CGA TCT CTG AAA CTT GAC ATG AAC CCA GGC ACT
K   D   G   T   R   Y   T   G   I   R   S   L   K   L   D   M   N   P   G   T
601/201                                                             631/211
GGT ATT TGG CAG AGC ATT GAT GTG AAG ACA GTG TTG CAA AAC TGG CTC AAA CAA CCT GAA
G   I   W   Q   S   I   D   V   K   T   V   L   Q   N   W   L   K   Q   P   E
661/221                                                             691/231
TCC AAC TTA GGC ATT GAA ATC AAA GCT TTA GAT GAG AAT GGT CAT GAT CTT GCT GTA ACC
S   N   L   G   I   E   I   K   A   L   D   E   N   G   H   D   L   A   V   T
721/241                                                             751/251
TTC CCA GAA CCA GGA GAA GAA GGA CTG AAT CCT TTT TTA GAA GTC AAG GTA ACA GAC ACA
F   P   E   P   G   E   E   G   L   N   P   F   L   E   V   K   V   T   D   T
781/261                                                             811/271
CCA AAA AGA TCT AGG AGA GAT TTT GGG CTT GAT TGT GAT GAG CAC TCC ACA GAA TCT CGA
P   K   R   S   R   R   D   F   G   L   D   C   D   E   H   S   T   E   S   R
841/281                                                             871/291
TGC TGT CGT TAC CCT CTA ACT GTG GAT TTT GAA GCT TTT GGA TGG GAT TGG ATT ATT GCA
C   C   R   Y   P   L   T   V   D   F   E   A   F   G   W   D   W   I   I   A
901/301                                                             931/311
CCT AAA AGA TAT AAG GCC AAT TAC TGC TCT GGA GAA TGT GAA TTT TTA TTT TTG CAA AAG
P   K   R   Y   K   A   N   Y   C   S   G   E   C   E   F   L   F   L   Q   K
961/321                                                             991/331
TAT CCT CAT ACC CAT CTT GTG CAC CAA GCA AAC CCC AAA GGT TCA GCC GGC CCT TGC TGT
Y   P   H   T   H   L   V   H   Q   A   N   P   K   G   S   A   G   P   C   C
1021/341                                                            1051/351
ACT CCT ACA AAG ATG TCT CCA ATT AAT ATG CTA TAT TTT AAT GGC AAA GAA CAA ATA ATA
T   P   T   K   M   S   P   I   N   M   L   Y   F   N   G   K   E   Q   I   I
1081/361                                                            1111/371
TAT GGG AAG ATT CCA GGC ATG GTA GTA GAT CGC TGT GGG TGC TCA TGA
Y   G   K   I   P   G   M   V   V   D   R   C   G   C   S   *
```

Ovine GDF-8

FIGURE 14g


murine
rat
human
baboon
porcine
ovine
bovine
chicken
turkey

FIGURE 15a




Decoration 'Decoration #1': Shade (with solid black) residues that match the Consensus exactly.

FIGURE 15b

# INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/02479

A. CLASSIFICATION OF SUBJECT MATTER
IPC(6) :C12N 5/00, 15/00, 15/09, 15/63
US CL :Please See Extra Sheet.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 800/2; 435/172.3, 69.1, 320.1, 325; 530/350, 387.1; 514/2, 44; 424/9.21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| Y | MCDOWELL et al. Effects of Exogenous Growth Hormone on Milk Production and Nutrient Uptake by Muscle and Mammary Tissues of Dairy Cows in Mid-Lactation. Australian Journal of Biological Sciences, Vol. 40, No. 3, pages 295-306, see Abstract. | 13 |
| Y | EVOCK et al. Pituitary Porcine Growth Hormone (pGH) and a Recombinant pGH Analog Stimulate Pig Growth Performance in a Similar Manner. Journal of Animal Science, Vol. 66, No. 8, pages 1928-1941, see Abstract. | 14 |

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

| | | | |
|---|---|---|---|
| * | Special categories of cited documents: | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" | document defining the general state of the art which is not considered to be of particular relevance | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "E" | earlier document published on or after the international filing date | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" | document member of the same patent family |
| "O" | document referring to an oral disclosure, use, exhibition or other means | | |
| "P" | document published prior to the international filing date but later than the priority date claimed | | |

| | |
|---|---|
| Date of the actual completion of the international search<br>25 MARCH 1998 | Date of mailing of the international search report<br>15 JUN 1998 |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231<br>Facsimile No. (703) 305-3230 | Authorized officer<br>JILL D. SCHMUCK<br>Telephone No. (703) 308-0196 |

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/02479

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| Y | FLAKOLL et al. Influence of Alpha-Ketoisocaproate on Lamb Growth, Feed, Conversion, and Carcass Composition. Journal of Animal Science, Vol. 69, No. 4, pages 1461-1467, see Abstract. | 15 |
| Y | DELI et al. Biochemical Study of Muscle Samples from Chicken Embryos Affected by Wofatox 50 EC. Archives of Toxicology, Vol. 8, pages 277-279, see Abstract. | 16 |
| Y | FAULKNER et al. Effect of Testosterone Propionate on Performance and Carcass Characteristics of Heifers and Cows. Journal of Animal Science, Vol. 67, No. 8, pages 1907-1915, see Abstract. | 12 |
| Y | ZHU et al. Survey of Major Histocompatibility Complex Class II Haplotypes in Four Turkey Lines Using Restriction Fragment Length Polymorphism Analysis with Nonradioactive DNA Detection. Poultry Science, Vol. 74, No. 7, pages 1067-1073, see Abstract. | 11 |

# INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/02479

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

800/2; 435/172.3, 69.1, 320.1, 325; 530/350, 387.1; 514/2, 44; 424/9.21

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MEDLINE, BIOSIS, EMBASE, CAPLUS, WPIDS, CONFSCI
search terms: growth differentiation factor-8, GDF-8, transgene, increased muscle, reduced cholesterol, mouse, pigs or porcine, cows or bovine, sheep or ovine, piscine, chicken or turkey or avian

**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 5/00, 15/00, 15/09, 15/63 — A1

(11) International Publication Number: **WO 98/33887**

(43) International Publication Date: 6 August 1998 (06.08.98)

(21) International Application Number: PCT/US98/02479

(22) International Filing Date: 5 February 1998 (05.02.98)

(30) Priority Data:

| | | |
|---|---|---|
| 08/795,071 | 5 February 1997 (05.02.97) | US |
| 08/847,910 | 28 April 1997 (28.04.97) | US |
| 08/862,445 | 23 May 1997 (23.05.97) | US |

(71) Applicant: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US).

(72) Inventors: LEE, Se-Jin; 6711 Chokeberry Road, Baltimore, MD 21209 (US). MCPHERRON, Alexandra, C.; 3905 Keswick Road, Baltimore, MD 21211 (US).

(74) Agent: HAILE, Lisa, A.; Fish & Richardson P.C., Suite 1400, 4225 Executive Square, La Jolla, CA 92037 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published**

*With international search report.*

*With amended claims.*

**Date of publication of the amended claims:**

11 September 1998 (11.09.98)

(54) Title: GROWTH DIFFERENTIATION FACTOR-8

(57) Abstract

A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-8 (GDF-8) chromosomally integrated into the germ cells of the animal is disclosed. Also disclosed are methods for making such animals, and methods of treating animals, including humans, with antibodies or antisense directed to GDF-8. The animals so treated are characterized by increased muscle tissue.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AL** | Albania | **ES** | Spain | **LS** | Lesotho | **SI** | Slovenia |
| **AM** | Armenia | **FI** | Finland | **LT** | Lithuania | **SK** | Slovakia |
| **AT** | Austria | **FR** | France | **LU** | Luxembourg | **SN** | Senegal |
| **AU** | Australia | **GA** | Gabon | **LV** | Latvia | **SZ** | Swaziland |
| **AZ** | Azerbaijan | **GB** | United Kingdom | **MC** | Monaco | **TD** | Chad |
| **BA** | Bosnia and Herzegovina | **GE** | Georgia | **MD** | Republic of Moldova | **TG** | Togo |
| **BB** | Barbados | **GH** | Ghana | **MG** | Madagascar | **TJ** | Tajikistan |
| **BE** | Belgium | **GN** | Guinea | **MK** | The former Yugoslav Republic of Macedonia | **TM** | Turkmenistan |
| **BF** | Burkina Faso | **GR** | Greece | | | **TR** | Turkey |
| **BG** | Bulgaria | **HU** | Hungary | **ML** | Mali | **TT** | Trinidad and Tobago |
| **BJ** | Benin | **IE** | Ireland | **MN** | Mongolia | **UA** | Ukraine |
| **BR** | Brazil | **IL** | Israel | **MR** | Mauritania | **UG** | Uganda |
| **BY** | Belarus | **IS** | Iceland | **MW** | Malawi | **US** | United States of America |
| **CA** | Canada | **IT** | Italy | **MX** | Mexico | **UZ** | Uzbekistan |
| **CF** | Central African Republic | **JP** | Japan | **NE** | Niger | **VN** | Viet Nam |
| **CG** | Congo | **KE** | Kenya | **NL** | Netherlands | **YU** | Yugoslavia |
| **CH** | Switzerland | **KG** | Kyrgyzstan | **NO** | Norway | **ZW** | Zimbabwe |
| **CI** | Côte d'Ivoire | **KP** | Democratic People's Republic of Korea | **NZ** | New Zealand | | |
| **CM** | Cameroon | | | **PL** | Poland | | |
| **CN** | China | **KR** | Republic of Korea | **PT** | Portugal | | |
| **CU** | Cuba | **KZ** | Kazakstan | **RO** | Romania | | |
| **CZ** | Czech Republic | **LC** | Saint Lucia | **RU** | Russian Federation | | |
| **DE** | Germany | **LI** | Liechtenstein | **SD** | Sudan | | |
| **DK** | Denmark | **LK** | Sri Lanka | **SE** | Sweden | | |
| **EE** | Estonia | **LR** | Liberia | **SG** | Singapore | | |

## AMENDED CLAIMS

[received by the International Bureau on 21 July 1998 (21.07.98);
original claim 2 amended; new claims 49-65 added;
remaining claims unchanged (4 pages)]

1. A transgenic non-human animal having a transgene disrupting or interfering with expression of growth differentiation factor-8 (GDF-8) chromosomally integrated into the germ cells of the animal.

2. The transgenic animal of claim 1, wherein the animal is selected from the group of species consisting of murine, avian, bovine, ovine, piscine, murine, and porcine.

3. The transgenic animal of claim 1 where the species is avian.

4. The transgenic animal of claim 1 where the species is bovine.

5. The transgenic animal of claim 1 where the species is porcine.

6. The transgenic animal of claim 1 where the species is ovine.

7. The transgenic animal of claim 1 where the species is piscine.

8. The transgenic animal of claim 1, wherein the transgene comprises GDF-8 antisense polynucleotide(s).

9. The transgenic animal of claim 1, wherein the transgene comprises a gene encoding a dominant negative GDF-8 polypeptide.

10. The transgenic animal of claim 1, wherein the animal is homozygous or heterozygous for GDF-8 polynucleotide.

11. A chicken or turkey egg produced by the transgenic animal of claim 3.

44. A method for identifying a compound that affects GDF-8 activity or gene expression comprising:

a) incubating the compound with GDF-8 polypeptide, or with a recombinant cell expressing GDF-8 under conditions sufficient to allow the components to interact; and

b) determining the effect of the compound on GDF-8 activity or expression.

45. The method of claim 44, wherein the effect is inhibition of GDF-8 activity or expression.

46. The method of claim 44, wherein the effect is stimulation of GDF-8 activity or expression.

47. An isolated polynucleotide encoding a truncated GDF-8 polypeptide wherein the truncation is a loss of the C-terminal active fragment of GDF-8.

48. The isolated polynucleotide of claim 47, wherein the polynucleotide is as shown in FIGURE 12a.

49. The transgenic animal of claim 1 where the species is murine.

50. A method for producing a transgenic non-human animal having a phenotype characterized by expression of a transgene otherwise not naturally occurring, wherein expression of the transgene disrupts or interferes with growth differentiation factor-8 (GDF-8) activity, comprising:

a) introducing a transgene in operable linkage with at least one expression regulatory sequence into a zygote of an animal;

b) transplanting the zygote of a) into a pseudopregnant animal;

c) allowing the zygote to develope to term; and

d) identifying at least one transgenic offspring from c) where expression of the transgene disrupts or interferes with GDF-8 activity.

51. The method of claim 50, wherein the introduction of the transgene into the embryo is by introducing an embryonic stem cell containing the transgene into the embryo.

52. The method of claim 50, wherein the introduction of the transgene into the embryo is by infecting the embryo with a virus containing the transgene.

52. The method of claim 52, wherein the virus is a retrovirus.

53. The method of claim 50, wherein the transgene encodes GDF-8 antisense polynucleotide(s).

54. The method of claim 50, wherein the transgene encodes a dominant negative protein that disrupts or interferes with GDF-8 activity.

55. The method of claim 50, wherein the transgenic animal is homozygous or heterozygous for GDF-8 polynucleotide.

56. The method of claim 50, wherein disrupting or interfering with GDF-8 activity in the transgenic non-human animal produces increased muscle mass as compared to a non-transgenic animal of the same species.

57. The method of claim 50, wherein the animal is selected from the group consisting of murine, avian, bovine, ovine, piscine, and porcine.

58. A method for producing a transgenic non-human animal having a phenotype characterized by expression of a transgene otherwise not naturally occurring, wherein expression of the transgene disrupts or interferes with expression of growth differentiation factor-8 (GDF-8), comprising:

a) introducing a transgene in operable linkage with at least one expression regulatory sequence into a zygote of an animal;

b) transplanting the zygote of a) into a pseudopregnant animal;

c) allowing the zygote to develope to term; and

d) identifying at least one transgenic offspring from c) where expression of the transgene disrupts or interferes with expression of GDF-8.

59. The method of claim 58, wherein the introduction of the transgene into the embryo is by introducing an embryonic stem cell containing the transgene into the embryo.

60. The method of claim 58, wherein the introduction of the transgene into the embryo is by infecting the embryo with a virus containing the transgene.

61. The method of claim 60, wherein the virus is a retrovirus.

62. The method of claim 58, wherein the transgene encodes GDF-8 antisense polynucleotide(s).

63. The method of claim 58, wherein the transgenic animal is homozygous or heterozygous for GDF-8 polynucleotide.

64. The method of claim 58, wherein disrupting or interfering with GDF-8 activity in the transgenic non-human animal produces increased muscle mass as compared to a non-transgenic animal of the same species.

65. The method of claim 58, wherein the animal is selected from the group consisting of murine, avian, bovine, ovine, piscine, and porcine.